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Chromosomal copy number aberrations are
one of the main mechanisms that give rise
to the proliferative capabilities of cancer
cells. These aberrations can be quanti-
fied with technologies that generate measure-
ments genome-wide and with high resolution.
Hence, they produce vast amounts of data,
which requires tailored bioinformatic solu-
tions for analysis and management. Two such
high-resolution and genome-wide technolo-
gies are DNA microarrays, which are succes-
sively replaced by next-generation sequencing
approaches. This dissertation describes three
novel bioinformatic solutions for copy number
analysis in cancer with these technologies.
CanGEM is a publicly-accessible database
solution for storage of raw and processed copy
number data from cancer research experi-
ments. The contents of the database can be
queried based on clinical and copy number
data. Clinical data is collected using appro-
priate controlled vocabularies. Copy number
data is collected as raw microarray data and
automated analysis identifies the locations of
chromosomal aberrations. In order to allow
integration of data measured with different
microarray platforms, a copy number status
is derived for every known human gene.
CGHpower is a statistical power calcula-
tor for copy number experiments that com-
pare two groups. It estimates genome com-
plexity of a cancer type in question from a pi-
lot data set of the sample series, and assesses
the number of samples required to satisfy sta-
tistical requirements. It can be used either in
the planning stages of experiments, includ-
ing as a justification in grant applications, or
to verify whether sufficient samples were in-
cluded in past experiments. Performance of
this bioinformatic solution is evaluated with
real and simulated data sets.
QDNAseq is a preprocessing solution to
detect copy number aberrations from shal-
low whole-genome next-generation sequenc-
ing data. It corrects the observed sequenc-
ing coverage for known systematic biases and
allows filtering of spurious regions in the
genome. A new list of such problematic re-
gions is derived from public data generated by
the 1000 Genomes Project. Performance of
the solution is evaluated relative to other sim-
ilar published solutions and DNA microar-
rays, and also compared to theoretical sta-
tistical expectations.
An application of the QDNAseq method
is also presented in a translational research
project with the aim to identify copy number
aberrations in tumors of patients with low-
grade glioma. Aberrations identified by shal-
low whole-genome next-generation sequenc-
ing and QDNAseq are used to evaluate asso-
ciations with patient survival, and also to as-
sess intratumoral heterogeneity and temporal
evolution of these tumors. A loss in chromo-
some 10q is identified to be associated with
poor prognosis, and the finding validated in
two independent data sets. From the assess-
ment of intratumoral heterogeneity and tem-
poral tumor evolution, the well-characterized
co-deletion of 1p/19q is found to be the only
chromosomal aberration that is consistently
present or absent across the entire tumor and
possible future recurrences. This is compati-
ble with the present view of its role as an early
event in the development of these tumors.
The text concludes with a discussion of
lessons learned from the development pro-
cess and application of the three described
bioinformatic solutions. Better awareness of
and adherence to established best practices
from the software development field would
have been useful, and together with more
careful consideration of implementation de-
cisions could have resulted in software that
was more apt for its purpose while also more
efficient to develop and maintain. Similar to
the presented solutions, much of the devel-
opment of custom bioinformatics software is
performed within academic research groups.
Closer attention to the software development
process itself could possibly be beneficial for




eräs tärkeimmistä mekanismeista syövän syn-
nyssä. Yhden äidiltä ja yhden isältä perityn
geenikopion sijaan osa perimästä voi olla mo-
nistunut useammaksi kopioksi, ja joidenkin
osien kohdalla yksi tai molemmat kopiot voi-
vat olla hävinneet. Kopiolukupoikkeamien to-
dentamiseen käytetään genominlaajuisia tek-
niikoita, joilla on tarkka erotuskyky. Ne tuot-
tavat suuria tietomääriä, joiden analysointi ja
käsittely vaativat räätälöityjä bioinformaatti-
sia menetelmiä. Tekniikoihin sisältyvät DNA-
mikrolevyt sekä ne käytännössä jo syrjäyt-
täneet uuden sukupolven sekvensointimene-
telmät. Tässä väitöskirjassa kuvataan kolme
uutta bioinformaattista ohjelmistoa kopiolu-
kupoikkeamien analysointiin syöpänäytteistä
näillä tekniikoilla.
CanGEM on julkinen tietokanta raa’an
ja prosessoidun mikrolevyaineiston keräämi-
seen yksittäisistä syöpätutkimuksista. Tie-
tokannan sisältöön voi tehdä hakuja klii-
nisten muuttujien tai kopiolukupoikkeamien
perusteella. Kliinisten muuttujien tallennuk-
seen käytetään asianmukaisia luokittelujär-
jestelmiä. Kopiolukuaineisto kerätään raakoi-
na mikrolevymittauksina, joista kopioluku-
poikkeamat tunnistetaan algoritmisesti. Jot-
ta eri mikrolevyalustoilla mitatun tiedon yh-
distäminen olisi mahdollista, kopioluku mää-
ritetään erikseen jokaiselle tunnetulle ihmisen
geenille.
CGHpower on menetelmä tilastollisten
voima-analyysien tekemiseen kahta ryhmää
vertailevista kopiolukututkimuksista. Aineis-
ton kopiolukupoikkeamien monimutkaisuus
arvioidaan koe-erästä näytteitä ja määrite-
tään tilastollisten vaatimusten edellyttämä
otoskoko. Menetelmää voidaan käyttää jo-
ko tutkimusten suunnitteluvaiheessa, mm. ra-
hoitushakemusten tukena, tai arvioimaan on-
ko jo tehdyissä kokeissa käytetty riittävää
määrää näytteitä. Suorituskyky mitataan se-
kä todellisilla että simuloiduilla aineistoilla.
QDNAseq on esikäsittelymenetelmä ko-
piolukupoikkeamien tunnistamiseen matalal-
la lukupeitolla ja genominlaajuisesti tuote-
tusta uuden sukupolven sekvensointiaineis-
tosta. Se korjaa havaittua lukupeittoa tun-
nettujen vinoumalähteiden osalta ja mah-
dollistaa kopiolukuanalyyseille ongelmallis-
ten perimän osien suodattamisen jatkokäsit-
telystä. Näistä ongelmallisista alueista kuva-
taan uusi luettelo, joka on johdettu 1000 Ge-
nomes -projektin julkaisemasta aineistosta.
Menetelmän suorituskykyä arvioidaan ver-
rattuna muihin vastaaviin julkaistuihin me-
netelmiin ja DNA-mikrolevyihin, sekä suh-
teessa teoreettisiin tilastollisiin odotuksiin.
Itse menetelmän lisäksi kuvataan QD-
NAseq:n sovellutus translationaaliseen tutki-
mukseen ja kopiolukupoikkeamien tunnista-
miseen alhaisen erilaistumisasteen glioomis-
ta. Todetaan kromosomin 10q häviämän yh-
teys huonoon ennusteeseen ja löydös vahvis-
tetaan kahdessa riippumattomassa aineistos-
sa. Tunnistettuja kopiolukupoikkeamia käy-
tetään myös kasvaimien epäyhtenäisyyden
ja ajallisen kehityksen tarkasteluun. Havai-
taan kyseiselle syöpätyypille yleisen 1p/19q-
häviämän olevan ainoa kopiolukupoikkeama,
joka on johdonmukaisesti joko läsnä taik-
ka puuttuu läpi sekä koko alkuperäisen syö-
päkasvaimen että mahdollisten uusiutumien.
Havainto sopii nykynäkemykseen kyseisen
poikkeaman synnystä hyvin varhaisessa vai-
heessa kyseisen syöpätyypin kehitystä.
Lopuksi tarkastellaan kuvattujen bioin-
formaattisten ohjelmistojen kehitys- ja so-
vellutusprosesseista opittuja asioita. Ohjel-
mistokehitysalan vakiintuneiden käytäntei-
den parempi tuntemus olisi ollut hyödyllistä,
ja yhdessä toteutusyksityiskohtien tarkem-
man harkinnan kanssa voinut auttaa tuot-
tamaan tarkoituksensa paremmin täyttäviä
sekä helpommin kehitettäviä ja ylläpidettä-
viä ohjelmistoja. Kuten tässä kuvatut, suu-
ri osa räätälöidyistä bioinformaattisista ohjel-
mistoista kehitetään akateemisissa tutkimus-
ryhmissä. Suurempi panostus itse ohjelmis-




Afwijkingen in het aantal chromosomen, of
delen van chromosomen, zijn een van de me-
chanismen die aanleiding geven tot het proli-
feratieve gedrag van kankercellen. Deze chro-
mosomale afwijkingen kunnen worden geme-
ten met genomische technieken met een hoge
resolutie. Deze technieken genereren zeer
grote hoeveelheden data, die op maat ge-
maakte bioinformatische oplossingen vereisen
voor analyse en databeheer. De twee meest
relevante genomische technieken met hoge re-
solutie zijn microarrays en ‘next generation
sequencing’. Hoofdstuk 1 van dit proefschrift
behandelt de literatuur van de data-analyse
voor chromosomale afwijkingen gemeten met
microarrays of ‘next generation sequencing’.
Het introduceert relevante bioinformatische
concepten, beschrijft het analytische proces
van ruwe data tot identificatie van numerieke
chromosoomafwijkingen in individuele tumo-
ren en het bioinformatisch onderzoek gericht
op de betekenis van die afwijkingen in grote
series tumoren.
Hoofdstuk 2 tot en met 4 beschrijven
drie nieuwe bioinformatische implementaties
ontwikkeld voor de analyse van deze chro-
mosomale afwijkingen in kanker. CanGEM
(Hoofdstuk 2) is een publiek toegankelijke
database voor het opslaan van ruwe en ver-
werkte chromosoomaantallen het kankeron-
derzoek. De inhoud van de database kan
worden doorzocht op basis van zowel klini-
sche als experimentele gegevens met betrek-
king tot chromosoomaantallen. Klinische ge-
gevens worden verzameld met behulp van ge-
controleerde woordenlijsten. Chromosoom-
aantallen worden verzameld als ruwe micro-
array data en begin- en eindpositie van de
afwijkingen worden steeds opnieuw automa-
tisch bepaald. Om de integratie van de data,
die gemeten worden met microarrays van ver-
schillende makelij, verder te faciliteren, wordt
het aantal chromosomen per gen afgeleid voor
ieder van de ca. 19.000 tot 20.000 menselijke
genen.
CGHpower (Hoofdstuk 3) is een methode
om te berekenen hoeveel tumormonsters sta-
tistisch nodig zijn om verschillen en overeen-
komsten in chromosomale afwijkingen tussen
twee groepen tumoren te kunnen vergelijken.
Er wordt een schatting gemaakt van de com-
plexiteit van de afwijkingen in een bepaald
type kanker met behulp van een beperkt aan-
tal monsters. Vervolgens wordt geschat hoe-
veel tumoren nodig zijn om aan de statisti-
sche eisen te voldoen. CGHpower kan in de
planningsfase van een subsidieaanvraag wor-
den gebruikt als rechtvaardiging van de voor-
gestelde aantallen naar een subsidiegever, of
kan gebruikt worden om te controleren of er
voldoende aantallen tumoren in een experi-
ment werden opgenomen. CGHpower wordt
geëvalueerd met behulp van experimentele en
gesimuleerde datasets.
QDNAseq (Hoofdstuk 4) is een methode
die een voorbewerkingstap maakt van ‘next
generation sequencing’ data naar chromo-
soomaantallen in het genoom van een tumor,
waarbij wordt uitgegaan van sequencing met
een diepte van slechts 10% van het gehele ge-
noom. QDNAseq corrigeert de waargenomen
genoomwijde dekking voor systematische fou-
ten en faciliteert de mogelijkheid om onregel-
matige gebieden in het genoom te verwijde-
ren. Een lijst van dergelijke systematische
fouten en onregelmatige gebieden is afgeleid
van publieke data die openbaar werd gemaakt
door het “1000 Genomes Project”. QDNAseq
wordt geëvalueerd ten opzichte van de micro-
arraytechniek en andere gepubliceerde soft-
ware voor de analyse van numerieke chromo-
soomafwijkingen met behulp van ‘next gene-
ration sequencing’. Tenslotte worden de uit-
komsten van QDNAseq op ‘next generation
sequencing’ data vergeleken met theoretische
statistisch verwachte resultaten.
In het voorlaatste hoofdstuk (Chapter 5)
wordt QDNAseq toegepast op translationeel
onderzoek dat tot doel heeft afwijkingen in
het aantal chromosomen of delen daarvan te
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identificeren bij tumoren van patiënten met
laag-gradige gliomen. Chromosomale afwij-
kingen geïdentificeerd middels ‘next genera-
tion sequencing’ en QDNAseq worden ge-
bruikt om associaties te bepalen met de over-
leving van de patiënt, de intratumorale hete-
rogeniteit van de tumoren en de evolutie over
tijd van deze tumoren. Een verlies van het
distale deel van chromosoom 10q wordt in dit
onderzoek geassocieerd met een slechte prog-
nose. Deze bevinding kon worden gevalideerd
in twee onafhankelijke patiëntenseries. Uit de
beoordeling van intratumorale heterogeniteit
en tumorevolutie blijkt tenslotte dat verlies
van chromosoom 1p samen met 19q de enige
afwijking is die consistent aan- of afwezig is
in de tumoren.
Net als bij de drie beschreven implementa-
ties voor de analyse van chromosomale afwij-
kingen in kanker, wordt veel bioinformatisch
onderzoek uitgevoerd in academische groe-
pen. De discussie (Hoofdstuk 6) behandelt
de opgedane ervaringen met betrekking tot








Chromosomal aberrations in cancer
Cancer is a disease in which control of the cell
cycle fails, leading to cell proliferation. This
is caused by aberrant signal processes within
and between cells. Perturbations in signal-
ing networks allow cancer cells to obtain their
characteristic traits, which include sustained
proliferative signaling, evasion of growth sup-
pressors and cell death, replicative immor-
tality, induction of angiogenesis, and activa-
tion of invasion and metastasis (Hanahan and
Weinberg, 2011).
One of the mechanisms through which
cells acquire the necessary alterations is chro-
mosomal instability, which includes alter-
ation of chromosomal copy numbers. Com-
pared to the normal diploid copy number
of two, the presence of additional copies,
or loss of one or both copies, can result in
tumorigenic alterations in cell homeostasis
(Albertson et al., 2003; Beroukhim et al.,
2010). Alternate chromosomal copy numbers
can be acquired (somatically), or be present
in the germ-line (hereditary). Throughout
this text, germ-line alterations are referred to
as copy number variations (CNVs) (Church
et al., 2010; 1000 Genomes Project Con-
sortium et al., 2015). Some CNVs have
been shown to affect cancer risk (Shlien and
Malkin, 2010). The focus of this dissertation,
however, is on acquired (or somatic) events,
which are referred to as chromosomal copy
number aberrations (CNAs). To discuss both
CNAs and CNVs at the same time, the term
copy number alterations is used.
Recurrent CNAs in cancer tissues have
a high probability to contain genes whose
function is crucial to normal cell home-
ostasis and perturbations therefore tumori-
genic (Beroukhim et al., 2007). Many such
genes are affected, directly or indirectly, by
CNAs (Futreal et al., 2004; Cox et al., 2005;
Beroukhim et al., 2010; Santarius et al., 2010;
Kim et al., 2013b). Within tumors localized
in the same organ, CNA patterns have been
shown to define subtypes (Fridlyand et al.,
2006; Chin et al., 2007a; Jong et al., 2007;
Habermann et al., 2009; Russnes et al., 2010).
Within these subtypes, prognostics and treat-
ment responses can be very different (Cur-
tis et al., 2012; Dancey et al., 2012), and
accurate identification of subtypes can thus
be of great clinical value (Macintyre et al.,
2016). Specific CNAs have also been linked
to different environmental risk factors, such
as asbestos-exposure (Nymark et al., 2006)
or smoking (Dumanski et al., 2014). Meta-
analyses of various cancer types have shown
that the observed CNA patterns differ be-
tween cancers whose precursor cells originate
from different germ layer lineages in the em-
bryo (Myllykangas et al., 2006; Jong et al.,
2007; Hoadley et al., 2014).
In order for CNAs to be tumorigenic, they
would need to affect cell signaling pathways.
These pathways are guided by proteins. Pro-
teins are translated from messenger-RNAs
(mRNAs), which in turn are transcribed from
DNA. The cancerous effect of a CNA would
therefore need to be reflected first on the
RNA level, and then on a protein level, re-
sulting either in changes in concentration, or
molecular modifications such as different con-
figurations, phosphorylations, and glycosyla-
tions. Such effects from CNAs can be direct
(higher level of transcription and translation
for a gene located within an amplification),
or indirect, such as CNAs affecting promoter
regions, micro-RNAs, or transcription factors
or other regulatory proteins.
Both protein (Zhang et al., 2016) and
RNA expression (Curtis et al., 2012) levels
show correlation with DNA copy number. In
fact, a proportion of differential RNA expres-
sion in colorectal cancer can be explained
in terms of underlying CNAs (Tsafrir et al.,
2006). CNAs that encompass oncogenes or
tumor-suppressor genes can therefore have a
direct effect on cell homeostasis.
Some RNAs, such as micro-RNAs (miR-
NAs), function as regulators of translation or
16
degradation of mRNAs. A single miRNA can
control hundreds of protein-coding genes, and
CNAs that contain miRNAs therefore have
tumorigenic effects (Varambally et al., 2008;
Croce, 2009). Other possible mechanisms of
action include CNAs encompassing transcrip-
tion factor binding sites, or regions respon-
sible for maintaining the three-dimensional
structure of chromatin (Gilbert and Allan,
2014).
As most functional consequences of CNAs
are probably carried out via RNA and pro-
teins, one may wonder, why not study those
directly instead of DNA? There are both
experimental and biological advantages and
disadvantages to any class of biomolecules
(Smeets et al., 2011). Compared to proteins,
the ability of nucleotide sequences to form
double helices is a big advantage from the ex-
perimental point of view. It allows one to use
single-stranded DNA molecules and measure
events involving the specific complementary
nucleotide sequence.
This applies similarly to both DNA and
RNA, and both have been used extensively as
targets for diagnostic and experimental tech-
niques in cancer research. Gene expression
profiles have been shown to have a strong
prognostic value for a wide range of malig-
nancies including leukemias as well as blad-
der, breast, esophageal, non-small cell lung,
and head and neck cancers (Bell, 2010).
Compared to RNA, one of the main ad-
vantages of DNA is its stability (Smeets et al.,
2011). For more than a century, pathology
institutes around the world have been rou-
tinely collecting specimens in their archives,
usually as formalin-fixed paraffin-embedded
(FFPE) blocks (Blow, 2007; Casparie et al.,
2007). Together with the accompanying clin-
ical data, these archives present a huge re-
source for cancer research and biomarker dis-
covery. For studies that require long clini-
cal followup, they may be the only available
source of material.
However, while FFPE-fixation works well
for histological purposes, not all biomolecules
preserve well. This is especially true for
RNA, which is often differentially degraded
in archival samples, obscuring expression an-
alytical procedures (Scicchitano et al., 2006;
Frank et al., 2007; Fedorowicz et al., 2009).
DNA is more stable, and therefore a more
robust target for diagnostics and studies
on such material. Also within DNA tech-
niques, some are more sensitive, while oth-
ers are more tolerant to degradation (Krijgs-
man et al., 2012). Since the ability to use
archival material is an important aspect in
cancer research, compatibility of techniques
with DNA isolated from FFPE is a valuable
criterion when choosing which techniques to
use.
Challenges for data analysis of
CNAs
Prior to reviewing analytical techniques for
CNAs in the next section, some aspects of
their biology are discussed here. The focus is
on those features that have a direct impact on
interpretation of data from high-throughput
analytical methods. Aspects that do not,
such as the mechanisms of their genesis, are
omitted.
Aberration length and magnitude
The size of CNAs varies from entire chromo-
somes and chromosome arms to focal aberra-
tions (Krijgsman et al., 2014). As technolo-
gies have improved, the spatial resolution to
detect CNAs has also increased, allowing ever
smaller events to be detected.
CNAs manifest as a range of chromosomal
copy numbers that deviate from the diploid
copy number in healthy somatic cells. Gains
of oncogenes and losses of tumor-suppressor
genes can both cause tumorigenic changes in
a cell.
For deletion of a given diploid locus, there
are only two options: deletion of one or
two copies, also called hemi- and homozy-
gous losses. Another nomenclature for dele-
tions is loss of heterozygosity (LOH), which
refers to a continuous stretch of DNA where
all SNPs (single nucleotide polymorphisms)
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appear homozygous. When such loss of one
chromatid is compensated with a duplication
of the sister chromatid, there is no alter-
ation in the overall copy number. This phe-
nomenon is termed copy-neutral loss of het-
erozygosity (cnLOH).
For gains, there can be a range of addi-
tional copies, which makes classification into
exact copy number categories more compli-
cated. In classical cytology terms, there is a
division into gains and amplifications. Gains
refer to one or a few additional copies, and
can be as large as entire chromosomes. Am-
plifications are invariably focal and contain
a large number of extra copies, up to over a
hundred (Krijgsman et al., 2014).
Ploidy, cellularity, and heterogeneity
CNAs discussed in the previous section affect
individual chromosomes, or parts thereof. In
addition to aneuploidy, an abnormal number
of chromosomes, cancers can also exhibit an
abnormal number of complete sets of chro-
mosomes. While normal somatic human cells
are diploid and carry two copies of all auto-
somal chromosomes, some cancers have only
one set, while others have multiple. Haploid
(or monoploid) tumors have lost one set of
chromosomes (Corver et al., 2014). This can
be an intermediate step that precedes global
cnLOH. Polyploid tumors, on the other hand,
have gained additional copies of all chromo-
somes. This leads to the possibility of ad-
ditional copy number levels that can be ob-
served in measurement data. While a diploid
cell can only undergo losses of one or both al-
leles, a tetraploid sample, for example, could
exhibit four discrete levels of losses. This is
similarly true for gains, and makes it progres-
sively more challenging to identify the exact
copy number behind a gain.
As described above, DNA copy numbers
are fundamentally discrete integers. How-
ever, when measuring copy numbers of entire
cancer samples with genome-wide techniques,
these discrete integer values are usually ob-
scured by admixed normal cells and intratu-
moral heterogeneity.
Cancer samples obtained from routine
clinical care (biopsies or resections) rarely
consist exclusively of tumor cells. Usually,
they also contain a varying proportion of nor-
mal cells. Since a CNA is present only in the
cancer cell population, its signal gets damp-
ened in proportion to the percentage of infil-
trating normal cells. This impacts its detec-
tion (Krijgsman et al., 2013). Since the pro-
portion of cancer cells, the cellularity, varies,
the same detection limits do not directly ap-
ply between samples. If the cellularities of
individual samples are known, the dilutive ef-
fect can be corrected. However, accurate es-
timation of cellularities under a microscope
can be challenging. Due to the aberrant size
and shape of cancer cells, there is great inter-
observer variability when pathologists judge
cellularity. This is in contrast to procedures
in clinical genetics and in the study of CNVs,
where uniform cell populations can generally
be assumed. Hence, while algorithms built
primarily for CNVs or CNAs both measure
the same phenomenon, namely DNA copy
number, they often make different assump-
tions, and their performance can be sub-
optimal if used in the other setting.
In addition to infiltration with normal
cells, the tumor itself can also be non-clonal
(Burrell et al., 2013). Various distinct cell
populations can be present either in separate
parts of the tumor, or diffused together (Alli-
son and Sledge, 2014; van Thuijl et al., 2014;
Jamal-Hanjani et al., 2017). This results in a
similar dampening of signals, as dictated by
the proportion of cells carrying a particular
aberration. It also introduces a mixture of
copy number levels in the measurement data.
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Review of literature for data analysis of CNAs
There are multiple techniques that can be
used to detect alterations in DNA copy num-
ber, and the discipline is called cytogenet-
ics (Hastings et al., 2016). Cytogenetic tech-
niques can be divided in techniques that mea-
sure one or few chromosomal locations, and
techniques that allow a genome-wide mea-
surement. Modern genome-wide techniques
produce vast amounts of data, and require
sophisticated computational and statistical
methods for their analysis and interpretation.
This interdisciplinary field is known as bioin-
formatics.
This chapter (Chapter 1) reviews meth-
ods developed for the analysis of chromo-
somal copy number aberrations in cancer.
It discusses the analysis of data obtained
with two genome-wide high-throughput tech-
niques, microarrays and next-generation se-
quencing (NGS). The focus is on experiments
where the aim is to analyze larger series of pa-
tient samples in order to interpret and charac-
terize the significance of the observed CNAs
(as opposed to for example diagnostics where
the aim is to detect the presence of absence of
specific CNAs in individual patient samples).
The purpose of a study with larger se-
ries of patients can be for example to iden-
tify associations with clinical variables, to dis-
cover subtypes present in the data set, or to
describe recurrent aberration patterns in a
previously uncharacterized cancer type. In
the following sections, analytical methods to
achieve these goals that involve interpretation
of CNAs in the context of a larger set of sam-
ples are referred to as downstream analyses.
Prior to proceeding to the downstream
analyses to interpret the significance of CNAs
in a data set, there are some preliminary an-
alytical steps that need to be taken. There
is no clear unambiguous consensus of which
steps exactly need to be included, but in
this text, they are collectively known as copy
number analysis. This is not to imply that
there is necessarily a clear separating bound-
ary between the two, and that every type of
analysis would clearly belong to one group or
the other. The distinction is made solely on
the conceptual level in order to facilitate dis-
cussion of the analytical workflow, and anal-
ysis of data originating from two different
laboratory techniques. Whereas downstream
analyses include standard statistical testing
and learning procedures, copy number analy-
sis is more dependent on the exact lab tech-
nique used to obtain raw data. Figure 1.1
shows an analytical workflow that starts from
raw data and ends in statistical tests and
learning methods. Intermediate steps will be
added in the following sections.
In the next section, microarrays and their
copy number analysis is discussed first. This
introduces concepts and provides context
that is useful for the subsequent review of
different approaches for copy number analysis





statistical tests and statistical learning methods
raw data
microarrays NGS
Figure 1.1: Analytical workflow. Starting from raw microarray or NGS data, the analytical
workflow proceeds first through platform-dependent copy number analysis and ends in appli-
cation of standard statistical tests and statistical learning methods. Intermediate steps are
described in the following sections, and an updated version of the diagram presented at the
end of this chapter.
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Microarrays for genome-wide CNA detection
Array laboratory process
DNA microarrays were developed at the end
of the previous century and consist of a set
of DNA molecules with specific base pair se-
quences fixed on a solid medium. These array
elements bind to molecules with the comple-
mentary nucleotide sequence, which can be
either DNA or RNA.
Array comparative genomic hybridization
(CGH) (Pinkel et al., 1998; Pollack et al.,
1999) uses microarrays to measure DNA copy
number. Its principle is similar to traditional
chromosomal CGH (Kallioniemi et al., 1992),
which uses metaphase spreads fixed on a glass
slide. The elements on the array can be ei-
ther BAC (bacterial artificial chromosome)
clones, cDNA molecules, or synthetic oligonu-
cleotides (Ylstra et al., 2006).
Briefly, the CGH array laboratory process
is as follows. DNA isolated from normal and
tumor samples are labeled with different flu-
orescent dyes. They are then allowed to si-
multaneously hybridize to the array, compet-
ing for the array elements. After unbound
DNA is washed away, dye intensities are mea-
sured with a scanner. Finally, image analysis
software is used to quantify the intensities of
normal and tumor DNA.
In addition to CGH arrays, genotyp-
ing arrays are used for copy number de-
tection. These were originally designed to
detect SNPs with alternative short probes
for the major and minor alleles. Compared
to the exactly matching and longer oligonu-
cleotides on CGH arrays, their signals for
copy number detection were somewhat nois-
ier. Therefore, newer generations of genotyp-
ing arrays, such as the Affymetrix Genome-
Wide Human SNP Array 6.0, contain dedi-
cated copy number probes in addition to the
SNP probes. Genotyping arrays are typi-
cally hybridized with the tumor sample only,
unlike the comparative CGH arrays (Ylstra
et al., 2006). For copy number analysis, a
separate normal signal is typically used, of-
ten in the form of a larger reference data set,
such such as the HapMap project (Interna-
tional HapMap Consortium, 2003). B-allele
frequencies (BAFs) from the SNP probes on
genotyping arrays allow detection of cnLOH,
which is not possible with CGH arrays. But
when working with FFPE material, CGH ar-
rays have been found to be more robust and
generally outperform genotyping arrays (Cur-
tis et al., 2009; Krijgsman et al., 2012).
Array data and meta-data
The exact format in which the obtained in-
tensities are stored varies between manu-
facturers. A typical structure is a tabular
text file, which, in addition to the numerical
intensities, also contains additional quality
control measurements or flags, and possibly
background intensity measurements. After
filtering potentially unreliable data points,
and possible background correction (Ritchie
et al., 2007), microarray data for copy num-
ber experiments is usually stored as log2-
transformed ratios between the test and ref-
erence sample intensities. The ratios are pre-
sented as a matrix, where rows correspond to
the elements of the array, and columns rep-
resent the individual specimens. When us-
ing genotyping arrays, an additional matrix
of BAFs can also be used.
In addition to the data itself (log2-
ratios and possibly BAFs), meta-data is also
needed. Each element on the array needs
to be annotated to define what it is mea-
suring. Ideally, CGH arrays are annotated
with the chromosome name and base pair lo-
cation of each arrayed element. These can be
provided by the array manufacturer, or ob-
tained from the DNA sequences of the array
elements with a tool such as BLAT (Kent,
2002). The elements can also be annotated
with gene names, but while this works well for
arrays that target only genes, such as cDNA
arrays, copy number arrays usually contain
elements that target genomic sequences lo-
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cated between genes.
Publication of microarray results in a sci-
entific journal usually requires that the orig-
inal data is made publicly available in a
database such as GEO (Gene Expression Om-
nibus; Edgar et al., 2002; Barrett et al., 2013)
or ArrayExpress (Kolesnikov et al., 2015).
Only by making the raw data and analyt-
ical procedures public, can others evaluate
the reproducibility of final results (Ioannidis
et al., 2009). In addition to the raw data
and meta-data characterizing the array ele-
ments, meta-data describing the experimen-
tal conditions should also be included. These
requirements are known as MIAME, Mini-
mum Information About a Microarray Ex-
periment (Brazma et al., 2001). Chapter 2
(Scheinin et al., 2008) will describe a public
and MIAME-compliant database that is fo-
cused on CNAs and cancer.
Copy number analysis of microarray
data
Raw microarray data needs to go through
copy number analysis, which is broken down
into discrete steps below, before it is ready
for downstream analyses. Preprocessing is
performed to account for technical artifacts,
such as dye biases and possible missing val-
ues. But after preprocessing, there are dif-
fering strategies on whether data is ready for
downstream analyses or if other subsequent
steps are still required. These possible in-
termediate steps include segmentation (which
refers to the identification of stretches of con-
secutive array elements that most likely share
the same copy number and are separated by
breakpoints) and calling (assignment of dis-
crete copy number levels to the segments).
Figure 1.2 outlines these steps, and the fol-
lowing sections describe them in more detail
and discuss their benefits (van de Wiel et al.,
2011).
Preprocessing of microarray data
In this text, the term preprocessing is used to
refer to the steps that are needed to prepare
the log2-ratios of individual samples for seg-
mentation and calling algorithms. It can in-
clude steps such as filtering, imputation, nor-
malization, and smoothing.
Filtering refers to unreliable values
that should be removed. These can include
data points flagged by array image analysis
software due to various reasons, such as be-
ing saturated or non-uniform, or array el-
ements for which it was later learned that
their sequences bind to multiple positions in
the genome. When this leads to missing val-
ues for some of the arrays in a data set, im-
putation can be used, with for example the
k-nearest neighbors algorithm (Troyanskaya
et al., 2001).
Normalization is used to eliminate
various sources of bias, such as differences in
the labeling efficiencies of the dyes. There are
methods for both intra- and inter-array nor-
malization, but the latter is usually not used
in the analysis of CNAs due to natural vari-
ation in signal intensities between samples
caused by varying cellularity, tumor hetero-
geneity, and ploidy. Normalization methods
usually center the (log2-transformed) data
around zero. The baseline at zero is inter-
preted as “normal” copy number, with gains
and losses defined as relative to the baseline.
In the case of polyploid or haploid samples,
the copy number of the most common level
naturally differs from the truly normal state
of two copies for a diploid species. When us-
ing genotyping arrays instead of CGH, the
BAFs can possibly be used to detect exact
copy numbers, and to define “normal” as ex-
actly two copies. Alternatively, an absolute
copy number for a single chromosomal loca-
tion can also be obtained with a technique
such as FISH (fluorescent in-situ hybridiza-
tion).
For identification of the baseline level, use
of the mode would be ideal, but can poten-
tially lead to ambiguous situations for com-
putation algorithms in case of multi-modal






Figure 1.2: Copy number analysis of an array CGH sample. Three separate steps can be iden-
tified in the process. These include preprocessing, segmentation, and calling. Not all three are
necessarily performed before proceeding to downstream analyses, as will be discussed later.
fore more common. More sophisticated nor-
malization methods have also been published
based on lowess (Staaf et al., 2007), ridge re-
gression (Chen et al., 2008), better correction
for spatial bias (Neuvial et al., 2006), or on
a stepwise framework that independently tar-
gets intensity, spatial, plate, and background
biases (Khojasteh et al., 2005).
If the proportion of cancer cells in the
sample is known, some software packages,
such as CGHcall (van de Wiel et al., 2007),
allow the data to be adjusted for the dilutive
effect of normal cells. This can be beneficial
when samples in the same data set vary in
terms of their cellularities.
Figure 1.3 shows an example array CGH
profile of a low-grade glioma (LGG) sample
that has been preprocessed by filtering out-
liers and median-normalized.
De-waving is an optional preprocessing
step to correct an occasional artifact that can
be observed as a wavy pattern, when copy
number data is ordered and plotted accord-
ing to their chromosomal position. It is re-
lated at least to GC content (the proportion
of guanine and cytosine bases), but might
also be affected by other factors (Marioni
et al., 2007), including cell cycle and dye bias.
During preprocessing, waves can optionally be
corrected either by regression on GC content
(Diskin et al., 2008), or using a calibration
data set (van de Wiel et al., 2009). The ben-
efit of the regression approach is that it does
not require calibration data, whereas the cal-
ibration data approach can also correct for
other sources of bias besides GC content.
Smoothing is another optional step,
which reduces technical variation by utiliz-
ing spatial information of array elements
along the chromosomes. The simplest ap-
proach is to use a moving window around
the array element of interest and calculate
the mean or median (CGH-Explorer, Ling-
jaerde et al., 2005; CLAC, Wang et al.,
2005; ChARM, Myers et al., 2004). Other
smoothing methods include quantile smooth-
ing (quantreg, Eilers and de Menezes, 2005),
adaptive weights smoothing (GLAD, Hupé
et al., 2004, and wavelet smoothing (Hsu
et al., 2005). Smoothing helps reduce noise,
but also decreases sensitivity and increases
risk of missing focal aberrations. Since
smoothing dampens signals on both sides of
copy number breakpoints, it can make it
harder for segmentation algorithms to per-
form well and detect the exact breakpoint lo-
cations.
Smoothing can sometimes also refer to
procedures that target only individual out-
liers. Segmentation methods that utilize seg-
ment means, such as the circular binary seg-
mentation (CBS) algorithm, can be sensi-
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Figure 1.3: A preprocessed array CGH copy number profile. Array elements are ordered
along the x-axis by their genomic positions, and y-axis shows median-normalized log2-ratios
between an LGG sample and a normal reference sample. Small triangles at the top and
bottom edges represent data points that fall outside the plot area. Upper left corner show
the number of array elements (approximately 164,000) and their length (60 base pairs). This
profile has not been de-waved since waviness is minimal. The sample shown here is from the
LGG study that is presented in Chapter 5 (van Thuijl et al., 2014). Although that study
uses NGS for CNA detection, CGH arrays were performed for some of the samples for quality
control purposes.
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tive to local outliers. Its implementation in
DNAcopy (Venkatraman and Olshen, 2007)
therefore first detects singleton outliers and
shrinks their values towards their neighbors.
Segmentation and calling of microarray
data
Algorithms designed to identify the locations
of possible CNAs can be used after the log2-
ratios have been preprocessed. This task can
be further divided into two discrete steps:
segmentation and calling. Although some al-
gorithms perform both simultaneously, such
as those based on hidden Markov models
(HMMs; Eddy, 2004), they can be concep-
tually distinguished from each other, and are
therefore discussed separately.
Segmentation refers to the identifica-
tion of stretches of consecutive array ele-
ments ordered by chromosomal position that:
1) most likely share the same copy num-
ber, and 2) are separated by breakpoints.
Their identification reduces noise and im-
proves sensitivity and specificity (Willen-
brock and Fridlyand, 2005). Another po-
tential benefit is better detection of the cor-
rect baseline, the level that represents normal
copy number. If few segments coincide with
the level at zero, the baseline can be adjusted
to fit the most common segment level. This
is referred to as post-segmentation normal-
ization.
Multiple segmentation algorithms have
been developed. The most widely used is
CBS (Olshen et al., 2004). Other examples
include aCGH-Smooth (Jong et al., 2004),
CGHseg (Picard et al., 2005), and mBPCR
(Rancoita et al., 2009). These methods fol-
low an approach with a local focus. Their
aim is to identify breakpoints between neigh-
boring segments, and these segments can be
described with their means or medians. An
alternative is a global, model-based approach,
that aims to identify a set of copy number
levels that fits all segments across the entire
genome. One example of this approach is
BioHMM (Marioni et al., 2006).
The way segmented data is stored varies
between methods. Since the breakpoints be-
tween segments vary from one sample to an-
other, it is not possible to simply use a similar
matrix as with preprocessed data, but now
with rows representing segments (except in
the case of a single sample). Instead, the
preprocessed data matrix is typically com-
bined with vectors of segment boundaries
for each sample. This can be further con-
verted to a matrix of the original dimensions
by replacing the log2-ratio of each array ele-
ment with the corresponding segment mean,
which makes the data straightforward to use
in downstream analyses.
Calling represents the assignment of a
discrete copy number state to each segment.
The term interpretation is also sometimes
used for this purpose. The simplest approach
is to use cutoffs to define when segmented
log2-ratios are too large or small to be consid-
ered “normal”, and instead represent “gains”
and “losses”, respectively. Correct cutoff val-
ues, however, are affected by cellularity, pos-
sible heterogeneity, and tumor ploidy. These
are often not precisely known and also vary
between samples.
Due to limitations of cutoff-based calling,
more sophisticated calling algorithms have
been developed, based on various types of
statistical models. Wang et al. (2005) were
the first to publish such a method with the
introduction of the CLAC algorithm. Many
other approaches have been published since,
and comparisons and reviews have been pub-
lished by Lai et al. (2005) and Wang (2009).
Compared to simple cutoffs, algorithms based
on statistical models generally produce more
reliable results with less false positives.
Depending on the algorithm, a call can
refer to an absolute number of copies, such as
“1” for a loss of one allele and “4” for a gain of
two extra copies. But more commonly, calls
relative to the most common, “normal”, level
are used. The minimum is three levels: “loss”,
“normal”, and “gain”, and further characteri-
zation is possible by separately including “ho-
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mozygous deletions” and “amplifications”.
Calling helps the interpretation of results
from copy number experiments, as it de-
scribes the findings in a biologically more in-
tuitive way compared to log2-ratios. It also
makes it more straightforward to make com-
parisons between arrays, platforms, and ex-
periments. Furthermore, it conceptually vali-
dates verification of results with another tech-
niques, such as FISH (Snijders et al., 2001;
van den IJssel et al., 2005), that verifies the
copy number call, not a log2-ratio.
While calls are easier to interpret, they
also result in loss of information, as contin-
uous log2-ratios are replaced with discrete
calls. Due to issues with cellularity, hetero-
geneity, and polyploidy, this information can
be valuable. Multiple calling algorithms are
based on mixture models, including CGHmix
(Broët and Richardson, 2006), CGHclassify
(Engler et al., 2006), and CGHcall (van de
Wiel et al., 2007). In addition to discrete
hard calls, these methods also return associ-
ated probabilities. They capture the related
uncertainties caused by, for example, tumor
heterogeneity. Use of call probabilities, or
soft calls as they are sometimes referred to,
can therefore combine the advantages and in-
terpretability of hard calls without suffering
from the associated information loss. An ex-
ample of segmented and called copy number
profile is shown in Figure 1.4 for chromosomes
7 and 9 of the same LGG sample as in Figure
1.3.
Unambiguous estimation of absolute calls
from log2-ratios alone may be impossible due
to issues with cellularity, heterogeneity, and
ploidy. The use of genotyping arrays provides
additional information in the from of BAFs,
which help estimation of absolute copy num-
bers (Attiyeh et al., 2009; Rancoita et al.,
2010; Ortiz-Estevez et al., 2012), and also aid
detection of breakpoint locations during seg-
mentation (Olshen et al., 2011).
Most segmentation and calling algorithms
have been developed to handle data mea-
sured with a single microarray platform at a
time, but there are also methods developed to
combine multiple platforms, such as MSCN
(Bengtsson et al., 2009) and MPCBS (Zhang
et al., 2010). Chapter 2 will also describe
one approach to deal with multiple array plat-
forms, by focusing on genes instead of array
elements.
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Figure 1.4: Segmented and called array CGH copy number profile. Chromosomes 7 and 9 of
the same low-grade glioma sample as in Figure 1.3. Gray horizontal bars represent segment
means, and the total number of segments detected is shown in the upper left corner. Call-
ing results are shown with colored bars. Single-copy “losses” are shown in bright red, and
“homozygous deletions” in dark red. These bars start from the bottom of the plot area and
the associated call probabilities can be read from the right-hand scale. Similarly, “gains” are
shown in bright blue and “amplifications” in dark blue, with bars that start from the top of
the plot area and probabilities of 1 - the value of the right-hand scale. As all of the bars
essentially cover the entire plot area, the call probabilities are very close to one and contain
little uncertainty.
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Next-generation sequencing for CNA detection
Sequencing laboratory process
The development of next-generation sequenc-
ing (NGS), or high-throughput sequencing,
methods allows the sequences of DNA and
RNA molecules to be deciphered much more
quickly and cheaply (Koboldt et al., 2010).
These methods have revolutionized many as-
pects of bio(medical) research, including can-
cer genomics and personalized medicine, with
many new predictive and prognostic markers
discovered (Meyerson et al., 2010).
NGS methods include technologies from a
number of companies, with Illumina, Roche
454, and SOLiD as the most popular systems
so far. Details of their respective procedures
do vary from each other, but the common fac-
tor is that each sequences fragments of DNA
in a massively parallel manner. From the per-
spective of data analysis, the practical differ-
ences are limited to the number of sequence
reads obtained per run and the lengths of
the reads. To explain the basic principles of
NGS, Illumina sequencing is used here as an
example, as it is the most widely used tech-
nology, and the original publications included
as Chapters 4 and 5 of this dissertation are
also based on Illumina data.
Briefly, isolated DNA is sheared to smaller
fragments, and adaptor molecules ligated to
each fragment. These adaptors allow the
fragments to bind to the surface of a solid
medium, the flow cell. PCR (polymerase
chain reaction; Saiki et al., 1988) is then per-
formed to multiply each individual molecule
into a cluster of DNA strands with the same
sequence to enhance detection. The flow
cell is filled with DNA polymerase and flu-
orescently labeled nucleotides that have been
modified to include a terminator, so that only
one base is incorporated at a time. A scanner
scans the flow cell separately for each of the
four dyes, and the fluorescent signals indicate
which base has been incorporated into which
cluster. Once the terminators and fluores-
cent dyes have been detached from the clus-
ters, the process is repeated. After a prede-
termined number of cycles, such as 50 or 100,
have been performed, the fragments can op-
tionally be turned over, and also their other
ends sequenced in a similar fashion to obtain
paired-end data.
Sequencing experiments can be divided
into several categories. Whole-genome se-
quencing (WGS) is used to study entire
genomes, either as de novo experiments to
assemble a novel reference genome sequence,
or more commonly as re-sequencing experi-
ments to identify how particular individuals
differ from an existing reference genome. In-
stead of sequencing the entire genome, tar-
geted experiments can also be performed that
focus only on specific areas. Before the pre-
pared DNA (or RNA) library is placed on the
flow cell, a subset of the fragments can be
captured and selected for sequencing. The
targeted subset can be for example the ex-
ome (whole-exome sequencing, WES), or a
specific set of genes, such as the kinome (Ma-
jewski et al., 2013) or a panel of cancer genes
(Sie et al., 2014). Since only a subset of the
genome is sequenced (about 1 % for WES),
this reduces costs and can therefore allow for
larger sample sizes.
A single Illumina instrument run pro-
duces millions or billions of reads, depend-
ing on the instrument model. This total ca-
pacity can be used for a single DNA sample,
but is often divided between multiple samples
with a technique referred to as multiplexing.
For multiplexing, each sample is assigned a
unique barcode sequence that is included in
its adaptor molecules. These sequences al-
low data originating from different samples
to be distinguished. There is no a priori ex-
act amount of data that can be generated per
sample. Depending on the goal of the exper-
iment, it can be flexibly controlled through
the number of samples that are multiplexed
together on each sequencing lane of a single
instrument run.
An important concept related to instru-
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ment throughput is the required amount of
sequencing (or read) coverage, which refers
to the number of times a single base position
has been sequenced. The higher the cover-
age, the higher is also the confidence with
which variations from a reference genome
can be detected. The required minimum
threshold depend on the application, statisti-
cal approaches used, and the accuracy of the
sequencing technology in question (Glenn,
2011; Wang et al., 2012). For Illumina, the
current error rate is approximately 0.5 %, and
sequence coverage of at least 10× or 30× is
generally recommended. However, the ob-
served coverage can vary greatly across dif-
ferent parts of the genome (or targeted areas
of the genome), so average coverage exceed-
ing 100× can be needed to adequately cover
some areas (Ross et al., 2013).
The quality of isolated DNA also affects
error rates and sequence coverage require-
ments. While DNA from archival FFPE ma-
terial is generally compatible with sequenc-
ing protocols (Schweiger et al., 2009; Wood
et al., 2010), deep sequencing might reveal
positions in the genome that are particularly
degraded. Also, the enrichment protocols for
WES or other types of targeted experiments
may show uneven performance with FFPE
material (Hedegaard et al., 2014).
NGS data and meta-data
A character string of DNA sequence (of the
same length) is produced for each cluster
once the scanned images have been processed.
Meta-data is also recorded for each base in
the form of a quality score, which repre-
sents the reliability of the base call in ques-
tion. After the sequence reads have been ob-
tained, they can be trimmed to remove un-
wanted sequences, such as those of the adap-
tor molecules. Then, except for de novo ex-
periments, the reads are usually aligned to a
reference genome with an algorithm such as
BWA (Li and Durbin, 2009) or Bowtie (Lang-
mead et al., 2009; Langmead and Salzberg,
2012).
Public access to raw data is the only way
to ensure transparent reproducibility of pub-
lished scientific experiments (Ioannidis et al.,
2009). Raw sequencing data can be submit-
ted to publicly accessible databases such as
The Sequence Read Archive (SRA; Kodama
et al., 2012) or The European Nucleotide
Archive (ENA; Leinonen et al., 2011). Pub-
lic availability of raw data is usually required
in order to publish results of microarray
experiments in scientific journals, but with
NGS this requirement is perhaps not (yet) as
widely enforced. One factor that may con-
tribute to the somewhat more relaxed stan-
dards could be the higher storage require-
ments. In addition, (deep) sequencing data
can potentially be highly identifiable, and pri-
vacy of the test subjects need to also be taken
into account.
Approaches for copy number analysis
by NGS
A number of methods have been published
that detect copy number alterations from
NGS data (Teo et al., 2012; Liu et al., 2013;
Zhao et al., 2013). Based on the underly-
ing principles, they can be grouped in five
general categories: 1) paired-end mapping, 2)
split-read, 3) depth of coverage, 4) assembly-
based, and 5) combinatorial methods (Alkan
et al., 2011). Each approach has its set of
strengths and limitations, and choice depends
on research goals and financial resources. The
following sections describe the basics of each
category and their applicability for cancer
and CNAs.
Comparisons of algorithms are often
based on simulations. Simulated data makes
it straightforward to measure sensitivity and
specificity of computational algorithms, as
the underlying truth is known. While sim-
ulators have been developed that reproduce
known biases from sequence context and em-
pirical platform-dependent errors (including
ART, Huang et al., 2012; pIRS, Hu et al.,
2012; GemSIM, McElroy et al., 2012; and
Wessim, Kim et al., 2013a), there is no com-
prehensive cancer simulator that would cap-
ture all the characteristics and complexities
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of tumor genomes. Therefore, instead of sim-
ulations, data generated from biological sam-
ples is often used, and the challenge becomes
to define which CNAs are real and which are
not. Array CGH can be used as a refer-
ence point, but limited resolution and lack of
reproducibility between array platforms and
processing algorithms makes it difficult to
achieve an unambiguous gold standard (Pinto
et al., 2011). Instead of benchmarked perfor-
mance, choice of method therefore often relies
on other factors, such as experimental design,
and the algorithm’s description, technical re-
quirements and implementation details (Liu
et al., 2013).
Paired-end mapping methods
The first methods to detect copy number al-
terations from NGS data were based on dis-
cordant read pairs. They are referred to
as paired-end mapping (PEM) methods, or
sometimes read-pair methods. As the name
implies, PEM methods require paired-end
data, i.e. both ends of the DNA fragments
need to be sequenced.
Discordant pairs refer to two sequence
reads from both ends of a single DNA
molecule that do not align to the reference
genome as expected. If the distance between
the read pair differs from the general distri-
bution of insert sizes, this could have been
caused by an insertion or deletion of genetic
material in-between. A read pair that aligns
to two different chromosomes is an indica-
tion of a translocation. A third possibility
is an incorrect orientation, indicating an in-
version event. Korbel et al. (2007) were the
first ones to describe a PEM-based method
to detect copy number alterations, later re-
leased the PEMer software tool (Korbel et al.,
2009). Other published algorithms include
BreakDancer (Chen et al., 2009), and Varia-
tionHunter (Hormozdiari et al., 2009).
PEM methods are fairly accurate in the
identification of breakpoint locations. But as
they require copy number events to occur be-
tween the two sequenced ends of a DNA frag-
ment, they also have significant limitations.
For example, CNAs of entire chromosomes
are not detected with PEM, since they do
not result in any discordant read pairs. In
general, the average insert size sets an upper
boundary for the size of detectable insertions
(Medvedev et al., 2009). Therefore, the pri-
mary application of PEM methods is not in
somatic CNAs, but in the study of heredi-
tary CNVs. In addition to alterations of copy
number, they are also able to detect other
types of structural variants (SVs), such as in-
versions (Sudmant et al., 2015).
Split-read methods
Split-read methods rely on breakpoints lo-
cated within reads, whereas PEM methods
identify cases where a breakpoint has oc-
curred between the two reads from both ends
of a DNA fragment. When a breakpoint is
contained within a read, the read might not
align to the reference genome, or might do
so only partially. Such reads are therefore
candidates for split-read methods. To iden-
tify the exact breakpoint location, short sub-
sets from the beginning and end of the read
are aligned independently. Each one is then
grown until the exact breakpoint is found.
As split-read methods require breakpoints to
be within reads, they depend heavily on read
length. They are therefore more suitable for
sequencing technologies that produce longer
reads, such as Roche 454 pyrosequencing.
Split-read methods depend on unique read
mapping, and reads that align equally well to
multiple locations in the genome, multi-reads,
are problematic.
The first published split-read method was
Pindel (Ye et al., 2009). One challenge for
split-read methods is the high computational
effort required to align very short sequences.
Pindel uses paired-end data facilitate this.
When one read of a pair aligns while the other
one does not, the location of the aligned read
can be used to reduce the search space for the
candidate read, and thus the computational
overhead. AGE incorporates its own align-
ment tool that targets only predefined SV
regions (Abyzov and Gerstein, 2011). Usu-
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ally split-read methods utilize WGS data, but
SLOPE was developed for targeted data and
a limited number of genomic regions of inter-
est (Abel et al., 2010).
Depth of coverage methods
The NGS approach that is conceptually most
similar to CGH microarrays, is termed depth
of coverage (DOC). The amount of read cov-
erage, or depth, along the genome is mea-
sured by counting reads. These counts re-
flect the underlying DNA copy number, and
can be thought of as analogous to fluo-
rescent signal intensities of CGH microar-
rays. A conceptual difference compared to
both PEM and split-read methods is that
they detect breakpoints (at the boundaries
of copy number alterations), while DOC de-
tects the copy number alteration (between
breakpoints). Although there are also meth-
ods based on density (such as SeqCBS; Shen
and Zhang, 2012), DOC methods usually di-
vide the genome into bins and count the num-
ber of reads in each bin. How the binning is
defined varies between methods. The num-
ber of reads in each bin can be fixed to a
specific value, and size of bins can be varied
accordingly along the genome, such as with
SegSeq (Chiang et al., 2009). More com-
monly, the size of bins is fixed across the
genome. The bins can either overlap, such
as with CNV-seq (Xie and Tammi, 2009), or
be adjacent to each other. Some algorithms
let the user choose the bin size, while oth-
ers determine it automatically based on the
amount of sequence data. When the aim is to
analyze a data set consisting of multiple sam-
ples, it can facilitate downstream analyses if
the same bin size is used for all samples. The
underlying principle behind all DOC meth-
ods is that the obtained sequence coverage
along the genome depends on the underlying
copy number. However, there are also vari-
ous biases that affect the observed coverage
(Aird et al., 2011; Nakamura et al., 2011; Ross
et al., 2013; Taub et al., 2010). Different au-
thors have taken different approaches on how
to handle them.
Due to its cost-efficiency, WES is an at-
tractive alternative to WGS for re-sequencing
experiments that aim to detect cancerous mu-
tations within coding regions of the genome.
Although some methods, such as Control-
FREEC (Boeva et al., 2012), can be used
with both WGS and WES data, many meth-
ods cannot handle WES data due to its dis-
continuity and biases introduced by the cap-
ture process. Dedicated tools have there-
fore been developed for WES data, such as
ExomeCNV (Sathirapongsasuti et al., 2011),
VarScan 2 (Koboldt et al., 2012), ABSO-
LUTE (Carter et al., 2012), and EXCAVA-
TOR (Magi et al., 2013). Guo et al. (2013)
have published a comparison of WES-based
copy number tools and array CGH, although
their emphasis is on CNVs instead of CNAs.
An alternative approach to DOC-based copy
number detection from WES (or other types
of targeted) data was taken by Kuilman et al.
(2015). They utilize off-target reads that
align to the reference genome outside the tar-
geted areas, and can thus be thought of to
represent data from a low-coverage WGS ex-
periment. Talevich et al. (2016) extended this
approach to utilize both on- and off-target
reads.
The workflow of DOC methods is covered
in more detail in a subsequent section. This
is because of its overall importance for the
study of CNAs, and also because the upcom-
ing Chapter 4 describes a DOC method, and
Chapter 5 an application of this method to a
set of LGG samples.
Assembly-based methods
Cancer genomes can undergo massive rear-
rangements, and the most flexible and com-
prehensive approach to detect them is to
use assembly-based methods. Instead of re-
lying on read alignment to an existing ref-
erence genome, these methods use overlap-
ping reads to assemble contigs, continuous se-
quences constructed from smaller fragments
(Staden, 1979). The contigs can then be com-
pared to the reference genome.
Instead of assembling completely de novo,
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a reference genome can be used as a guide,
which can improve computation times and
contig quality. This is referred to as
“comparative genome assembly” (Pop et al.,
2004). Assembly-based methods include
Velvet (Zerbino and Birney, 2008), ABySS
(Simpson et al., 2009), SOAPdenovo (Li
et al., 2010), Cortex (Iqbal et al., 2012), and
Magnolya (Nijkamp et al., 2012).
While assembly-based methods offer a po-
tentially unbiased approach to discover novel
variants, they have large computational de-
mands and require high sequence coverage
(40×) (Li et al., 2010). In practice, this
makes them suitable only for the (thorough)
analysis of individual or small number of
cases, instead of larger data sets. Also, highly
repetitive parts of the genome are challenging
to assemble, and additional techniques that
produce longer continuous sequences might
be needed, if such areas need to be covered
as well.
Combinatorial methods
There are also packages that are based on a
combination of approaches presented above,
most commonly PEM with another cate-
gory. The most common combination is
to use DOC to detect copy number alter-
ations, and further improve breakpoint detec-
tion by incorporating PEM. These methods
include SDDetect (Zeitouni et al., 2010), CN-
Ver (Medvedev et al., 2010), Genome STRiP
(Handsaker et al., 2011), GASVPro (Sindi
et al., 2012), and inGAP-sv (Qi and Zhao,
2011). Another approach is the combina-
tion of PEM and split-read methods. How-
ever, these are primarily utilized to detect
SVs, not CNAs. Such methods include Nov-
elSeq (Hajirasouliha et al., 2010) and SVseq
(Zhang and Wu, 2011). HYDRA combines a
PEM-based method and local de novo assem-
bly (Quinlan et al., 2010), and BreaKmer is a
combination of split-read and local assembly
(Abo et al., 2015).
Compared to PEM, split-read methods
provide more accurate detection of break-
point locations and therefore offer another
complement for DOC. Such methods have
been presented by Nord et al. (2011) and
McKernan et al. (2009). Since PEM methods
generally require WGS data, the combination
of DOC and split-read methods are more suit-
able for target-enriched, such as WES, data.
Copy number analysis of DOC data
After briefly describing different approaches
of copy number detection from NGS data,
this section takes a more detailed look into
the analysis of DOC data, for three reasons.
First, two of the original publications in-
cluded in this dissertation are based on DOC.
Second, since DOC bears many conceptual
similarities to the analysis of microarray data,
some of what was covered on microarray anal-
ysis in the beginning of this chapter also be
applied to DOC copy number data as well.
And third, as will be discussed later, similar
approaches for downstream analyses can be
used for both microarray and DOC data.
The structure of bin-level DOC data is
very similar to that of microarrays; a ma-
trix with rows corresponding to bins along the
genome and columns representing individual
samples. The difference is that instead of flu-
orescent intensities, the matrix contains read
counts. In general, its analysis also follows
a similar path as with microarrays: prepro-
cessing followed by segmentation and calling
(Figure 1.2).
Preprocessing corrects for biases, such
as GC content and mappability, and fil-
ters out problematic areas, such as cen-
tromeres, telomeres, and other repetitive se-
quences. Segmentation and calling iden-
tify breakpoints and estimate copy numbers.
Available software packages vary in whether
they contain all or part of these steps.
Preprocessing of DOC data
The most-characterized bias in observed se-
quencing coverage is caused by GC con-
tent (the proportion of guanine and cytosine
bases), as first described by Bentley et al.
(2008). Most DOC methods calculate the
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GC content of each bin, and use the value
to correct the read count for the bin (Yoon
et al., 2009). Benjamini and Speed (2012)
have shown that this is a good approximation
in most cases, but can be further improved
by separately calculating the GC content of
each DNA fragment that has been sequenced.
This requires paired-end data so that both
end points, and therefore the entire sequence,
of the fragment are known.
Another widely recognized source of bias
is mappability, which refers to the unique-
ness of sequences in the reference genome. It
depends on the length of the sequence and
the number of mismatches allowed (White-
ford et al., 2005). If Fk(x) is the frequency
at which the k-mer sequence at position x in
the genome can be found in the entire ref-
erence genome (and its reverse complement),




. Regions with low mappa-
bilities contain highly repetitive sequences,
which are problematic for all copy number
detection methods. Excluding them from the
analysis helps reduce false positives. Mappa-
bilities can be calculated with programs such
as GEM tools (Derrien et al., 2012). DOC
methods typically use the average mappabil-
ity of a bin for corrections and/or filtering.
The simplest approach to handle biases,
is to require a separate normal reference sam-
ple, and to divide the read counts of the test
sample with those of the reference. Since
the bin GC contents and mappabilities are
naturally the same for both samples, they
could both be assumed to be similarly af-
fected. However, as the GC content bias de-
pends on the GC content of the molecules
being sequenced, it is affected by the distri-
bution of fragment lengths (Benjamini and
Speed, 2012). If these vary between DNA
libraries, the extent of the GC content bias
will also be affected. Therefore, relying on
a ratio between test and reference samples is
an insufficient approach to handle this bias.
Also, an approach such as the one taken by
CNAnorm of performing a correction for GC
content, but only after taking the ratio is sub-
optimal (Gusnanto et al., 2012). Ideally, GC
content bias should be corrected separately
for each sample, including possible reference
samples.
Not all DOC methods require normal ref-
erences samples. Two such algorithms are
FREEC (Boeva et al., 2011) and readDepth
(Miller et al., 2011). They both perform cor-
rections for GC content and mappability, and
also filter out low-mappability regions. Chap-
ter 4 (Scheinin et al., 2014) describes the QD-
NAseq method, which also is also based on
DOC and does not require a reference sam-
ple.
Segmentation and calling of DOC data
As in the previous sections, here segmen-
tation and calling refer to identification of
continuous stretches along chromosomes that
most likely share the same copy number and
are separated by breakpoints, and assignment
of discrete copy number levels to these seg-
ments. Similar algorithmic approaches are
used for these purposes as with microarrays.
Patchwork (Mayrhofer et al., 2013), Ex-
omeCNV (Sathirapongsasuti et al., 2011),
and VarScan 2 (Koboldt et al., 2012) all
perform segmentation with the popular CBS
algorithm, which was originally developed
for the analysis of CGH microarrays (Ol-
shen et al., 2004; Popova et al., 2009; Ol-
shen et al., 2011). OncoSNP-SEQ (Yau,
2013) and HMMCOPY (Ha et al., 2012)
are both based on HMMs, another popular
analytical approach for CGH arrays. For
calling, many methods are based on sim-
ple cutoffs, including BIC-seq (Xi et al.,
2011), ExomeCNV (Sathirapongsasuti et al.,
2011), FREEC (Boeva et al., 2011), read-
Depth (Miller et al., 2011), SegSeq (Chiang
et al., 2009), and VarScan 2 (Koboldt et al.,
2012). Due to challenges caused by cellular-
ity, heterogeneity, and polyploidy, cutoffs of-
ten need to be defined on a case-by-base ba-
sis, and more sophisticated approaches based
on statistical models could result in similar
improvements in calling as with microarrays.
One reason for the use of cutoffs could be that
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many copy number methods for NGS are fo-
cused on detecting aberrations in individual
samples, not for the concurrent analysis of
larger data sets.
Like CGH microarrays, low-coverage
DOC methods are unable to detect cnLOH.
When sequence coverage is deep enough for
variant calling, DOC data can be supple-
mented with variant allele frequencies. These
aid in detection of cnLOH, and can also allow
estimation of cellularity (for example Patch-
work, Mayrhofer et al., 2013; CNAnorm,
Gusnanto et al., 2012; OncoSNP-SEQ, Yau,
2013; HMMCOPY, Ha et al., 2012; and
Control-FREEC, Boeva et al., 2012) and
ploidy (Patchwork, CNAnorm, OncoSNP-
SEQ, and HMMCOPY). As WES experi-
ments have higher coverage, methods devel-
oped for WES data have typically been de-
signed to incorporate allele frequencies in es-
timation of copy numbers.
For the analysis of cancer samples and de-
tection of CNAs, it should be noted that some
DOC copy number methods that have been
developed specifically for germline CNVs
might include assumptions and optimizations
that make them unsuitable for somatic CNAs
(Magi et al., 2012). For example, JointSLM
(Magi et al., 2011), ERDS (Zhu et al., 2012),
and CoNIFER (Krumm et al., 2012) reduce
false positives by filtering out sharp, non-
recurrent peaks, since they are thought to
represent artifacts. If these methods are ap-
plied to tumor genomes, somatic CNAs might
remain undetected.
Analysis of DOC data conceptually con-
sists of the same steps as array CGH anal-
ysis: preprocessing followed by segmentation
and calling. In microarray analysis, the im-
plementation of these methods is often rela-
tively modularized and they can be combined
as desired. As an example, users can choose
to perform wave corrections with either re-
gression on GC content (Diskin et al., 2008)
or using a calibration data set (van de Wiel
et al., 2009), and free to choose their segmen-
tation and calling methods of choice. How-
ever, many DOC methods are not designed to
be modular in the same way. They perform
their entire pipeline of preprocessing, segmen-
tation and calling, and then produce one or
more output files. Therefore, it can require
extra effort to, for example, combine the pre-
processing of one method with the segmen-
tation and calling of another. The format
and contents of these output files also vary
between methods. For example, readDepth
(Miller et al., 2011) returns only segment-
level ratios and calls without full bin-level
preprocessed data. It is therefore impossible
to combine its preprocessing with other pack-
ages. FREEC (Boeva et al., 2011) on the
other hand produces all three levels of prepro-
cessed, segmented and called data, thus mak-
ing it possible for users to combine it with
other methods if they so wish.
The microarray community has benefited
enormously from standardization and modu-
larization. The popular Bioconductor suite
(Gentleman et al., 2004; Huber et al., 2015)
defined MIAME-compliant (Brazma et al.,
2001) and extensible data structures for mi-
croarray data, which have been used by nu-
merous packages. Due to the common data
structures, these tools can be used in a mod-
ular fashion. Also, meta-packages that com-
bine multiple tools together facilitating com-
parisons have been developed (Diaz-Uriarte,
2014) Due to the maturity of array technol-
ogy, many analytical CNA packages are also
relatively mature. They have accumulated
years of usage from numerous labs with real
experimental data. This has resulted, at least
in the best-case scenarios, in improvements
in efficiency and fine-tuning options, and also
exposure and fixing of possible programming
mistakes. Segmentation and calling methods
that have been developed for arrays are there-
fore interesting candidates for the analysis of
preprocessed DOC data as well.
Array methods usually assume the log2-
ratios follow a Gaussian distribution, while
read counts come from a Poisson distribu-
tion. However, most DOC methods do ap-
proximate the Poisson with Gaussian. Excep-
tions include readDepth (Miller et al., 2011),
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which uses a negative-binomial, and BIC-seq
(Xi et al., 2011), which is based on minimiz-
ing a modified BIC (Bayesian information cri-
terion) and an approach where the distribu-
tional assumption cancels out of the equa-
tion. Therefore, use of the Gaussian distri-
bution should not rule out use of array meth-
ods with DOC data. Furthermore, an ap-
propriate transformation can be used. The
Anscombe transform (A : x → 2
√
x+ 38 )
transforms a Poisson distributed variable to
one with an approximately standard Gaus-
sian distribution (Anscombe, 1948).
Efforts towards shared data structures for
DOC data would facilitate not only modular
use of tools developed for DOC data, but also
utilization of already established microarray
methods. And since common data structures
already exist for microarrays, they offer a
potential candidate for developers of DOC-
based methods as well. This would also facil-
itate downstream analyses.
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Downstream analyses of CNAs
The term downstream analyses is used here to
refer to procedures used not to detect CNAs
of individual samples, but rather for the in-
terpretation of CNAs in a series of cancer
samples. This type of downstream analy-
ses include standard statistical testing and
learning procedures, such as hypothesis test-
ing, clustering, and classification. This sec-
tion discusses characteristics of copy number
data, and corresponding analytical steps to
be taken into account while applying these
procedures. Most of the specific software
packages mentioned in this section were origi-
nally developed for microarray data analysis,
but can often be directly (or possibly with the
Anscombe transformation) applied for DOC-
based NGS data as well. Copy number alter-
ations detected from NGS data with another
type of method besides DOC can also easily
be converted to a format suitable for these
packages. The focus is on experiments that
utilize copy number data alone. Integration
of copy number with mRNA or miRNA ex-
pression (Louhimo et al., 2012), DNA methy-
lation (Sokolova et al., 2016), or proteomic
(Zhang et al., 2016) data is therefore not cov-
ered, although these integrative experiments
can be crucial for identification of the driving
cancer genes behind specific CNAs and thus
better understanding of their significance.
Three topics that apply to all categories of
downstream analyses are 1) the type of data,
2) the sample size, and 3) the dimensional-
ity of the data, and these topics are briefly
described first. 1) The type of data, refers
to whether preprocessed, segmented, or called
copy number data is used. There is no un-
ambiguous consensus on which one should be
used for downstream analyses, and there are
examples of all three in published literature
(van Wieringen et al., 2007).
2) Sample size refers to the number of bio-
logical samples (typically number of columns
in the data matrix) in the data set. While
the question of adequate sample size is rele-
vant to all types of downstream analyses, it
is most clearly defined in the context of hy-
pothesis testing with statistical tests. Sam-
ple size calculations (or power calculations)
can be used to define how many samples are
needed to achieve a pre-determined level of
statistical confidence. These calculations can
be roughly divided to two groups: a) meth-
ods that ask the user to specify values for the
required parameters (effect size, variance, de-
sired significance level, and desired statistical
power), and b) methods that estimate these
parameters from a pilot data set. Chapter 3
(Scheinin et al., 2010) will present our efforts
to develop a tool for sample size calculations
in the setting of CNAs between two groups of
cancer samples.
3) Dimensionality of the data refers to
the number of genomic features (rows in the
data matrix). These can be elements on
a microarray or DOC sequence bins in an
NGS experiment. The next section intro-
duces an additional option, dimensionality-
reduction through regioning, and discusses its
potential benefits.
Regioning to reduce dimensionality
Individual copy number data points are dis-
persed along the chromosomes, and break-
points can occur anywhere between (or
within) these elements. This applies equally
to data points that correspond to elements
on a microarray or DOC bins from an NGS
experiment, but also to data that has been
transformed so that each known gene is rep-
resented as a separate data point. As the
size of CNAs vary from entire chromosome
arms to focal aberrations, an individual CNA
can contain anything from thousands of data
points to only one or two. For multivari-
ate downstream analyses, such as clustering,
this could have profound consequences as
large CNAs can be given much more weight
than smaller ones, even though the latter can
be biologically just as important (Krijgsman
et al., 2014).
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Another challenge that is common with
genomics data is known as “the curse of di-
mensionality”. It refers to the fact that the
number of biological samples included in a
typical experiment is much smaller the num-
ber of genomic features measured per sample.
This can lead to a massive multiple testing
issue, which can be mitigated if the dimen-
sionality can be reduced.
For copy number experiments, dimension-
ality can be reduced by regioning. That is,
by identifying stretches of consecutive fea-
tures along chromosomes that behave simi-
larly across the entire data set, and collapsing
them to single data points. Thus, regions can
be thought of as a data-driven unit that aims
to capture the underlying biological phenom-
ena behind copy number alterations. The def-
inition of similar behavior can be strict, or
some loss of information can be allowed in
the detection of breakpoint locations (van de
Wiel and van Wieringen, 2007). An example
of regioning results is presented in Figure 1.5,
which shows a frequency plot of CNAs in 98
LGG patient samples.
Regioning in this sense requires the use of
called data. Dimensionality can also be re-
duced with PCA (principal component anal-
ysis) on preprocessed data, and the resulting
components though to represent supersets of
genomic features. Interpretation of such data
can be difficult, but the procedure can help
to make visualizations in two or three di-
mensions. Similar factoring can also be per-
formed with called data (Jöreskog and Mous-
taki, 2001).
Now that copy number analysis of mi-
croarray and DOC-based NGS data (Figure
1.2) and dimensionality reduction with re-
gioning have been described, the workflow
diagram presented in Figure 1.1 can be up-
dated. The full analytical workflow from raw
data into statistical tests and statistical learn-
ing methods is presented in Figure 1.6.
Identification of recurrent aberrations
The goal of some CNA studies is to identify
the most frequent aberrations for a specific
cancer type or subtype. If these CNAs are
sufficiently small, it can be possible to pin-
point which of the genes within the aber-
ration are the driving oncogenes or tumor-
suppressor genes. This often requires inte-
gration of other types of information, such
as which genes are expressed in the tissue
or cell type in question under normal con-
ditions, which genes located within gains or
losses show over or under-expression, respec-
tively, in the cancer samples, or functional
assays to screen for tumorigenic activity of
the gene products.
Rouveirol et al. (2006) first introduced the
concept of recurrent minimal aberrations. If
the regioning described in the previous sec-
tion has been performed, the most common
aberrations can be identified simply by com-
paring aberration frequencies of consecutive
regions, and pinpointing regions with higher
frequencies than their neighbors. A number
of other approaches and software packages
have also been described, including the pop-
ular GISTIC (Genomic Identification of Sig-
nificant Targets in Cancer; Beroukhim et al.,
2007) algorithm. The packages vary in their
required input (calls, or preprocessed or seg-
mented log2-ratios). Use of called data has
the advantage of reduced noise, but may lead
to lower sensitivity due to the loss of infor-
mation compared to log2-ratios (Shah, 2008).
On the other hand, use of log2-ratios can
suffer from differences in magnitude between
samples, caused by differences in cellularity,
and possible polyploidy and heterogeneity.
These issues can be reduced with the use of
call probabilities (soft calls) that combine the
noise-reducing effect of calls without losing
information on the certainty of the aberra-
tion (Rueda and Diaz-Uriarte, 2009).
Statistical tests for association with
clinical data
Many CNA studies aim to identify associa-
tions between specific aberrations and clinical
variables. To detect CNAs associated with a
clinical outcome, such as tumor progression,
relapse, treatment success, or survival, stan-
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Figure 1.5: Frequency plot of CNAs. Frequencies of gains (shown with blue bars) and losses
(red) of the 98 NGS samples of the LGG study (Chapter 5; van Thuijl et al., 2014). After
copy number analysis (preprocessing, segmentation, and calling), dimensionality has been












Figure 1.6: Full analytical workflow of CNAs. Starting from raw microarray or NGS data,
the analytical workflow proceeds first through platform-dependent copy number analysis,
which for microarrays and DOC-type NGS can be separated into preprocessing, segmenta-
tion, and calling. As a preliminary step in downstream analyses, dimensionality-reduction
with regioning helps with multiple testing issues and better captures the underlying biology
behind CNAs of various sizes. As there is no clear consensus on whether all included steps
are necessary, the dashed arrows depict alternative workflows. Other approaches for NGS
besides DOC are not included in the diagram.
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dard statistical tests are used. Such tests can
be performed on log2-ratios (preprocessed or
segmented) or called data (per original ge-
nomic feature or per region).
Methods such as the standard Student’s t-
test assume Gaussian distributions. This as-
sumption is not valid for log2-ratios of copy
number data, because of the discrete nature
of the underlying biology. Non-parametric,
rank-based tests, such as Wilcoxon–Mann–
Whitney test (Mann and Whitney, 1947), are
therefore more suitable. But since they have
been designed to have power for shift rather
than multi-modality, tailored non-parametric
tests could be more optimal (van Wieringen
et al., 2008a).
When working with copy number calls,
one can use common non-parametric tests,
such as the χ2 (chi squared) test for group
comparisons, or the log-rank test for survival.
These tests can be used for original genomic
features or regions. As regioning reduces di-
mensionality, the multiple testing corrections
are not as severe, which improves sensitivity
(van de Wiel et al., 2005; van de Wiel and
van Wieringen, 2007). Chapter 5 will cover
an example of the log-rank test with regions
for the association between CNAs and sur-
vival of LGG patients.
The use of discrete hard calls fails to
take into account their possibly uncertainty
(caused for example by the varying propor-
tion of cells that contain a specific aberra-
tion), and therefore loses information com-
pared to the log2-level data. Higher power
can be achieved with the inclusion of the call
probabilities (soft calls) (van de Wiel et al.,
2007; González et al., 2009).
Clustering for subtype discovery
Another common goal of copy number studies
in cancer research is data-driven subtype dis-
covery. Cluster analysis, or clustering, is an
unsupervised learning method with the aim
to group samples so that objects within a
group (or cluster) are more similar to each
other than to those in other groups. Various
metrics can be used to measure this similarity
(van Wieringen et al., 2008b).
As cancer is a heterogeneous group of dis-
eases, it is well suited for cluster analysis.
Cancers of a given tissue or organ typically
consist of multiple different subtypes. Anal-
ysis of CNA patterns has been shown to be
successful in identifying these subtypes (Chin
et al., 2007b; Smeets et al., 2011). Simi-
larly, meta-analyses of various cancer types
has shown that cancers with similar etiol-
ogy, cell-of-origin, or topographical location
cluster together based on their CNA pro-
files (Myllykangas et al., 2006; Jong et al.,
2007). Clustering of CNA data was initially
performed with log2-ratios, first with prepro-
cessed (Wilhelm et al., 2002) and then with
segmented data (Jong et al., 2007). Tailored
clustering methods for copy number data
have since then also been developed. These
include k-means (Liu et al., 2006) and hierar-
chical (van Wieringen et al., 2008b) clustering
approaches. Both present distance measures
that have been developed to deal with dis-
crete data.
If the distance metrics are calculated from
all original genomic features, larger aber-
rations are given considerably more weight
than smaller ones. However, as the biolog-
ical consequences of a small focal aberration
can be as important as those of a whole-
chromosome arm (Krijgsman et al., 2014), di-
mensionality reduction through regioning can
lead to alternate, presumably improved, clus-
tering (van Wieringen et al., 2008b; Liu et al.,
2007). Chapter 5 (van Thuijl et al., 2014)
will present examples of clustering for LGG
patients based on copy number regions and
soft calls.
In addition to the distance-based meth-
ods discussed above, model-based approaches
have also been used, for example using HMMs
(Shah et al., 2009). A comparison of cluster-
ing methods for copy number data has been
published by Brito et al. (2013). An alter-
native approach for subgroup discovery is to
use PCA (or another similar dimensionality
reduction technique), and to identify clusters
by visual inspection of low-dimensional plots
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(Somiari et al., 2004; Unger et al., 2008). The
downside is harder interpretability of differ-
ences between subtypes, because the result-
ing components ignore the order and location
of the original features along the genome, and
thus do not represent a entity with a biologi-
cal interpretation.
41
Aims of this dissertation
The aim of my PhD was to develop bioinformatic solutions for copy number analysis in
cancer. Broken down to separate projects that are covered by the original articles included
in this dissertation as upcoming chapters, the aims were as follows:
1. To develop a database solution for storage of raw and processed copy num-
ber data from cancer samples. A solution should support queries based
on clinical variables and specific copy number alterations. It should also
be MIAME-compliant and publicly accessible. The developed solution, a
database called CanGEM, is described in Chapter 2.
2. To develop a solution for sample size calculations for copy number exper-
iments that compare two groups of cancer samples. A solution should al-
low the assessment of how many samples are required to satisfy statistical
requirements. It should use pilot data to estimate the necessary model pa-
rameters. The CGHpower sample size tool is described in Chapter 3.
3. To develop a solution to detect copy number aberrations from cancer sam-
ples with NGS and the DOC approach. A solution should allow corrections
for known systematic biases and filtering of problematic areas in the genome.
It should also be compatible with archival material. The QDNAseq prepro-
cessing method is described in Chapter 4, and an application is presented
for a series of low-grade glioma patient samples in Chapter 5.
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Sakari Knuutila3 and Juha Saharinen1,2,*
1Genome Informatics Unit, Biomedicum Helsinki, Finland, 2Department of Molecular Medicine, National Public
Health Institute of Finland, KTL and 3Departments of Pathology, Haartman Institute and HUSLAB, University of
Helsinki and Helsinki University Central Hospital, Helsinki, Finland
Received August 15, 2007; Revised September 16, 2007; Accepted September 17, 2007
ABSTRACT
The use of genome-wide and high-throughput
screening methods on large sample sizes is a
well-grounded approach when studying a process
as complex and heterogeneous as tumorigenesis.
Gene copy number changes are one of the main
mechanisms causing cancerous alterations in
gene expression and can be detected using array
comparative genomic hybridization (aCGH).
Microarrays are well suited for the integrative
systems biology approach, but none of the existing
microarray databases is focusing on copy number
changes. We present here CanGEM (Cancer
GEnome Mine), which is a public, web-based data-
base for storing quantitative microarray data and
relevant metadata about the measurements and
samples. CanGEM supports the MIAME standard
and in addition, stores clinical information using
standardized controlled vocabularies whenever
possible. Microarray probes are re-annotated with
their physical coordinates in the human genome and
aCGH data is analyzed to yield gene-specific copy
numbers. Users can build custom datasets by
querying for specific clinical sample characteristics
or copy number changes of individual genes.
Aberration frequencies can be calculated for these
datasets, and the data can be visualized on the
human genome map with gene annotations.
Furthermore, the original data files are available for
more detailed analysis. The CanGEM database can
be accessed at http://www.cangem.org/.
INTRODUCTION
With the exception of few hematologic malignancies
that are characterized by a single chromosomal change,
e.g. the BCR-ABL1 fusion gene in chronic myelogenous
leukemia (1), cancer is generally a complex disease.
Especially carcinomas, which usually undergo prolonged
carcinogenesis and account for over 80% of cancer-related
deaths (2), are usually characterized by chaotic genomic
changes. Chromosomal or gene copy number alterations
are one of the most important mechanisms that perturb
normal gene function by inducing changes reflected in
gene expression (3). Other types of changes include
mutations (inherited or somatic), translocations and
changes in epigenetic make-up that affect the gene
regulation machinery and protein structure and function.
During carcinogenesis and cancer progression, activation
and malfunction of a number of cancer genes are
required for cancer cells to gain the independence of
growth supporting signaling and immunity to growth
restrains, evade apoptosis and replicate unlimitedly,
sustain angiogenesis and escape the control of the
anatomical primary site, thus, acquire the hallmarks of
cancer (4). In addition to cancer, gene copy number
aberrations are also important in many congenital
disorders, especially small deletions that are detectable
using high-resolution aCGH.
Array comparative genomic hybridization (aCGH) is
a technique that uses microarrays to detect changes in
gene copy number, and is widely used in cancer research
to characterize different tumors and hematologic malig-
nancies (5). Arrays can be manufactured using different
techniques, and recently synthetic oligonucleotides have
been gaining popularity from spotted BAC or cDNA
clones (6). As the selection of used arrays is wide, it is
necessary to be able to integrate data measured with
different platforms, in order to be able to do large-scale
studies. This is further emphasized by the in-house
manufactured spotted arrays.
Copy number aberrations comprise of deletions and
amplifications, which promote cancer by acting on tumor
suppressor genes and proto-oncogenes, respectively. These
genes can be commonly termed as ‘cancer genes’. Because
aberrations are formed through a process of common
*To whom correspondence should be addressed. Tel: +358 9 4744 8969; Fax: +358 9 4744 8480; Email: juha.saharinen@ktl.fi
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
breakpoint errors in DNA replication and/or repair
followed by natural selection, the altered genomic
regions usually contain not only cancer genes, but also
bystanders. Identification of the driving genes is essential
in understanding cancer biology as well as for clinical
applications, namely, prognostics, diagnostics and thera-
peutics, where specific targets are sought after. Because
of the complexity of carcinogenesis and the nature of
the process creating aberrations, large-scale screening
studies are needed to achieve this goal.
The existing microarray databases [such as
ArrayExpress (7), Gene Expression Omnibus (8), and
Stanford MicroArray Database (9)] are focused on gene
expression data and do not provide tools for studying
copy number changes. We present here CanGEM (Cancer
GEnome Mine), which is a public, web-based database
service for storing clinical information about tumor
samples and related microarray data. Emphasis is on
copy number changes, but also other types of microarray
data can be stored, including locus heterogeneity and
gene expression data, typically when collected from the
same samples.
DESIGN, IMPLEMENTATION AND USAGE OF
CANGEM
Database structure
The structure of the CanGEM database is MIAME-
compliant (10) and flexible in allowing the storage of
different file formats from different software packages.
Figure 1 summarizes the relationships between different
data entities that are used in this article to describe
the database.
Annotation of samples
In order to support systematic research, samples in
CanGEM are annotated using classification systems
based on controlled vocabularies, instead of free text
descriptions common in many gene expression microarray
databases. To describe the topographical and morpholo-
gical attributes of the cancer, we are using chapter II
(Neoplasms) of the International Statistical Classification
of Diseases and Related Health Problems (10th Revision;
ICD-10) and International Classification of Disease for
Oncology (3rd Edition; ICD-O-3) of the World Health
Organization (WHO). They are both three-step hierarchi-
cal ontologies that allow a precise classification of the
cancer types and morphologies. If it is not possible to
classify a particular sample up to the most detailed level,
the definition can be left at the previous, broader stage.
It is also possible to assign multiple definitions to a
single sample.
We have also adopted the classification system of































Figure 1. Database structure. This figure summarizes the relationships
between the different data entities that are used in the database.
Microarray results are obtained from a single microarray hybridization
and contain a text file with a numerical representation of the measured
spot intensities obtained from the scanned array with an image analysis
software. It can also include the image file itself. In addition to these
files, results contain links to the biological specimens (samples),
experimental procedures (protocols) and the specific microarray plat-
form that were used to obtain the results. The protocols section is
divided into eight different stages: extraction, digestion, amplification,
labeling, hybridization, washing, scanning and image analysis. Together
they correspond to the methods section of an article preceding the
data analysis stage. Sample and protocol information is submitted
to the database separately from the microarray results to allow the
reuse of the same samples and protocols for multiple hybridizations.
An example is a study that integrates the results of multiple array
techniques, such as both copy number and expression data. A number
of results can be combined into a series, and multiple series can
be further combined to form an experiment, which corresponds to
a published article. All of the data entities mentioned above are
contained within projects, which allow user permissions to be specified
on a per user account or per research group basis. The service can
therefore be used to aid data sharing between collaborators in
preliminary prepublication stages, or to give access to manuscript
referees. Even though this could also allow the users to continue to
limit the availability of their data, everything uploaded to the CanGEM
database should be made publicly available once the researchers’ get
their results published. There are also two data types that are user-
account specific: uploads and datasets. They are only visible to that
specific user account. Uploads are files (e.g. microarray result files) that
have been uploaded to the web server, but not yet used to create an
actual database entry. Datasets are user-defined collections of micro-
array data, and can be constructed manually or as saved search queries.
These smart datasets get updated automatically and can be configured
to send email alerts when their contents change, i.e. when new
microarray data become available that match previously defined search
criteria, e.g. of tissue type, cancer type and age group of interest. The
difference between datasets and microarray results, series and experi-
ments, is that the latter ones are defined by the original submitter and
are the same for everybody, while every user can create custom datasets
to meet their specific needs. , Asterisk represent the numbers next to
the lines connecting the boxes describe the relationship between the two
data entities. For example, each microarray result is linked to either
one or two samples depending on the array type, and this is denoted
with 1..2. Each sample can be used for an arbitrary number of
microarray results, which is depicted with the symbol.
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to classify gene expression libraries (11). It contains a total
of 10 categories, of which we are using six: anatomical
system, cell type, development stage, pathology, tissue
preparation and treatment. eVOC provides hierarchical
classification systems with a varying number of levels.
As with ICD, it is possible to assign multiple ontology
terms to a single sample.
For classifying the stage of the cancer, we are using the
TNM Classification, which is a systematic way of
describing the size and spread of a tumor. It uses three
values to describe the size of the primary tumor (T), and
whether the cancer has spread to the lymph nodes (N), or
to more distant locations in the body (M).
In addition to these classification systems, we are also
collecting information about exposure to environmental
risk factors, patient sex, tumor size, survival, cause of
death, and whether surgery has been done and if it was
curative or not. All of the clinical attributes as well as the
ICD and eVOC ontologies can be used to search for
samples in the database.
Our current sample annotations are rather cancer-
specific, but in the future we will be updating the system
to better account for other possible uses of array CGH.
Annotation of microarray platforms
Different microarray platforms contain different sets of
probes identified by different sets of IDs, which makes
it difficult to integrate data from multiple sources.
When working with array CGH, this problem is further
complicated by the fact that the technique is not gene-
centric. BAC arrays, still used for CGH, contain probes
that can be 300 kb long and contain several genes. Oligo
arrays on the other hand can contain probes that have
been specifically designed to match regions between genes.
To overcome this problem, we are using probe sequences
to re-annotate the microarray probes to physical coordi-
nates of the human genome with a custom iterative
algorithm based on MegaBlast (12). Further, this
approach enables CanGEM to unite aCGH, LOH and
gene expression data through physical coordinates in
the future.
In the case of oligonucleotide arrays, the entire sequence
of the probe is known, and it often corresponds to
an unambiguous and continuous chromosomal sequence.
However, with cDNA probes, in most cases, intronic
regions split probes to more than one matching exons
resulting in multiple blast hits. Also, in the case of
cDNA or BAC arrays, the probes are generally too long to
be sequenced entirely, and the sequenced sections are from
the ends of the probe (preferably from both). After all the
sequences for a specific probe have been analyzed,
CanGEM joins the mapping results together if all hits
are from the same chromosome, and the entire length
of the joined probe does not exceed 2.5 Mbp of genomic
DNA (the longest human gene in Ensembl 45 is 2 304 117
base pairs). If these conditions are not met, the probe
is marked as ambiguous and excluded from further
analysis. The probe-to-genome mapping results are
saved to CanGEM and used for analysis of submitted
microarray data, and the mapping procedure is repeated
when a new build of the human genome becomes
available. Currently, all the microarray platforms
available in CanGEM have been mapped to both NCBI
builds 35 and 36. The mapping process is illustrated in
Figure 2A.
Currently, the two-color platforms suitable for
array CGH in CanGEM include cDNA and oligo-based
arrays from Agilent Technologies (12K cDNA, 22K
oligos, 44K oligos for CGH and expression, 244K oligo
CGH) and one custom cDNA array. Supported one-color
expression platforms include Affymetrix U133 and U95
arrays. Furthermore, introduction of new array platforms
is done easily.
Submission of data to CanGEM
CanGEM is an open and publicly accessible data
repository. However, in order to submit data to
CanGEM, users need to register for a (free) user account,
which then becomes the owner of that data. Currently,
all data submission operations are done through a web
browser, and the different data entities are created by
filling out simple web forms. For submissions of larger
sets of data, a batch tool is available for inserting
multiple microarray results. Also, new samples can be
created using an existing one as a template speeding
up the process, as samples in a single microarray experi-
ment usually share similar characteristics. Step-by-step
documentation of the submission process can be found
from the CanGEM website. The availability of the
submitted data can be controlled as explained in more
detail in the legend of Figure 1.
This project has been reviewed and approved by
the Ethical Review Board of Helsinki and Uusimaa
Hospital District and authorized by the Clinical Review
Board of Helsinki University Central Hospital. For
ethical reasons, it is forbidden to store any information
that could identify the individual patients in CanGEM.
This includes any kind of identification codes, but can
also encompass extremely rare clinical cases, whose
uniqueness could be individualizing. It is the responsibility
of the user submitting data to ensure that this require-
ment is fulfilled, and therefore users willing to submit data
to CanGEM have to get a free user id and password.
Processing of the data submitted to CanGEM
After a microarray experiment is uploaded to the data-
base, the data are analyzed using a predefined procedure.
The process is semi-automated, involving the data being
checked by a human curator. This only includes technical
details, such as ensuring that the sample attributes are
in place, but does not cover quality control of the
arrays, which is left to the user. The details of the analysis
algorithm for the R statistical analysis environment can
be found from the library package provided on the
CanGEM website. In brief, the data are filtered for
outliers, background-corrected and lowess normalized in
R/Bioconductor using the limma package (13). As the
normalization procedure is the same for all different
microarray platforms, we have chosen not to use methods
that depend on the array design, such as print-tip lowess.
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Different normalization schemes for array CGH data have
been compared in (14) and of the included methods that
are not dependent on array design, lowess was found to
perform best in removing technical bias, while maintain-
ing the biological significance. After normalization, the
data is combined with the physical coordinates for the
specific microarray platform precalculated with the probe-
to-genome analysis, and all the probes that have been
marked as ambiguous or did not produce any hits are
removed. Also, data from chromosome Y is removed if
the patient is not a male and chromosomes X and Y if the
sex does not match with the reference sample. The CGH
profiles are calculated using the ACE algorithm of the
CGH Explorer program (15), which converts the log
ratios to discrete levels of normal, amplified, or deleted
copy number, represented with the numbers 0, 1 and 1,
respectively. The algorithm also calculates estimates of
false discovery rates, and the ‘medium’ option is selected
from the presented alternatives balancing between sensi-
tivity and specificity.
Because different array platforms contain different
probes targeting different areas of the genome, the results
are converted to gene-specific copy numbers as follows.
For each gene, it is first checked if there are probes on
the array that overlap with the position of the gene, in
which case the copy number for that gene is calculated
from the overlapping probes. If there are no such probes,
the copy number is calculated from the values of the
last preceding probe and the first one tailing the gene.
If the probes in question all have the same value (1; 0;
+1), then that value is chosen for the gene. If they have
different values, the gene gets a copy number of 0,
meaning normal or unchanged, state. This process is
illustrated in Figure 2B. The gene-specific copy numbers
are then stored in the database to allow searching, and
calculations of aberration frequencies.
Browsing and searching CanGEM data
Data in CanGEM can be searched either using a free-text
search box on the front page of the service, or by using
a detailed search form for complex queries using the
clinical attributes used to describe samples. This also
includes the hierarchical classification systems of ICD and
eVOC, in which case a search for a more generic term
(e.g. digestive organs) also returns all the results that have
been mapped to a child of that ontology term
(e.g. stomach and colon). It is also possible to search
using the copy number status of a given gene. Further,
search results can be saved as datasets for future reference
and gene aberration frequencies can be calculated
and visualized for these subsets of CanGEM data.













convert copy numbers from
probe to gene-based
Figure 2. (A) Mapping probes to physical coordinates of the genome. First, all available sequences for a specific probe are analyzed with MegaBlast,
and the results are joined together if they meet the conditions outlined in the main text. The figure shows this process for five probes on a CGH
microarray. Probe 1 yields two blast hits, which are joined together to get the coordinates for that probe. Probes 2, 3 and 5 only produce single hits.
Probe 4 gives two matches that are in different chromosomes, and the probe is therefore marked as ambiguous and excluded. (B) Converting probe-
based data to gene copy numbers. The physical coordinates of the microarray probes, obtained through the predone probe-to-genome mapping
process for the used array platform, are used to convert probe-based copy number data to gene-centric. The image shows three genes in this genomic
region. The position of gene 1 overlaps with probe 1 on the array, so the copy number of gene 1 is the same as the copy number of probe 1. Gene 2
has two overlapping probes (2 and 3), so its copy number is calculated from these two probes. Gene 3 has no overlapping probes, so its value is
derived from the last preceding probe (3) and the first one tailing the gene (probe 5). If the copy number for a gene is calculated from multiple
probes, and all these probes share the same value (1, 0 or +1), the gene will receive the same value. If the probes have different values, the gene will
be assigned a normal, or unchanged, copy number (0).
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will be automatically updated when new data matching
the search conditions becomes available, and email
alerts can be sent for such changes. Different microarray
data entities are shown using a hierarchical browsing
interface as shown in Figure 3.
Data visualization
CanGEM provides an integrated data visualization
engine, based on GBrowse (16) and Dazzle/DAS (17)
packages. The selected samples are shown with the
CGH copy number data on the human genome, together
with other annotations from a local installation of
the Ensembl database. The user can zoom into a
particular region of interest and select the preferred sets
of annotations to be displayed. The visualization system
provides a quick and easy way to see chromosomal
aberrations in the regions of interest and an example
of the output is shown in Figure 3. For individual samples,
the user can choose to display log ratios and/or probe
or gene-based copy numbers. For a collection of samples,
the plot shows the frequencies of gains and losses.
It is also possible for users to visualize their own
private annotations together with data from CanGEM,
or to use another visualization agent that supports the
GFF file format.
Retrieval of data from CanGEM
All the data submitted and made publicly available can
be downloaded, together with the original raw data files
as well as the CanGEM processed numerical data.
This allows e.g. performing custom data analysis using
the software package and algorithm of choice.
Downloading can be done from the web user interface,
or using the provided library package for the R statistical
analysis environment. Documentation for the available
functions is provided within the package.
DISCUSSION
We have presented here a database service for storing
clinical information about tumor samples and microarray
data, with emphasis on array CGH. The probes on
different microarray platforms are mapped to physical
coordinates of the human genome and microarray
data are analyzed to yield gene-specific copy numbers
facilitating the integration of data measured with different
array platforms. Data mining of gene copy number
changes provides valuable insight into the extremely
complicated process of tumorigenesis, and public data-
bases are a prerequisite for this kind of large-scale
analysis. Such an approach is indispensable when trying
to find aberrations that correlate with a specific diagnostic,
prognostic or therapeutic trait, such as poor prognosis
or drug resistance. These features might go unnoticed
in individual studies, because of the heterogeneity in
the processes of tumor progression and aberration
formation, but public databases help to improve the
statistical power of such analyses.
Figure 3. (A) Browsing interface. A hierarchical user interface is provided for accessing microarray data. (B) Data visualization. The GBrowse
software package showing both gene and probe-based copy number aberrations and also the original probe log ratios.
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Abstract
Background: Determining a suitable sample size is an important step in the planning of microarray experiments. 
Increasing the number of arrays gives more statistical power, but adds to the total cost of the experiment. Several 
approaches for sample size determination have been developed for expression array studies, but so far none has been 
proposed for array comparative genomic hybridization (aCGH).
Results: Here we explore power calculations for aCGH experiments comparing two groups. In a pilot experiment 
CGHpower estimates the biological diversity between groups and provides a statistical framework for estimating 
average power as a function of sample size. As the method requires pilot data, it can be used either in the planning 
stage of larger studies or in estimating the power achieved in past experiments.
Conclusions: The proposed method relies on certain assumptions. According to our evaluation with public and 
simulated data sets, they do not always hold true. Violation of the assumptions typically leads to unreliable sample size 
estimates. Despite its limitations, this method is, at least to our knowledge, the only one currently available for 
performing sample size calculations in the context of aCGH. Moreover, the implementation of the method provides 
diagnostic plots that allow critical assessment of the assumptions on which it is based and hence on the feasibility and 
reliability of the sample size calculations in each case.
The CGHpower web application and the program outputs from evaluation data sets can be freely accessed at http://
www.cangem.org/cghpower/
Background
Array comparative genomic hybridization (aCGH) is a
technique that uses microarrays to perform high-resolu-
tion and genome-wide screening of DNA copy number
changes. Its most important applications are in cancer
research [1] and clinical genetics [2]. In this paper we
focus on aCGH experiments comparing two groups of
cancer samples. Previously, we introduced the Wilcoxon
test with ties to identify chromosomal copy number dif-
ferences when comparing two groups [3]. The goal of
comparing two groups is generally to identify disease bio-
markers, chromosomal regions (or genes therein) for sur-
vival, therapy, progression, et cetera. An important
problem that arises in the planning of aCGH experiments
is the choice of the sample size, which we explore here.
Data analysis of microarray experiments comparing two
groups generally involves calculating a test statistic for
each array element and setting a cutoff for rejecting the
null hypothesis of no difference between the groups.
With a single array element, there are therefore two typi-
cal errors that can occur in the process. A type I error
occurs when the null hypothesis is rejected even though
it was actually true and the cut-off was exceeded only by
chance. A type II error involves accepting a null hypothe-
sis that should have been rejected, thus failing to identify
a true difference. To broaden the perspective from indi-
vidual array elements to the framework of multiple test-
ing covering the entire microarray, two concepts are used:
false discovery rate (FDR) [4] and average power. FDR is
the expected percentage of discoveries that are false. Sta-
tistical power is the probability of recognizing a single
array element with a true difference, and average power
refers to the expected percentage of true positives that is
identified. In general, it is desirable to have the FDR as
close to zero and average power as close to one as possi-
ble. Setting the cut-off for rejecting the null hypothesis is
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a delicate balance between sensitivity and specificity;
while a stringent cut-off lowers the FDR, it also lowers
average power and vice versa.The only way to improve
both, or one without affecting the other, is to increase the
number of biological replicates and thus perform more
arrays. Sample size calculations can generally be divided
into two categories. The first category asks the user to
define values for certain parameters, such as the effect
size (fold change of a differentially expressed gene) and
the proportion of genes that are truly differentially
expressed [5-9]. The second category estimates these
parameters from existing data [10,11]. The method pro-
posed here follows the latter approach and therefore
requires pilot data.
To adapt mRNA expression array power calculations
for aCGH and copy number changes, two key aspects
need to be taken into account. Instead of concentrations
of individual mRNA molecules, the underlying biology
measured by aCGH consists of blocks of chromosomal
DNA. Each block is (presumably) present in a normal
copy number of two, but may contain areas of one or two-
copy losses and one or more gains. Higher level amplifi-
cations can also be present. The aberrations contain both
driver and passenger genes, and the breakpoints may vary
from one sample to another.
As the entity being measured is DNA present in a dis-
crete number of copies (0, 1, 2, 3, 4, ...), but individual
array elements yield log2 ratios, aCGH data preprocessing
generally involves the following steps that aim to better
capture the biological relevance. Normalization first
removes technical artifacts and makes the log2 ratios
comparable across different hybridizations. Segmentation
then identifies areas that share a common copy number
and are separated by breakpoints. Finally, calling deter-
mines a discrete copy number level for each segment. At
the moment, there is no clear consensus regarding the
optimal stage of preprocessing from which the data
should be used for downstream analysis. We discussed
the topic and proposed that in most cases the recom-
mended choice be to use calls, which have the clear
advantage of having an attached biological meaning [12].
For power calculations however, the use of calls is prob-
lematic, as it would require the use of the chi-square test,
for which no method of sample size calculation in large
FDR-based multiple testing contexts is presently avail-
able. While both normalized and segmented log ratios
allow the use of a t-test, they fail to take full advantage of
the adjacency of consecutive array elements. Aberrations
typically show great variation in their sizes ranging from
focal amplifications to gains and losses of entire chromo-
some arms. Working directly with the original array ele-
ments does not take this into account, and gives larger
aberrations significantly more weight than smaller ones
as they contain more array elements. A possible improve-
ment is therefore to replace array elements with regions,
which are defined as a series of neighboring array ele-
ments sharing the same copy number signature. This
reduces dimensionality with little loss of information
[13]. Throughout this paper, the term regions is used to
refer to the results of this analysis step.
For CGHpower, we are combining the advantages of
regions with the feasibility of log ratios, by replacing the
hard calls with median log ratios of all the array elements
within a region. Together with these region-wise log
ratios (RWLRs), the regions are then taken as a represen-
tation of the underlying biology (i.e. chromosomal
regions with varying copy number levels). Each region is
coupled to a null hypothesis stating that the means of the
two groups do not differ from each other, which is the
framework required for the power calculations proposed
here. Regions that have a true difference between the two
groups (generally normal copy number in one group and
a gain, loss or amplification in the other) will be referred
to as "differentially behaving regions".
After this preprocessing, power calculations are per-
formed using regions as Ferreira et al. [14] previously
described for both real and simulated gene expression
data. T-statistics and p-values are calculated for each
region from the RWLRs. All p-values from non-differen-
tially behaving regions are expected to follow a uniform
distribution, while those from the differentially behaving
ones should follow another, unknown distribution (G).
Two separate estimators of G are calculated: a non-para-
metric ( ) and a parametric one (Ĝn), which assumes
that G follows a normal distribution. Both of these esti-
mators depend on another unknown parameter, γ, which
is the proportion of non-differentially behaving regions.
When the estimate of γ used to calculate Ĝn and 
moves away from its true value, the difference between
the two G estimators increases. The estimate of γ is there-
fore chosen so that this difference is minimized. The lim-
iting density of effect sizes (λ) is then estimated using
deconvolution, and so is G. Once these estimates have
been calculated, approximate sample size calculations
can be made using an adaptive version of the Benjamini-
Hochberg method for multiple testing. While the original
method [4] allows control over the FDR, the adaptive ver-
sion also allows the estimation of average power [10].
While optimizing the protocol, there were certain
options that we considered: whether to calculate the
RWLRs as the mean or median of the log ratios, whether
to use the Student's t-test assuming equal variances or
Welch's t-test that allows unequal variances, and finally
whether to calculate the p-values from normal or Stu-
dent's t-distribution. All of the possible combinations
were tested, and the optimum performance was observed





Scheinin et al. BMC Bioinformatics 2010, 11:331
http://www.biomedcentral.com/1471-2105/11/331
Page 3 of 10




To evaluate the performance of CGHpower, eight
recently published aCGH data sets that could be divided
into two groups were collected. They will be referred to
as Chin et al. [15], Douglas et al. [16], Fridlyand et al.
[17], Myllykangas et al. [18], Nymark et al. [19], Postma et
al. [20], Smeets et al. [21] and Wrage et al. [22] A total of
five different array types were used among the data sets:
VUmc 30 K spotted oligo [23] for data sets [15,20,22],
Agilent Human 1 cDNA Microarray for [18,19], 3 K BAC
array [24] for [16], 2 K BAC array [25] for [17] and 6 K
BAC array for [21]. Table 1 provides a summary of the
cancer and array types, together with group definitions
and sizes.
Simulated Data Sets
In addition to real data sets, evaluation was also per-
formed with simulated data. While generating the simu-
lations, we attempted to implement realistic aspects of
both signal and noise of tumor profiles. In the context of
an aCGH experiment comparing two groups, the signal
consists of aberrant regions that are specific to one of the
groups. Noise consists of regions common to both
groups, random aberrations in individual samples, and
technical noise. Further characteristics are also that the
sizes of the aberrant regions vary from entire chromo-
somes to focal aberrations, the exact start and end posi-
tions of a region vary slightly from one sample to another,
and even a "common" region might not be be present in
all of the samples.
The simulated data were generated by introducing arti-
ficial aberrations into a data set of clinical genetics sam-
ples of patients with mental retardation and no or few
chromosomal aberrations [26]. To achieve a simulated
data set of the desired size, resampling was performed
with replacement. Aberrant regions were then randomly
introduced as follows. A single array element was chosen
at random as the starting point of a region. The size of the
region was then chosen at random with a 10% probability
for a single cytoband, 30% for three consecutive bands,
30% for six consecutive bands, 20% for the whole chro-
mosome arm, and 10% for the entire chromosome. The
type of the aberration was randomly chosen as a gain or
loss with equal probabilities, but for the smallest aberra-
tions of individual cytobands, a 2% probability for ampli-
fications was also included. When introducing a region to
a set of samples, the exact samples receiving the aberra-
tion were sampled from the Bernoulli distribution with p
= 70%. Randomness was also introduced to the exact start
and end positions of aberrations in individual samples by
shifting the starting and ending array elements by a ran-
dom number between -10 and 10.
A simulated data set of 15 + 15 arrays was generated
with 30 common regions, and 5 regions for each individ-
ual sample. These copy number changes do not separate
the two groups from each other, and therefore represent
background noise. This data set is referred to as Simula-
tion 0. Single regions specific to the two groups were then
Table 1: Evaluation data sets
Data Set Array Type Probes Regions Cancer Type Groups (Samples)
Chin et al. spotted oligo 26,755 223 breast ER+ (113) vs. ER- (57)
Douglas et al. BAC 3,032 142 colorectal MSI (7) vs. CIN (30)
Fridlyand et al. BAC 1,877 231 breast TP53+ (10) vs. TP53- (52)
Myllykangas et al. cDNA 11,342 260 gastric diffuse (15) vs. intestinal (23)
Nymark et al. cDNA 10,953 242 lung asbestos-exposed (11) vs. non-exposed (9)
Postma et al. spotted oligo 26,755 111 colorectal good (16) vs. bad response (16)
Smeets et al. BAC 4,196 143 head and neck HPV+ (12) vs. HPV- (12)
Wrage et al. spotted oligo 25,549 23 lung BM+ (13) vs. BM- (15)
Simulation 0 in-situ oligo 42,331 440 (15) vs. (15)
Simulation 5 in-situ oligo 42,331 489 (15) vs. (15)
Simulation 10 in-situ oligo 42,331 525 (15) vs. (15)
Eight public data sets were collected to evaluate the performance of CGHpower. They represented five different cancer types and BAC, cDNA 
and oligo-based microarray platforms, with resolutions varying from 2 K to 27 K array elements. The last column contains the distinguishing 
factor used to divide the data set into two groups, along with the number of arrays in each group. The simulated data sets were generated 
by introducing artificial aberrations into a set of clinical genetics samples. A total of 11 simulations were generated, and the remaining ones 
are available at http://www.cangem.org/cghpower/. ER = estrogen receptor, MSI = microsatellite instability, CIN = chromosomal instability, 
HPV = human papilloma virus, BM = bone marrow metastasis.
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introduced to Simulation 0 yielding data set Simulation 1.
This process was repeated ten times resulting in a set of
11 simulations with the amount of differential signal
ranging from none in Simulation 0 to 10 regions specific
to each group in Simulation 10. Only Simulations 0, 5 and
10 are presented in this paper, but the full CGHpower
outputs for all of them are available on the program's web
page.
Preprocessing
All evaluation data sets were preprocessed starting from
raw log2 ratios. First, the data were median normalized.
Wavy patterns typically seen in many aCGH profiles were
removed [26] from the 30 K arrays [15,20,22]. Normal-
ized log ratios were segmented using the DNAcopy algo-
rithm [27] and called by CGHcall [28] to identify gains,
losses and amplifications. Regions between breakpoints
were then collapsed into single data points, when shared
between most of the samples [13]. Finally, the median log
ratio was calculated for each of these regions in each sam-
ple, resulting in region-wise log ratios (RWLRs). All algo-
rithms were run with default parameters, and sex
chromosomes were excluded from the data.
Sample Size Calculations
For each region, t-statistics were calculated with a
Welch's t-test allowing unequal variances and p-values
computed from the normal distribution. The proportion
of non-differentially behaving regions (γ) was estimated
by minimizing the difference between parametric (Ĝn)
and non-parametric ( ) estimators of G, which is the
unknown distribution of the p-values from differentially
behaving regions. The limiting density of effect sizes
(λ)and G were then estimated using deconvolution.
Finally, with FDR fixed at 10%, these parameter estimates
were used to approximate average power as a function of
sample size.
Results and Discussion
Estimates of average power as a function of sample size
were calculated for the eight evaluation data sets and 11
simulations (Figure 1). The reliability of the power calcu-
lations depends directly on the the quality of parameter
estimation, which in turns depends on compliance with
required assumptions. The first assumption is that the
proportion γ of non-differentially behaving regions be
"substantially" smaller than 1 (e.g. ~0.9 will typically do,
but 0.99 will not). The second assumption is that the
RWLRs be approximately normally distributed, being
neither particularly asymmetric (skewness) nor heavily
tailed or extremely peaky (kurtosis). The complete CGH-
power program output contains diagnostic plots from
different stages of the power calculations procedure.
These plots help determine to which extent these
assumptions are fulfilled. While it is impossible to know
what the true values of γ and λ are, one can easily evaluate
how well the two estimators of G agree with each other
(the "goodness-of-fit"). If they show a clear discrepancy,
the accuracy of parameter estimation is questionable and
the resulting power calculations consequently unreliable.
Different scenarios in the quality of parameter estimation
observed with the evaluation data sets are examined for
each of the data sets to estimate the reliability of the cal-
culated power.
The data sets Douglas et al., Smeets et al., Fridlyand et
al. and Chin et al. are examples where the goodness-of-fit
of the G estimators was satisfactory, ranked in this order
according to their fits (Figure 2A). What appears to be the
most important factor distinguishing these data sets from
the others, is the density of the p-values. If there is no dif-
ference detected between two groups, p-values are
expected to follow a uniform distribution, and their den-
sity function appears as a flat line. When the number of
differentially behaving regions increases (γ moves away
from 1), density at low p-values increases and the func-
tion is expected to be convex (Figure 2B). This can also be
seen on the simulations where the amount of differential
signal gradually increases from Simulation 0 to Simula-
tion 10. Along with the increase in density for low p-val-
ues, also the goodness-of-fit systematically improves
(data and figures at http://www.cangem.org/cghpower/).
Less satisfactory performance was observed with data
sets of Postma et al. and Myllykangas et al. The good-
ness-of-fit shows more disagreement between the two
estimators of G (Figure 2C) and as a result power esti-
mates are less reliable. The density is increasing for low p-
values, but slightly less and the function is not convex as
expected (Figure 2D). Compared to Simulation 0, which
has no true differences between the groups, the increase
in p-value density for the data set of Myllykangas et al. is
very small. One explanation is that there is simply not
enough differential signal that is detectable with a t-test.
Alternatively, the number of differentially behaving
regions might be too low ( i.e. γ is too close to 1). While
these data sets do give γ estimates of 0.75 and 0.55,
respectively, these estimates cannot be trusted if the esti-
mates of G disagree with each other. Therefore it is rec-
ommended that the goodness-of-fit plot be used to assess
the reliability of the estimates of other parameters. Also,
judging from the results with the simulated data sets,
CGHpower seems to underestimate the true value of γ.
While assumptions regarding γ seem to be most impor-
tant, the RWLRs are also assumed to be normally distrib-
uted. The program output contains histograms of the
skewness (asymmetry) and kurtosis (peakedness) of the
RWLRs, superimposed with those of a normal distribu-
tion (data on the CGHpower web page). Assumptions of
ɶG
n
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normality become more critical with small sample sizes
and less important with large ones. Within the evaluation
data sets, most violations of normality were observed
with the Chin et al. data set, yet this is one of the better-
performing ones in terms of goodness-of-fit. This might
be explained by the relatively large sample size (170) of
the study. Another factor besides the number of arrays, is
the number of regions found after the preprocessing step.
The larger the number of regions, the better the perfor-
mance of the parameter estimation and therefore the reli-
ability of power calculations. The assumption of
normality is therefore more crucial with samples contain-
ing very few biological differences.
The data sets of Nymark et al. and Wrage et al. are
examples where our method failed to work, despite the
differences reported and technically as well as biologi-
cally validated. In the case of Nymark et al. the obtained
power curve is a flat line (Figure 1). This can happen
when parameter estimation fails. The explanation can be
found from the density of the p-values, but now the
assumptions were violated more severely than in the
cases of Postma et al. and Myllykangas et al. The density
function is actually concave and shows even less density
at low p-values than would be expected by chance (Figure
2F). With Wrage et al., failure can be observed at the pre-
processing step, as only 23 regions are detected (Table 1).
Figure 1 Power calculations for evaluation data sets. Average power estimated as a function of sample size for the eight evaluation data sets and 
three simulations. False discovery rate was fixed at 10%. The horizontal position of the small symbols mark the actual size of the data set that was used 
to calculate the estimates in each case. Real data sets are shown with solid lines and three of the simulations with dotted lines. Additional simulations 
are available at http://www.cangem.org/cghpower/.
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Figure 2 Diagnostic plots. The goodness-of-fit of the two estimators of G and densities of p-values for three data sets illustrating different scenarios 
in the performance of CGHpower. The data set of Douglas et al. shows A) a satisfactory goodness-of-fit following from B) a convex p-value density 
function. Mediocre operation is demonstrated with the data set of Postma et al. C) An inferior fit results from D) a p-value density which shows a slight 
increase for small values, but is not convex as expected. Nymark et al. represents failed execution. E) The disagreement between the G estimators is 
slightly more severe and the estimated power curve is a flat line (Figure 1). F) P-values exhibit even less density at low values than would be expected 
by chance. In such circumstances, it is recommended that data preprocessing be carried out before uploading and only the power calculations part 
be performed in CGHpower.
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Since the sex chromosomes are excluded from the analy-
sis, this means that only one copy number breakpoint was
detected in the whole genome using the fixed CGHpower
preprocessing described above. As preprocessing and
power calculations procedures are fixed earlier in CGH-
power, it was not optimized it for every aCGH platform
or data set. Allowing the user to fine-tune different set-
tings and immediately see the result of each change
would require implementing a more complex user inter-
face, similar to desktop software, which would be imprac-
tical for a single-purpose web tool. As an alternative
option, if the goodness-of-fit and density plots indicate
that power calculations failed, users can perform prepro-
cessing independently, turn off the preprocessing step
from the program, and perform the power calculations
only.
Consistency as the Pilot Size Is Increased
CGHpower was initially developed to be used on smaller
pilot data sets in the planning stages of larger microarray
experiments or for verifying power achieved in past
experiments. We wanted to evaluate whether the result-
ing power estimates hold while more and more arrays are
added to the data set. Assuming that a pilot of 10 + 10
arrays has estimated an experiment with 40 + 40 arrays
should result in an average power of approximately 70%.
The data set of 80 arrays is then generated and for verifi-
cation the power calculations are repeated with the entire
data set. If the new results indicate that the achieved
power is in fact only 50%, and that 20 + 20 new arrays are
needed in order to achieve our goal of 70%, then the two
power calculations have to be declared inconsistent. To
evaluate whether the power estimates remain consistent
while the pilot size is increased, power was calculated
with smaller subsets of the Chin et al. data set, since it is
our largest one. This data set contains a total of 170 arrays
(113 vs. 57), which was split into smaller subsets to repre-
sent pilots of a larger study. Nine resamplings ranging
from 10% (11 vs. 6 arrays) to 90% (102 vs. 51) of the origi-
nal data set were randomly selected for the power calcu-
lations. Each resampling was repeated 10 times and the
results were averaged. Two of the ten repetitions of the
10% subset and one repetition in the 20% subset experi-
enced a failed power estimation resulting in flat power
curves as with the Nymark et al. data set. These cases
were removed before averaging the results. A plot of the
resulting power estimates shows that except for the
smallest subset (11 vs. 6 arrays), the results appear to be
consistent (Figure 3). This suggests that as long as the
pilot is of sufficient size, power estimates generated with
CGHpower using smaller pilot data sets are in fact repre-
sentative of a subsequent larger study. While the exact
requirement for a "sufficient pilot" is hard to define
beforehand, the power calculations can be repeated when
more arrays are performed to see whether power esti-
mates are still changing or have been stabilized.
Conclusions
We have explored sample size calculations in the context
of aCGH and copy number changes and propose a dedi-
cated tool for this purpose. From a pilot data set, CGH-
power estimates the biological diversity between two
groups of cancer samples and estimates average power as
a function of sample size using an adaptive version of the
Benjamini-Hochberg method for multiple testing [4,10].
Pilot data is used for parameter estimation and this
requires certain assumptions to hold in an approximate
sense. We have evaluated the performance of CGHpower
with eight published data sets, four of which show satis-
factory performance using predefined preprocessing
measures. Among these data sets were BAC and oligo-
based array platforms, whose resolution varied from less
than 2 K for BACs to almost 27 K for oligos. The differ-
ences in resolution did not have a direct impact on the
obtained power estimates, which should be determined
more by the amount of biological variation between the
two groups.
In two data sets violations of critical assumptions lead
to problems in parameter estimation and therefore power
estimates are less reliable. More severe violations and/or
the inflexibility of a completely predefined analysis proce-
dure lead to failed execution for the two other data sets.
Even though the proposed method has its limitations, it is
to our knowledge the only proposed one for aCGH data
and copy number changes. As the program allows perfor-
mance evaluation through diagnostic plots, critical judge-
ment can be applied for each data set.
As a summary on the evaluation of CGHpower results,
users should consider paying attention to the following:
1) Do the copy number profile plots appear similar to the
aberrations that you have detected in your own analysis?
If CGHpower does not seem to detect the important
aberrations, consider performing the preprocessing
before uploading and use CGHpower only for the power
calculations. 2) Do the estimators of G agree with each
other? If the goodness-of-fit is poor, so will other parame-
ter (and resulting power) estimates. 3) Is the density func-
tion of the p-values convex, and showing a higher density
at small p-values? A straight or concave function might
be caused by too small effect size, or γ being too close to
one. 4) Excess skewness and/or kurtosis in the data might
also affect the performance, but this seems to be less cru-
cial.
The proposed method uses log ratios instead of calls,
even though we feel the latter is generally the preferred
choice when working with aCGH data. Calls have the
benefit of a clear biological meaning and are therefore
easier to interpret. However, their use for power calcula-
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tions in the context of FDR is problematic, as it would
require using the chi-square test, a setting that is not as
well developed as the Gaussian one. Also, as log ratios are
the basis for calls in the first place, they do contain all the
necessary information even though they are not as clear
to interpret.
In comparison to sample size calculations for mRNA
expression arrays, the differentiating factor for aCGH
studies is the concept of regions, which stems from the
different biological phenomenon underlying the microar-
ray log2 ratios. Compared to the number of array ele-
ments, the number of regions is relatively small, which
presents challenges to parameter estimation from the
data. As the total number of regions is remarkably
smaller than with expression arrays, the estimation might
fail if the number of differentially behaving regions is too
small, even if there is a true difference between the
groups.
An important concern when performing power calcu-
lations is the actual power requirement. A power curve
typically plateaus out at some point, indicating satura-
tion. Increasing the average power from e.g. 60% to 70%
requires a significantly bigger increase in sample size than
is needed for an increase from 50% to 60%. Therefore it is
Figure 3 Consistency as the pilot size is increased. To evaluate whether power estimates obtained from smaller pilots are in fact representative of 
larger data sets, the calculations were performed with subsets of the Chin et al. data. Resampling without replacement was used to obtain subsets 
from 10% to 90% of the original data set. Each resampling was repeated ten times and results averaged. The horizontal position of the small symbols 
mark the size of the subset used to obtain each power estimate.
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difficult to set a a predefined gold standard of adequate
power. One option is to try to find where the slope of the
power curve is decreasing rapidly. This should give a rea-
sonable compromise between statistical power and cost
of the experiment. Another aspect worth pointing out, is
that the level of power needed also depends on the
research question. For example, if the goal is to construct
a classifier that can classify future samples into one of the
two groups, a lower level of average power might yield a
perfectly satisfactory classifier even though not all differ-
ences are detected.
Availability and requirements
CGHpower is a web-based application and can be freely
accessed at http://www.cangem.org/cghpower/. It allows
direct uploads and can also automatically retrieve data
stored in the CanGEM database [29]. The computation
times of CGHpower may vary considerably depending on
the number of samples and array elements in the data set,
and also on the prevailing load of the Linux cluster where
the calculations are performed. As an example, running
times for a data set of 30 samples and 42 K array elements
have been around 1-1.5 hours in our test runs. The soft-
ware has been implemented in R [30] and the source code
is available upon request.
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Detection of DNA copy number aberrations by shallow whole-genome sequencing (WGS) faces many challenges, in-
cluding lack of completion and errors in the human reference genome, repetitive sequences, polymorphisms, variable
sample quality, and biases in the sequencing procedures. Formalin-fixed paraffin-embedded (FFPE) archival material, the
analysis of which is important for studies of cancer, presents particular analytical difficulties due to degradation of the
DNA and frequent lack of matched reference samples. We present a robust, cost-effective WGS method for DNA copy
number analysis that addresses these challenges more successfully than currently available procedures. In practice, very
useful profiles can be obtained with ~0.13 genome coverage. We improve on previous methods by first implementing
a combined correction for sequence mappability and GC content, and second, by applying this procedure to sequence
data from the 1000 Genomes Project in order to develop a blacklist of problematic genome regions. A small subset of these
blacklisted regions was previously identified by ENCODE, but the vast majority are novel unappreciated problematic
regions. Our procedures are implemented in a pipeline called QDNAseq. We have analyzed over 1000 samples, most of
which were obtained from the fixed tissue archives of more than 25 institutions. We demonstrate that for most samples our
sequencing and analysis procedures yield genome profiles with noise levels near the statistical limit imposed by read
counting. The described procedures also provide better correction of artifacts introduced by low DNA quality than prior
approaches and better copy number data than high-resolution microarrays at a substantially lower cost.
[Supplemental material is available for this article.]
Alteration in chromosomal copy number is one of the main
mechanisms by which cancerous cells acquire their hallmark
characteristics (Pinkel et al. 1998; Hanahan and Weinberg 2011).
For > 20 yr, these alterations have been routinely detected first by
genome-wide comparative genomichybridization (CGH) (Kallioniemi
et al. 1992) and subsequently by array-based CGH (Snijders et al.
2001) or single nucleotide polymorphism (SNP) arrays (Ylstra et al.
2006). Nowwhole-genome sequencing (WGS) offers an alternative
to microarrays for many genome analysis applications, including
copy number detection.
Several methods have been developed to estimate DNA copy
number from WGS data. They can be grouped into the following
four categories, each of which has its own set of requirements,
strengths, and weaknesses (Teo et al. 2012): (1) Assembly-based
methods construct the genome piece by piece from the sequence
reads instead of aligning them to a known reference; these
methods have the greatest sensitivity to detect deviations from the
reference genome, including copy number changes and genome
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rearrangements, but require high sequence coverage (typically
403) (Li et al. 2010) and therefore incur high cost; (2) split-read
and (3) read-pair methods map sequence reads from both ends of
size-fractionated genomic DNA molecules onto the reference ge-
nome; these methods can provide information on copy number
and genome rearrangements, but they impose requirements on
molecule sizes and therefore are highly sensitive to DNA integrity;
and (4) depth of coverage (DOC)methods infer copy number from
the observed sequence depth across the genome anddonot require
both ends of the molecule to be sequenced.
Archival tissue is an invaluable resource for biomarker detection
studies (Casparie et al. 2007). Projects investigating cancers with
long survival, such as diffuse low-grade gliomas (LGGs) with a subset
of patients surviving > 25 yr after diagnosis (van Thuijl et al. 2012),
require long-term clinical follow-up. Archival FFPE tissue is often the
only source of material for study (Blow 2007). The use of such
samples has been challenging due to poor DNA quality; hence, array
CGH results, for example, have been variable (Mc Sherry et al. 2007;
Hostetter et al. 2010; Krijgsman et al. 2012; Warren et al. 2012). To
make large archival sample series accessible for genome research,
a robust technique is required that performs well on diverse sample
types, with high resolution, quality and reproducibility, and at low
cost without the necessity for a (matched) normal sample. Here we
focus exclusively on DOC methods, because they are theoretically
most compatible with DNA isolated from FFPE material.
Typically, DOC methods for copy number divide the refer-
ence genome into bins and count the number of reads in each,
although there are also bin-free intensity-based implementations
(Shen and Zhang 2012). Copy number is then inferred from the
observed read counts across the genome. To compensate for
technological bias, many DOC algorithms, such as CNV-seq (Xie
and Tammi 2009), SegSeq (Chiang et al. 2009), BIC-seq (Xi et al.
2011), and CNAnorm (Gusnanto et al. 2012), compare tumor
signal to a normal reference signal, similar to array CGH. Com-
monly, a pool of different individuals is used as a normal reference
DNA. In many applications, including cancer genome analysis,
matched normal DNA from the same patient is preferable to avoid
detection of germline copy number variants (Feuk et al. 2006),
allowing focus solely on somatic aberrations (Perry et al. 2008).
Two DOCmethods, readDepth (Miller et al. 2011) and FREEC
(Boeva et al. 2011), do not require a reference signal. This has three
principal advantages: the cost is reduced by half, archival material
for which matched normal reference tissue is unavailable (most
cases) can be analyzed, andmeasurement noise from the reference
sample is avoided. Achieving these benefits requires accurate
computational correction for biases in the DOC sequence data
since they are no longer being normalized by comparison with
data from a matched reference specimen.
Here we describe a multiplexed, single-read (SR), shallowWGS
procedure based on the Illumina platform that produces improved
DOC copy number profiles. Because DOC profiles are fundamen-
tally based on counting the number of sequence reads, the mini-
mum achievable noise can be easily calculated. We show that
a larger proportion (most) of the samples we have analyzedwith our
procedures show noise levels at the theoretical minimum than with
other analysis methods. We achieve the improved performance by
simultaneous (rather than sequential) correction of primary read
counts for sequence mappability and GC content, and by using
a comprehensive empirical approach for recognition and filtering of
problematic genome regions. We also show that compared to pre-
vious shallow WGS analysis procedures, our approach provides
improved correction of spurious localized profile variations, which
are presumably due to sample quality problems; and microarray
analysis costs more and yields a poorer signal-to-noise ratio than
shallow WGS. Thus our DOC profiles provide a more accurate rep-
resentation of the genome copy number structure than can be
obtained by other approaches and should allow segmentation and
calling algorithms to more sensitively recognize true aberrations.
Results
Shallow WGS and alignment to the reference genome
Shallow WGS was performed with DNA isolated from FFPE sec-
tions of 15 LGGs (van Thuijl et al. 2014), two oral squamous cell
carcinomas (SCCs AB042 and AB052) (Bhattacharya et al. 2011),
and the breast cancer cell line BT474 on the Illumina HiSeq 2000
using run mode SR50, which sequences only one end of the DNA
molecules for 50 base pairs. In general, these DNA samples were
multiplexed with others so that each HiSeq sequencing lane con-
tained between 18 and 22 total samples.We use sample LGG150 to
illustrate our analysis procedures in the main article text and fig-
ures because it contains a range of different types of genome al-
terations that are typical for solid tumors. Complete analyses of all
LGG samples, BT474, AB042, and AB052, including whole-ge-
nome plots and enlarged views of chromosome 1, are presented in
Supplemental Figures S1–S3. In addition, we present noise data
from more than 1000 mostly formalin-fixed archival specimens
obtained from many hospitals throughout Europe.
On average, we obtained 9.2 million total reads per sample
(range 3.1–23.9) for the multiplexed samples, of which 8.2 million
(range 3.0–22.9) aligned to the human reference genome with the
sequence alignment algorithm BWA (Li and Durbin 2009). We
filtered out PCR duplicate reads and reads with mapping qualities
lower than 37 (highest value returned by BWA), resulting in a final
average read count of 6.0million (range 2.4–18.1) per sample. Read
counts for the 15 LGGs, AB042, AB052, and BT474 are provided in
Supplemental Table S1.
Binning of sequence reads
We divided the human reference genome into nonoverlapping,
fixed-sized bins. We use 15-kb bins in the analysis presented here
because this results in approximately the same number of bins as
the number of array elements on 180K oligonucleotide CGH arrays
and provides reasonable noise levels with as few as 6million reads.
We note, however, that any bin size could be used, and such an
option is provided in the accompanying software package,
QDNAseq. Removal of 12,893 bins that were completely com-
posed of uncharacterized bases (denoted with N’s in the human
reference genome sequence) resulted in a total number of 179,187
autosomal bins. We determined raw copy number estimates by
counting the number of reads in each bin. Themedian-normalized
log2-transformed read counts, the raw copy number profile, for
sample LGG150 is shown in Figure 1A. Regions of low-level loss
and gain (e.g., on chromosomes 10 and 20, respectively) are ap-
parent in the profile. In addition, some very narrow regions of
highly elevated read counts and a substantial number of bins with
very low read counts are present. The horizontal stripes of data
points are due to the integer nature of the read counts. Experience
based on classical cytogenetics and array CGH suggests that many
features of this profile reflect characteristics of the sequencing and
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Correction of read counts
It is well established that raw read counts are affected by GC con-
tent and mappability of the sequence reads (Benjamini and Speed
2012; Derrien et al. 2012; Rieber et al. 2013). Published analysis
methods generally correct for these factors independently if cor-
rections for both are used. Although independent correction is
effective for many cases, genome profiles from some samples, es-
pecially those that are formalin-fixed, contain clearly artifactual
variations. Independent correction for GC and mappability is ap-
propriate only if these two factors do not interact in their effects on
read counts. We desired to determine if simultaneous correction
might provide improved read count profiles. We implemented si-
multaneous correction by calculating themedian read count for all
bins with the same combinations of GC andmappability (Fig. 1B).
We then fit a LOESS surface through the medians (Fig. 1D). To
correct the raw read count of a bin, we divided the raw count by the
LOESS value of its combination ofGC andmappability. (Fitting the
LOESS has the benefit of stabilizing the values for bins with closely
related GC and mappability.) Following this procedure, the cor-
rected profile for LGG150, after log2-transformation and centering,
is much cleaner (Fig. 1C) than before correction. The correction of
bins with low counts is particularly noticeable, but at the cost of
introducing bins with read counts that appear to be anomalously
high. Copy number profiles and plots of the median read counts as
a function of GC content and mappability are shown for the 15
LGGs, AB042, AB052, and BT474 in Supplemental Figures S1 and S2.
Blacklisting bins to exclude problematic regions
Examination of Figure 1C shows the presence of multiple very
narrow peaks and some apparent deletions that might indicate
aberrations. Some of these structures, for example many of the nar-
row peaks, appear to have been introduced by the GC-mappability
correction.Many of these features are highly recurrent across, both
tumor andnormal, samples (data not shown). Recurrence alonemay
imply that these peaks represent common germline copy number
variations (CNVs). The observation that they are frequently located
in (peri-)centromeric and (sub-)telomeric regions, however, sug-
gested that a large number are artifacts.
Figure 1. Correction to read counts. Copy number profiles from (A) uncorrected and (C ) corrected read counts; (B) median read counts per bin as
a function of GC content and mappability; and (D) the corresponding LOESS fit for sample LGG150. Regions of the isobar plots that are white contain no
bins with that combination of GC andmappability. In the copy number profiles, bins are ordered along the x-axis by their genomic positions, and the y-axis
shows median-normalized log2-transformed data. Small triangles at the top and bottom edges represent data points that fall outside the plot area. Upper
left corners show the number and size of bins.Upper right corners of themedian read counts plot shows the total number of sequence reads, and upper right





the average number of reads per bin. The measured standard deviation ðbsDÞ is calculated from the data with a mean-scaled and 0.1%-trimmed first-order
estimate, prior to log2 transforming the data for plotting (see text).




The presence of chromosomal regions with anomalous be-
havior is well established and has led others, for example, the
ENCODE Project Consortium, to develop blacklists of sequences
to exclude from their analyses (The ENCODE Project Consortium
2012). Some of these sequences map to regions with known repeat
elements, such as satellites, centromeric, and telomeric repeats.
Therefore we tested the effect of removing bins withmappabilities
below the arbitrary threshold of 50 and bins overlapping with the
ENCODE blacklists (Fig. 2A). Clearly, the profiles are improved, but
many regions of potentially artifactual variation remain (indicated
by black dots in Fig. 2A). Changing the mappability threshold af-
fects the results to some degree but fails to sufficiently remove the
problematic regions without also removing a major proportion of
the bins (see Supplemental Fig. S4).
Given the insufficiency of the ENCODE blacklist for copy
number analysis and the apparent recurrence of the problematic
regions, we developed our own data-driven list of problematic
genome regions. We started by analysis of a collection of normal
genomes, which has the potential to identify problematic se-
quencemotifs as in ENCODE, unknown problems in the reference
genome sequence, and common CNVs. We obtained the required
sequence data from the publicly available WGS data set from the
1000 Genomes Project (1000G) (The 1000 Genomes Project Con-
sortium 2012). After selecting samples that were sequenced in
a manner similar to our experimental setup (Illumina platform,
low-coverage, SR50), we identified and downloaded 38 cases. The
individuals have a substantial range of ethnic backgrounds (nine
CEU, eight JPT, seven YRI, five CHB, three ASW, two PUR, one
CLM, one IBS, one LWK, and one MXL).
The 38 samples were then processed as described above. The
difference between the actual count and the LOESS fitted valuewas
determined for each bin based on its GC and mappability values.
These residuals were recorded for each sample, and the median of
the residuals across the 38 samples was calculated per bin. The
distribution of themedian residual values is sharply peaked, which
reflects the fact that normal diploid samples are being analyzed,
but has ‘‘fat’’ tails, representing bins with anomalous behavior and
those with CNVs (Fig. 2B). We chose to blacklist all bins with
Figure 2. Blacklisting problematic regions. (A) Copy number profile for sample LGG150with bins overlapping with the ENCODE blacklist highlighted in
red, bins withmappabilities below 50 highlighted in blue, and the overlap between the two in yellow. (B) Distribution of median residuals per bin from the
1000 Genomes Project across the 38 samples. Residuals are defined as the distance between observed read counts and the fitted LOESS surface, divided by
the LOESS value. The outer plot shows the entire range of values with two discrete peaks. The minor peak around 1.0 results from repetitive sequences.
Reads that align equally well to multiple locations in the genome are filtered out. Repetitive sequences therefore have a lower than expected number of
readsmapped. Themajor peak around zero containsmost of the bins, and the inset shows amagnification of the peak, with the dotted vertical bars and the
shaded area showing the cutoff of 4.0 standard deviations (as estimated with a robust first-order estimator) for blacklisting. (C ) Copy number profile of
sample LGG150 with bins in the novel blacklist based on residuals of the 1000 Genomes samples highlighted in red. (D) The final copy number profile of
sample LGG150 after filtering out bins in the ENCODE and 1000G blacklists.
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median residuals greater than 4.0 standard deviations, using a ro-
bust first-order estimator (von Neumann et al. 1941) that focuses
on the width of the central peak to determine the standard de-
viation. This procedure removed 10,413 bins. We based our choice
of the cutoff on the distributions of residuals found with a number
of different bin sizes ranging from 1 to 1000 kb (Supplemental Fig.
S5). The cutoff can be adjusted in the QDNAseq package if other
values are desired. Changing it by one standard deviation in either
direction, however, does not materially affect the results.
We were concerned that the initial presence of bins with high
residuals, whichwere candidates for blacklisting, had the potential
to affect the LOESS fit of the initial read counts. Therefore, we
implemented an iterative process, recalculating the LOESS cor-
rection after removal of the problematic bins found in the previous
cycle and again determining the residual distribution. Bins with
residuals greater than the same numerical cutoff values established
in the first iteration were removed. The list of excluded bins, our
blacklist, stabilized at 11,124 bins after 14 iterations. Figure 2C
shows the profile of LGG150with our blacklisted bins highlighted.
This blacklist contains many bins not included in the ENCODE
list and also includes 97% (6200 of 6404) of the bins with
mappabilities below50.Overlaps betweenour blacklist, the ENCODE
list, and bins with mappabilities below 50 are presented in Sup-
plemental Figure S6. We intentionally were not conservative in
blacklisting, since the copy number of a blacklisted locus can be
imputed from neighboring bins (assuming no very focal aberra-
tions are present), and most analytical packages handle this im-
putation automatically (van de Wiel et al. 2011).
For analysis of experimental samples, we routinely remove
bins contained in the union of the ENCODEblacklist and our 1000
Genomes-based list at the beginning of the analysis so that their
anomalous values do not affect the LOESS GC-mappability fit; al-
though in practice the procedure seems to be fairly robust to the
presence of these outliers. Similarly, the LOESS fit could be affected
by copy number aberrations present in the data. Therefore, our
software allows the correction described in the previous section to
be implemented iteratively. After the initial analysis, bins with
large LOESS residuals, which presumably are located in copy
number aberrations, are excluded and the analysis is repeated. This
cycle is iterated until the list of bins that are used stabilizes. We
found this approach to be of little benefit in most cases, and the
data presented in this paper have been corrected without this
iterative step.
In total, this procedure removed 12,278 of the 15-kb bins
(6.9%). Together with the 12,893 bins that consist of only
uncharacterized nucleotides (N’s in the reference genome se-
quence), they form 954 separate continuous regions, which are
listed in Supplemental Table S2.We also list the 2273 genes that fall
within these regions, which thus includes genes in common germ-
line CNVs. Figure 2D shows the final profile of sample LGG150
with the blacklist filtering and GC-mappability correction applied.
Whole-chromosome losses can be seen involving chromosomes 10
and 22, and a gain of 20. A focal amplification is also present on
chromosome 7, as well as a homozygous deletion on 9p. Final
profiles for all LGG samples, BT474, AB042, and AB052 are shown
in Supplemental Figures S1–S3.
Noise and detection limits
Noise in copy number profiles has contributions from the statistics
of counting sequence reads as well as the many steps in the ana-
lytical chain from sample acquisition and fixation through DNA
isolation, sequencing, and computational processing. Since the
variances of independent noise sources are additive, it is conve-
nient to use the variances of the profiles to investigate their noise
characteristics. Profiles normalized so that the mean value is 1.0
have variances due to counting statistics equal to 1/N, where N is
the average number of reads per bin (neglecting small effects due to
copy number aberrations and the counting corrections). Thus, the
difference between the variance of the copy number profile and
the variance due to counting statistics (1/N) for that profile gives
a measure of the noise contribution from the entire sample han-
dling and analytical process, independent of sequence depth.
Therefore we examined the dependence of the variances of our
profiles on sequence depth.
We first tested the dependence of the variance on read depth
aloneby subsampling reads froma single data setwith 108.4million
mapped reads of sample AB042. The subsampled data ranged over
a factor of 100, from about 600 to 6 reads per bin.We performed the
subsampling five times at each subsampling level and calculated the
variances using a mean-scaled and 0.1%-trimmed first-order esti-
mator. This estimator emphasizes bin-to-bin variation so that it is
not affected by copy number aberrations (see Methods). Figure 3A
shows the variance of the subsampled data for AB042 versus the
variance due to counting statistics (1/N). A regression line fitted to
the subsampled data has a slope of 1.026 and intercept of 0.00107,
very close to the theoretical 1/N counting statistics (slope = 1; in-
tercept = 0). The similar behavior of the measured and theoretical
slopes indicates that variance versus read depth behaves essentially
as expected. The fact that the intercept of the fitted regression line is
close to zero indicates that the noise introduced from the sample
quality and the analytical process is negligible. Thus, the noise is
dominated by counting statistics at the read depths typical for
shallowWGSanalysis (30 readsper bin). [Wenote that copynumber
profiles are typically log2-transformed in our figures. If the variance
were to be calculated based on the transformed profile, the contri-
bution due to read depth would be log2(e)
2/N » 2.08/N].
We also examined the noise introduced by the library prep-
aration and sequencing procedures by performing 10 independent
sequencing runs from one DNA isolation of sample AB052. The
variances of these profiles are also plotted in Figure 3A. The slope
and intercept of the regression line are 1.003 and 0.000781, re-
spectively. Thus, the total variance is again very close to the vari-
ance due to counting statistics (1/N), indicating that the library
preparation and sequencing procedures have an insignificant
contribution to the total variance. Further, the profiles from most
of the LGG samples and the cell line BT474, which represent
completely independent samples, also had variances very close to
the theoretical counting statistics limit (Fig. 3A). Thus, DNA sam-
ples from a range of specimens obtained from our laboratories
provided near optimal data using this measure.
Importantly, the variance characteristics shown in this small
set of examples are generally representative of our experience
with a large body of clinical specimens from many sources. We
have now analyzed over a thousand samples obtained frommore
than 25 hospitals in five countries, mostly from FFPE tissues. A
minority consisted of snap-frozen tissue samples or DNA extracted
from cells freshly obtained from peripheral blood, sputum,
swabs of the oral mucosa, or cancer cell lines. The samples rep-
resented a wide spectrum of neoplasms, mainly carcinomas, but
also neuroectodermal and mesenchymal neoplasms, as well as
non-neoplastic tissues and cells, generally submitted for detection
of somatic aberrations. In most cases, DNAs were isolated in the




protocols. Sampleswere sequenced in pools of;20 per lane. Figure
3B shows the variances of the resulting profiles versus 1/N for these
samples. This figure shows that for the vast majority of samples,
the overall variance in our profiles is dominated by the read depth.
In our experience, profiles with a variance corresponding to greater
than 30 reads per bin, around 6 million total reads for 15-kb bins
(;0.13 sequence coverage), are suitable for most subsequent
analyses. Because the noise is dominated by counting statistics for
most samples, it is possible to make instructive estimates of the
smallest aberrations that can be detected as a function of read
depth. In Supplemental Figure S7, we present estimates for gain
and loss as well as a simple analytical formula applicable for a wide
range of situations.
We note that some samples have variances clearly above the
1/N line (Fig. 3B). New sample preparation and analysis of several
of these excessively noisy samples indicates that the noise is re-
producible, both in magnitude and in shape along the genome,
suggesting that it has its origin in the sample. Most likely it is due
to degraded/damagedDNA resulting from the fixation and storage.
Increasing sequence depth will not reduce this noise relative to the
(1/N) line for variance due to counting statistics.
The software package QDNAseq
The software package QDNAseq was developed to implement the
novel profile correction and blacklisting approach described above
and to perform downstream segmentation and calling of aberra-
tions using well established software tools. QDNAseq uses BAM
files as input because they are produced by the commonly used
alignment algorithms such as BWA (Li and Durbin 2009). The
program is implemented in R (R Core Team 2014) and is available
in Bioconductor (Gentleman et al. 2004). Detailed information
concerning its operation is included in the Bioconductor vignette.
Briefly, bin size, LOESS parameters, and blacklisting parameters are
adjustable. Blacklisted bins can be visualized, as in Figure 2, A and
C. Options are to either filter out bins overlapping with the
ENCODE blacklist (1723 bins when using the 15-kb bin size) and/or
the blacklist we developed from the 1000G data (11,124 bins). A
key feature of QDNAseq is the use of fixed-sized bins, which is
necessary for most published downstream procedures that handle
series of tumor samples (van deWiel et al. 2011). Use of fixed-sized
bins furthermore allows calculation of annotation data (GC content,
mappability, overlap with ENCODE blacklist, 1000G residuals) in
advance, facilitating computation and analysis procedures. Analysis
is therefore relatively rapid. For example, processing of the LGG150
sample included in this paper takes 75 sec from the input BAM file to
the filtered and corrected profile in Figure 2D on a standard work-
station or laptop with a 2.3 GHz Intel Core i5 CPU. Included in the
QDNAseqpackage is also anoption to compare tomatched reference
samples should that be desired (see Supplemental Fig. S8).
The output of QDNAseq is read counts per bin, which have
been corrected, filtered, normalized, and optionally log2-trans-
formed. QDNAseq was built in a modular fashion such that anal-
ysis tools and pipelines for downstream segmentation and copy
number calling previously developed for microarrays (for review,
see van de Wiel et al. 2011), for example, can be readily applied.
Downstream analysis can also be performed and was tested with
the commercially available software suite Nexus Copy Number
(BioDiscovery). QDNAseqhas also beenmade available inChipster
(Kallio et al. 2011) and Galaxy (Goecks et al. 2010) and allows
export of the copy number results into the Integrative Genomics
Viewer (IGV) (Thorvaldsdottir et al. 2013). The popular segmen-
tation package DNAcopy (Venkatraman and Olshen 2007) can be
invoked directly fromwithinQDNAseq. In addition to the existing
user-definable parameters available in DNAcopy, an option to
smooth signals over a specified number of consecutive bins has
been added in QDNAseq. For calling (annotation of segments with
copy number states such as gain, amplification, or loss), the
package CGHcall (van de Wiel et al. 2007) can be invoked at the
user’s discretion.
Figure 3. Dependence of variance on sequence depth. (A) The relationship between sequence depth and variance ðbs2DÞ for 15 LGGs (black), cell line
BT474 (blue), 10 independent library preparations of SCC sample AB052 (yellow), and subsamplings of AB042 data (red). All individual samples are within
the left half of the graph, with the subsamplings extending to the right half as well. The black line shows the linear expectation of the variance as 1/N, where
N is the average number of reads per bin. Lines fitted through the AB042 subsamplings and AB052 repeats have slopes of 1.026 and 1.003, and intercepts
of 0.00107 and 0.000781, respectively. (B) The relationship between sequence depth and variance for more than a thousand samples sequenced at our
institute.
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Comparison to other algorithms and array CGH
Multiple algorithms have been developed for DOC DNA copy
number analysis. Most compare the tumor sample to a reference
signal and thus require acquisition of an appropriate reference
sample and additional sequencing. Two algorithms have been
published for analysis of shallow WGS that do not require a refer-
ence signal, readDepth (Miller et al. 2011) and FREEC (Boeva et al.
2011). Both adjust read counts and/or filter out bins based on GC
content and mappability, but lack other blacklisting options such
as those based on ENCODE or the 1000 Genomes-based blacklist.
Both have integrated segmentation and calling to identify gains
and losses. Since the novel aspects of QDNAseq occur in the de-
termination of the filtered and corrected read count profile, we
opted to evaluate the performance of QDNAseq relative to the
preprocessing parts of these other analysis packages. However,
readDepth does not output bin-level data so we could only com-
pare our results with FREEC. A third program, CLImAT, was re-
cently published which, among other things, infers copy number
from the observed sequence depth without requiring a reference
signal (Yu et al. 2014). The goal of this program, however, is to use
relatively deep (103 genome coverage) sequencing to obtain in-
formation that is not available from a small number of reads (0.13
genome coverage), which is the focus of our work. The CLImAT
algorithm uses a simpler form of simultaneous GC and mappability
correction that is likely to be too noisy at our read depth, so we did
not evaluate it.
Both QDNAseq and FREEC perform better than the Agilent
array CGH platform at the sequencing depths used here. Figure 4,
A, B, and C shows the profiles of sample LGG150 obtained with
QDNAseq, array CGH, and FREEC, respectively. The data from
QDNAseq and FREEC are very similar in their calculated noise, but
FREEC contains several focal apparent gains and losses that are not
present in the QDNAseq data due to blacklist filtering. These arti-
factual features in FREEC output are at risk of being interpreted as
true aberrations. Array CGH has greater noise and more outliers
than with both sequencing analyses, with a standard deviation
of 0.19 compared to 0.17 for sequencing analyses. Moreover,
the deflections for the copy number changes are larger for the
sequencing methods than for array CGH. The average signal-to-
noise ratio (SNR) for 12 whole-chromosome aberrations among
Figure 4. Comparison to other methods. (A) Final copy number profile of sample LGG150 obtained with QDNAseq after removing blacklisted bins and
correcting read counts for GC content and mappability. This procedure results in 166,909 bins, and highlighted in red are those 750 bins that are not
contained in the output of FREEC. (B) Copy number profile of sample LGG150 obtained with an Agilent 180K microarray with 164,378 unique array
elements. (C ) Copy number profile of sample LGG150 obtained with FREEC with 170,474 bins. Highlighted in red are those 4315 bins that are not
contained in the output of QDNAseq. Note that many of the red bins are in focal peaks that have the potential of being called aberrations but which are
probably spurious since they are contained in the QDNAseq blacklists. (D) Noise ðbs2DÞ for QDNAseq versus FREEC calculated from the thousand samples in
Figure 3B. Only the 166,159 bins present in the output of both algorithms were used in order to eliminate differences caused by blacklisting spurious bins.




the 15 LGG samples was 1.89, 1.91, and 1.40 for QDNAseq, FREEC,
and aCGH, respectively (Supplemental Table S3).
Comparison of data obtained with QDNAseq and FREEC on
the entire set of ;1000 samples shows that the variance with
FREEC was never lower than with QDNAseq and often somewhat
higher (Fig. 4D). To assure that the comparison concentrates on
differences in read count corrections and not the filtering of
blacklisted bins, the variance calculations were performed only on
the set of bins contained in the output of both programs. This
shows that the simultaneous correction for GC content and
mappability implemented in QDNAseq always performs at least as
well as the sequential corrections in FREEC and is better for some
samples.
Simultaneous correction for GC content and mappability out-
performs separate corrections for cases in which the two parameters
interact. The interaction can be seen from examination of the LOESS
surfaces for the various samples. For sample LGG150 presented in
Figure 1, read counts always increase with increasing mappability
regardless of GC content. Thus to a reasonable approximation there
is minimal interaction. In contrast, samples LGG155 and LGG259
both have read count maxima along the mappability-axis that vary
with GC content (Supplemental Figs. S1, S2). Consequently, a single
correction curve for GC that is applied to all mappabilities, and vice
versa, will not properly correct these samples.
The major benefit of our simultaneous correction approach is
seen in the removal of spurious regions of variation in the profiles.
Supplemental Figure S9 shows profiles for the whole genome and
for chromosome 1 generated from the same sequencing data by
QDNAseq and FREEC for all 15 LGG samples, two SCCs, and BT474.
Examination of the profiles for LGG151 and LGG155 shows clearly
that small features in the profiles produced by FREEC are corrected
by QDNAseq. Similar features also occur on other chromosomes.
Improved correction of this sample-related variability allows use of
more sensitive segmentation and calling procedures for a given level
of false positives. Three of the 15 LGG samples showed significant
improvement using QDNAseq. Thus our correction procedure fa-
cilitates correct biological interpretations from samples with a wider
range of quality.
Discussion
We have described a shallow WGS procedure designed to obtain
high-quality DNA copy number information from fresh and ar-
chival samples. The method was developed in the process of ana-
lyzing over a thousand tumor DNA samples obtained from more
than 25 hospitals in five countries, mostly from FFPE tissue. Our
goal was to provide the best possible read count profiles so that
subsequent segmentation and calling steps would be able to sensi-
tively detect true aberrations at acceptable levels of false positives.
The data presented show that our corrected profiles have noise
levels very near the fundamental limit imposed by the statistics of
read counting formost samples, and are less sensitive toDNAquality
induced artifacts than profiles produced by prior approaches. The
predictable nature of the major noise source of our read count
profiles represent a considerable interpretive simplification com-
pared tomicroarray DNA copy number profiles, in which the noise
sources are obscure and copy number changes are frequently re-
duced inmagnitude due to array performance (Snijders et al. 2001;
Ylstra et al. 2006).
Our procedure contains two novel features: simultaneous
correction of counts for GC content and mappability, and empir-
ical recognition of problematic regions of the genome based on
analysis of a group of normal samples. Here, we demonstrate the
performance of QDNAseq on 1000 samples, mostly from archival
FFPE cases. The simultaneous correction for GC and mappability,
using a LOESS fit of the raw count data to the average values of
these parameters for each sequencing bin, always performs at least
as well, and in more degraded DNA samples better, than the sep-
arate corrections that are used by most existing algorithms. Nev-
ertheless, it is also evident that our correction remains inadequate
for some samples. It is likely that a more thorough understanding
of the impact of formalin fixation and the distribution of base
composition and mappabilities within the sequencing bins will
result in improved ability to obtain useful copy number data from
samples that remain problematic. Further, although our blacklist
was developed from 38 normal samples representing a variety of
ethnicities from the 1000 Genomes Project, similarly derived
blacklists tailored to the ethnicity of the population from which
the samples were obtained would allow more precise blacklisting
of common germ-line CNVs relevant for that population.
Shallow WGS is cost effective. Our experience indicates that
high quality DNA copy number information can be obtained with
;6 million reads per sample (;0.13 genome coverage). High-
capacity instruments such as the Illumina HiSeq can obtain this
read depth with a multiplex analysis of 20 samples per lane. We
achieved a further increase in efficiency by sequencing only 50 bp
from one end of the DNA molecules, which also allows the use of
compromised samples with short DNA fragments. This level of
sequence depth provides better resolution than is available from
microarrays and costs significantly less. Shallow sequencing has
a particular cost benefit if combined with exome sequencing be-
cause the initial preparation for both is the same. The additional
cost of the shallow sequence run is marginal (;5% extra) and
provides high-resolution genome-wide copy number information.
If the shallow sequencing run is performed prior to exome en-
richment and the exome sequencing run, it can also serve as the
ultimate quality control. Although we obtained most of our data
on an Illumina HiSeq instrument, the use of smaller capacity se-
quencers, such as the Illumina MiSeq, offer rapid turnaround and




Fifteen LGGs (van Thuijl et al. 2014), two SCCs (Bhattacharya et al.
2011), and the breast cancer cell line BT474 were used to develop
and illustrate the shallow WGS pipeline presented. All material
used from LGG and SCC tumors was derived from FFPE archival
samples. Patient consent was obtained for SCCs as published pre-
viously (Bhattacharya et al. 2011). LGG samples were collected
from five Dutch hospitals (VU University Medical Center in
Amsterdam, Academic Medical Center in Amsterdam, Radboud
University Medical Center in Nijmegen, St. Elisabeth Hospital in
Tilburg, and Isala Klinieken in Zwolle). Sample collection was ap-
proved by the Medical Ethics Committees of all five hospitals.
Areas containing > 60% tumor cells were outlined on hematoxylin
and eosin-stained slides, and 10 subsequent 10-mm sections were
used for DNA isolations.
DNA from the LGG samples was isolated as previously described
(van Essen andYlstra 2012). DNA concentrationsweremeasuredwith
the Nanodrop 2000 (Fisher Scientific), and 500 ng was used as input
for ShallowWGS laboratory preparation. DNA from the SCC samples
was isolated as previously described (Bhattacharya et al. 2011),
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DNA concentrations were measured with the Qubit 2.0 fluorom-
eter dsDNA BR Assay (Life Technologies), and 250 ng DNA used as
input for shallow WGS laboratory preparation. The BT474 breast
tumor cell line was cultured and DNA isolated as previously de-
scribed (Krijgsman et al. 2013). DNA concentration was measured
with the Qubit fluorometer and 250 ng used as input.
Shallow WGS laboratory preparation
DNA was sheared on a Covaris S2 (Covaris) with the following
settings: duty cycle 10%, intensity 5.0, bursts per sec 200, duration
240 sec (FFPE), duration 300 sec (fresh and fresh-frozen), mode
frequency sweeping, power 23V, temperature 5.5°C to 6°C, water
level 15. Sample preparation was then performed with the TruSeq
DNA kit V2 (Illumina). After end repair and 39 adenylation, adapter
ligation was performed with 1 mL of adapter index for fresh (frozen)
samples and 0.55 mL of adapter index for FFPE samples. Final se-
quence library amplification was performedwith 10 PCR cycles for
FFPE derived DNA samples or eight cycles for DNA derived from
fresh or fresh-frozen samples. One PCR cycle included 10 sec 98°C,
30 sec 60°C, and 30 sec 72°C. The PCR program started with 30 sec
98°C and ended with 5 min 72°C. The final holding temperature
was 10°C.
The yield of the sequence library was assessed with a Bio-
analyzer DNA 1000 and/or HS DNA (Agilent Technologies). Li-
braries with small PCR products (;120 nt in length caused by
unligated adapter dimers) or large PCR products (> 1000 nt in
length caused by an exhausted PCR mix) were selected for clean-
ing. Cleaning was performed by using a double-sided bead size
selection procedure with Agencourt AMPure XP beads (Beckman
Coultier). Libraries were equimolarly pooled with 18–22 barcoded
samples and 7 pM molarity loaded per lane of a HiSeq Single End
Flowcell (Illumina). This was followed by cluster generation on
a cBot (Illumina) and sequencing on a HiSeq 2000 (Illumina) in
a single-read 50-cycle run mode (SR50).
Alignment to reference genome
Sequence reads were aligned to the human reference genome build
GRCh37/hg19 downloaded from Ensembl (Flicek et al. 2013) with
BWA 0.5.9 (Li and Durbin 2009), with a maximum edit distance of
2 and base trimming quality of 40. PCR duplicates were marked
with Picard 1.61 (http://broadinstitute.github.io/picard/), and fil-
tered out with SAMtools 0.1.18 (Li et al. 2009) together with reads
with mapping qualities (MAPQ) lower than 37. We note that the
maximumpossible value and the distribution ofmapping qualities
varies between aligners, and a different cutoff might be suitable for
e.g., Bowtie (Langmead and Salzberg 2012), which was tested here
but did not show an improvement over BWA for copy number
assessment.
Annotations for genomic bins
The genome was divided into nonoverlapping, fixed-sized bins of
15 kb. GC content of each binwas calculated as number of C andG
nucleotides divided by number of A, C, G, and T nucleotides in the
reference sequence. The percentage of characterized nucleotides
was calculated by dividing the number of nucleotides A, C, G, and
T with the bin size (15 kb). This is used to adjust read counts for
bins partially covered by uncharacterized nucleotides (N’s) or in-
complete bins at the very ends of chromosomes.
Mappability is a measure of the uniqueness of a specific se-
quence in the reference genome and depends on the length of the
sequence and the number of mismatches allowed. If Fk(x) is the
frequency at which the k-mer sequence at position x is observed in
the reference genome sequence and its reverse complement, the
mappability of this position is defined as Mk(x) = 1/Fk(x). In this
paper, we use the term mappability to refer to the average
mappability of all 50-mer sequences within a bin, allowing for two
mismatches, and scaling the value from0 to 100. These valueswere
calculated from the ENCODE alignability track for 50-mers (data
version January 2010) with the bigWigAverageOverBed program
downloaded from the UCSC Genome Browser (Kent et al. 2002;
Rosenbloom et al. 2013).
The ENCODE blacklisted regions (March 2012 Freeze) were
used to calculate percent overlap with each bin. Pregenerated bin
annotations are available for human reference genome build
GRCh37/hg19 and bin sizes of 1, 5, 10, 15, 30, 50, 100, 500, and
1000 kb.
Binning and correction of read counts
The number of sequence reads in each bin was calculated. Read
counts were adjusted for those 487 bins that are only partly cov-
ered by characterized nucleotides in the reference genome se-
quence. For a bin containing a proportion r of uncharacterized
nucleotides, no reads could be mapped to this fraction of the bin,
and the read count was therefore adjusted by dividing it by 1  r.
Next, median read counts were calculated as a function of GC
content and mappability. For this purpose, GC content and
mappability values were rounded to integers (IEC 60559 standard).
A two-dimensional LOESS surface was then fitted to the observed
median read counts. The read count for each bin was then cor-
rected by dividing it with the fitted LOESS value.
Optimal parameters for the LOESS correction were evaluated
with an odd-even cross-validation as follows: Bins were divided
into odd and even bins, and only odd ones were used to calculate
the LOESS correction as above. The same correction was then ap-
plied to both odd and even bins, and the absolute values for dif-
ferences in adjusted counts between adjacent odd and even bins
were calculated. A test statisticwas calculated as a trimmedmeanof
the absolute values after removal of the upper 10% to account for
copy number breakpoints. Parameter values of span = 0.65 and
family = ‘symmetric’ were chosen to minimize the value of the test
statistic.
1000 Genomes residuals
The blacklist based on 1000 Genomes samples was generated as
follows. Publicly available samples from the 1000Genomes Project
that matched the experimental setup were downloaded (Illumina
single-read of at least 50 bp, low coverage, whole-genome se-
quencing). For samples with read lengths longer than 50 bp, the
reads were truncated to the first 50 bp. In total, 38 samples that
matched the experimental setup were available. Alignment and
two-dimensional LOESS correction were then performed as outlined
above. Residuals [(observed read count  LOESS fit)/LOESS fit] from
the correction were recorded, and medians per bin were then cal-
culated across the 38 samples. Cutoff for exclusion was set at 4.0
standard deviations (as estimated with a robust first-order estimator
[von Neumann et al. 1941]). After bins exceeding this cutoff were
removed, the LOESS correction was repeated without these
anomalous bins and residuals calculated again. This process was
repeated until the list of bins to be excluded stabilized.
Noise, comparison to other algorithms, and array CGH
FREEC (version 6.4) (Boeva et al. 2011) was run with a bin size of
15 kb, mappability-based read count correction turned on, mini-




settings were selected to mimic QDNAseq as closely as possible. As
a measure of noise, we used an estimator based on first-order dif-
ferences (von Neumann et al. 1941). This noise estimator is sen-
sitive to uncorrelated bin-to-bin read count differences along the
profile, but is largely unaffected by correlated behavior of groups of
bins such as steps in the profile due to true copy number aber-
rations or long-range waviness. For robustness against large out-
liers, we excluded 0.1% of extreme values from both ends of
the distribution. Unless specified otherwise, terms ‘‘standard
deviation’’ and ‘‘variance’’ used in this paper refer to this mean-
scaled 0.1%-trimmed first-order estimate and its square, re-
spectively. They are calculated for a linear representation of the
profiles even though we present log2-transformed profiles for
display convenience. The standard deviation of a profile, denoted
by bsD, and the theoretically expected standard deviation based on
read counting, denoted by E s, are given above each profile.
All samples were profiled with CGH arrays that contained
180K in situ synthesized 60-mer oligonucleotides evenly distrib-
uted (every 17 kb) across the genome (Agilent Technologies).
BT474 CGH arrays were performed previously (Krijgsman et al.
2013) and data downloaded from the GEO database (Edgar et al.
2002) with accession numberGSM903069. Labeling, hybridization,
scanning, and feature extraction were carried out as previously de-
scribed (Krijgsman et al. 2013) with pooled normal reference sam-
ples. After median normalization, wave-correction was performed
with NoWaves (van de Wiel et al. 2009), which would account for
GC variation across the genome. The SCC samples have also been
previously characterized by 2K BAC arrays which data are available
in GEO with accession GSE28407 (Bhattacharya et al. 2011).
Data access
QDNAseq package is available through Bioconductor (http://www.
bioconductor.org/) (Gentleman et al. 2004). Source code is avail-
able in GitHub (https://github.com/ccagc/QDNAseq/), and for the
version used to generate data presented in this paper, also in the
Supplemental Material. Sequence and microarray data have been
submitted to the European Genome-phenome Archive (EGA;
http://www.ebi.ac.uk/ega/) (Leinonen et al. 2011) which is hosted
at the EBI, under accession number EGAS00001000642.
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Abstract
Background: The disease course of patients with diffuse low-grade glioma is notoriously unpredictable. Temporal
and spatially distinct samples may provide insight into the evolution of clinically relevant copy number aberrations
(CNAs). The purpose of this study is to identify CNAs that are indicative of aggressive tumor behavior and can
thereby complement the prognostically favorable 1p/19q co-deletion.
Results: Genome-wide, 50 base pair single-end sequencing was performed to detect CNAs in a clinically
well-characterized cohort of 98 formalin-fixed paraffin-embedded low-grade gliomas. CNAs are correlated with
overall survival as an endpoint. Seventy-five additional samples from spatially distinct regions and paired recurrent
tumors of the discovery cohort were analyzed to interrogate the intratumoral heterogeneity and spatial evolution.
Loss of 10q25.2-qter is a frequent subclonal event and significantly correlates with an unfavorable prognosis. A
significant correlation is furthermore observed in a validation set of 126 and confirmation set of 184 patients. Loss
of 10q25.2-qter arises in a longitudinal manner in paired recurrent tumor specimens, whereas the prognostically
favorable 1p/19q co-deletion is the only CNA that is stable across spatial regions and recurrent tumors.
Conclusions: CNAs in low-grade gliomas display extensive intratumoral heterogeneity. Distal loss of 10q is a late
onset event and a marker for reduced overall survival in low-grade glioma patients. Intratumoral heterogeneity and
higher frequencies of distal 10q loss in recurrences suggest this event is involved in outgrowth to the recurrent
tumor.
Background
Diffuse low-grade gliomas (LGGs) are regarded as slow
growing malignant brain tumors and patients can live up
to 30 years with this disease. In a subset of patients the
tumor exerts a more aggressive behavior and survival
can be as short as two years [1]. Personalized timing of
postoperative treatment is crucial to forestall progression
in the latter group whilst preventing long-term side-effects
for patients with more favorable prospects [2]. The disease
course of patients with LGGs is correlated with gene
mutations, such as in p53 and IDH1, hypermethylation
of MGMT as well as chromosomal copy number aberra-
tions (CNAs). Regarding the latter, assessment of com-
bined loss of 1p and 19q currently is implemented in
routine clinical care in specific glioma subgroups given
its favorable prognostic and predictive value [3,4]. Other
CNAs, such as losses of chromosomes 10 and 11p, have
been reported to be prognostically unfavorable, but have
not been introduced into clinical practice yet, possibly
due the limited number of samples included in the stud-
ies and/or lack of validation [5-7]. Unfavorable events
might go undetected as a consequence of intratumoral
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heterogeneity in gliomas [8], which is particularly salient
if they are only present in the more malignant subclones
of LGGs that seed outgrowth of a recurrent tumor [9],
thereby promoting a large extent of resection. As
current knowledge on the temporal and spatial evolu-
tion of CNAs in LGGs is limited, we evaluated CNAs
in a clinically and histologically representative cohort
of formalin-fixed archival samples using shallow whole
genome sequencing (shallow WGS). We demonstrate
that loss of part or whole chromosome 10q is prognos-
tically unfavorable and often present in a subclonal
manner.
Results
Clinical and histological data
We studied 173 formalin-fixed paraffin-embedded (FFPE)
samples from 98 LGG patients, including spatially distinct
regions and paired recurrent tumors, by shallow WGS.
Patients had either deceased or had passed the median
survival time of six years for LGGs. Other inclusion cri-
teria and patient characteristics of this discovery cohort
are summarized in Figure 1 and Table 1. Age at diagno-
sis, overall survival and postoperative treatment (type
and timing) varied extensively between patients, but not
between the five participating hospitals, which contrib-
uted nearly equal numbers of cases. Comparison of
overall survival between patients treated immediately
after surgery and those for whom postoperative treat-
ment was withheld did not reveal statistically significant
differences. Characteristics of the LGG patients of the
French validation (n =126) [5] and confirmation cohorts
(n =184), the latter from publicly available data from
The Cancer Genome Atlas (TCGA) [10], are also listed
in Table 1. Due to the retrospective character of this
study, the cohorts are not matched; there is considerable
variation in duration of follow-up and the percentage of
patients deceased and for which information on overall
survival is available, as well as in the distribution of histo-
logical subgroups.
Copy number detection by shallow WGS in LGGs
To obtain genome-wide copy numbers from the FFPE
samples of our discovery cohort, we evaluated the use of
shallow WGS. First, for sample LGG284 a paired-end
100 (PE100) sequence run was performed. Copy number
profiles were produced by counting the unique sequence
Figure 1 Accrual of samples and clinical data of the discovery cohort. Samples were selected based on criteria listed in the boxes
connected with vertical arrows. Reasons for exclusion of samples are listed in boxes in the right panel, connected with horizontal arrows. The
number below each box represents the number of patients. Boxes below the dotted line list criteria for collection of recurrent tumors and
spatially distinct regions of LGGs. AII, astrocytoma; H&E, hematoxylin and eosin; OII, oligodendroglioma; OAII, oligoastrocytoma.
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tags per 15 kb bin of the paired-end 100 bp reads from
both ends (PE100 in Figure S1A in Additional file 1), the
single 100 bp read from one end (SR100 in Figure S1B in
Additional file 1) and the trimmed first single 50 bp read
from the same end (SR50 in Figure S1C in Additional file 1).
The noise (measured as variance) of the different profiles
is very similar and CNAs observed are indistinguishable
from each other, which implies that the uniqueness of the
50 bp sequence tags suffices to infer copy number levels,
and longer reads are not necessary. Array comparative
genomic hybridization (array CGH) was performed on the
same DNA sample, which confirmed the CNAs detected
(Figure S1D in Additional file 1). For an additional eight
samples both 50 bp single-read (SR50) shallow WGS and
array CGH were applied as technical validation. Shallow
WGS and array analysis invariably yielded the same CNA
profiles (Figure S2 in Additional file 1). Based on this in-
formation, all subsequent analyses were performed using
50 bp single-read (SR50) shallow WGS since it is more
cost-effective and allows the use of samples with short
DNA fragments, which are frequently obtained with FFPE
materials. The most frequent CNAs, detected in more
than 10% of cases, are whole or partial loss of chromo-
somal arms 9p, 10q, 12p, 13 and 14, as well as gain of
chromosomal arms 7q, 8q, 10p and 11q. The most fre-
quent CNAs in this cohort are co-deletion of 1p and
19q often accompanied by loss of whole chromosome 4,
all commensurate with previous reports [11] (Figure 2).
The prognostic value of CNAs in discovery, validation and
confirmation cohorts
Association of survival with CNAs detected in the dis-
covery cohort was tested. In addition to the known
prognostically favorable 1p/19q co-deletion, five further
chromosomal losses at chromosomes 9p, distal 10q,
11p, 13q, and 22q presented with statistical significance
(Table 2). No associations were observed with gains.
Significant regions were verified in the French validation
cohort of 126 diffuse LGG patients (Table 1). Loss of
distal 10q was an unfavorable CNA in both cohorts,
whereas losses of chromosomal regions at 9p, 11p, 13q
and 22q were not substantiated in the validation cohort
(Table 2). In the discovery cohort, median overall sur-
vival for patients with or without loss of whole or distal
10q was respectively 6.6 years versus 16.7 years (18/98,
P-value =0.009). The size of chromosome 10 deletion
varies from whole chromosome loss (5/18) to 22.5 Mbp
distal loss (10q25.2- 10qter). An association between
loss of this region with overall survival was finally tested
in the TCGA dataset of LGG. Despite the limited num-
ber of patients deceased in this cohort (Table 1), a sig-
nificant association with overall survival was observed
(P-value =0.0018) (Figure 3), which confirms that distal
10q is a prognostically unfavorable chromosomal aberration.
In the discovery cohort, absence of IDH1 or IDH2muta-
tion (11/98) was overrepresented in patients with distal
10q loss (7/11; five with whole chromosome 10 loss and
two with distal 10q loss). After splitting the cohort by IDH
status, a trend for distal 10q loss was observed; in the IDH
mutant subgroup (n =87) the log rank test for loss of 10q
(n =11) yielded a P-value of 0.077, and in the IDH wild-
type subgroup (n =11), a similar P-value of 0.068 was
yielded through the test for distal loss of 10q (n =7).
Co-deletion of 1p/19q was predominantly detected in
LGGs with oligodendroglial histological features while loss
of distal 10q was more frequently identified in astrocytic
LGGs. However, there was no one-to-one relationship be-
tween histological features and these CNAs (Figure 2).
Co-deletion of 1p/19q combined with distal 10q loss was
observed in three LGGs of the discovery cohort and four
LGGs of the validation cohort (all with oligodendroglial
features) and none in the confirmation cohort. This lim-
ited number of patients does not allow for proper statis-
tical survival analysis, but median survival of the patients
in these cohorts combined (13.4 years) suggests that loss
of 1p/19q and distal 10q counteracts overall survival.
Table 1 Characteristics of diffuse low-grade glioma















Female 50 (51%) 59 (47%) 93 (51%)
Age at diagnosis (years)
Mean 40.3 39.8 40.8
Median 39.6 39.4 39
Range (21-83) (18-76) (14-87)
Duration of follow-up of patients
still alive at last evaluation (months)
Mean 133.6 39.6 23.7
Median 129.0 30.9 10.7
Range 72-288 1-187 1-185
Patients deceased 46 (47%) 32 (25%) 18 (10%)
Overall survival of patients
deceased at last evaluation
(months)
Mean 89 48.6 63.5
Median 149.0 51.8 65.6
Range 1-361 0.1-98 1.2-132.6
Histological subtypes
Oligodendroglioma 43 (43%) 53 (42%) 87 (47%)
Astrocytoma 42 (42%) 23 (18%) 40 (22%)
Oligoastrocytoma 15 (15%) 50 (40%) 57 (31%)
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Simultaneous testing of both CNAs classified LGG pa-
tients with a favorable (1p/19q co-deletion), unfavorable
(distal 10q loss), or intermediate (both) prognosis in all
three cohorts (Figure 3A,B,C). In the discovery cohort,
hazard ratios of 1p/19q co-deletion without distal 10q loss
and of distal 10q loss without 1p/19q co-deletion were
0.30 (95% confidence interval 0.15 to 0.58), and 2.91 (95%
confidence interval 1.53 to 5.55), respectively (Table 3).
Intratumoral heterogeneity of CNAs in LGGs
In addition to the above-mentioned CNAs detected in
single samples, we studied intratumoral heterogeneity by
shallow WGS of multiple, spatially distinct regions ob-
tained during the same surgery. Among other CNAs, dis-
tribution of 10q loss was assessed, illustrated for LGG240
in Figure 4 (more examples are provided in Additional file 2).









































Figure 2 Unsupervised clustering of CNAs in the discovery cohort. Histological subtypes and patients are color-coded on the x-axis and
chromosomes are ordered on the y-axis, 1 to 22 from bottom to top. Shades of green enable visualization of individual chromosomal arms, their
size varying by the number of regions. Hence, a chromosomal arm with many breakpoints based on CNAs is depicted as larger compared with
one with fewer breakpoints. Red, copy number loss; blue, copy number gain; black, no CNA. OII, oligodendroglioma; OAII, oligoastrocytoma;
AII, astrocytoma.
Table 2 Prognostically unfavorable chromosomal regions of loss in diffuse low-grade gliomas




Discovery cohort Validation cohort
(P-value) (P-value)
9 24450001 28650000 9p21.3-21.1 21 7 0.039 1
10 112950001 135435000 10q25.2-qter 18 10 0.009 0.041
11 195001 14250000 11p15.5-15.2 13 15 0.0006 1
13 19500001 92550000 13q12.1-31.3 17 13 0.0001 1
22 34350001 51180000 22q12.3-13.33 11 8 0.000004 1
Frequency and P-value in discovery and validation cohorts calculated by log rank test and adjusted for multiple testing by Benjamini Hochberg and Holm
Bonferroni, respectively. Positions according to GRCh37/hg19.
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1p/19q co-deletion p 0.0001
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distal loss 10q p 0.018 



















1p/19q co-deletion p 0.74
distal loss 10q p 0.0018 
C
Figure 3 Kaplan Meier plots for distal 10q loss and 1p/19q co-deletion in (A) discovery, (B) validation and (C) confirmation cohorts. The
dark blue line indicates loss of distal 10q without 1p/19q co-deletion versus the rest of the cohort (n =15, P-value =0.001 in (A), n =8, P-value =0.018 in
(B), and n =14, P-value =0.0018 in (C). The green line indicates 1p/19q co-deletion without distal loss of 10q (n =38, P-value =0.0001 in (A), n =41,
P-value =0.0005 in (B), and n =47, P-value =0.74 in (C). The light blue line indicates 10q loss and 1p/19q co-deletion (n =3, P-value =0.39 in (A), n =4,
P-value =0.94 in (B), and n =0 in (C). The grey line indicates neither 10q deletion nor 1p/19q co-deletion (n =42 in (A), n =73 in (B), and n =123 in (C).
The y-axis represents the fraction of patients alive, cumulative survival (Cum. Surv.), and the x-axis time in months. Censored patients are indicated with
a vertical bar.
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deflection of 10q was observed (a smaller distance from
the 0-line than for the losses in 1p, 4, or 19q (Figure 4A)
[12]. Assuming clonality of the 1p/19q co-deletion [13],
this difference in extent of copy number loss suggests that
10q loss would only be present in about 30 to 35% of the
tumor cells (Figure S3 in Additional file 1).
To further delineate intratumoral heterogeneity of
CNAs in this sample, the originally outlined area was di-
vided into three sub-regions and an additional tumor re-
gion within the same paraffin section was included
(Figure 4B). The 1p/19q co-deletion as well as chromo-
some 4 loss were present in all sub-regions and
assumed to be clonally present. Losses of chromosomes
9, 10, 13, 15, 18 and gain of chromosome 11 were
present in one or few sub-regions and assumed to be
heterogeneously present (Figure 4C). To technically
validate the intratumoral copy number heterogeneity
observed in LGG240, array CGH was performed for all
but one (insufficient amount of DNA) of the spatially
distinct regions, which confirmed either clonality of
1p/19q and chromosome 4 losses or heterogeneity of
all six chromosomally aberrant regions (Figure S4 in
Additional file 1). Three additional samples with a
clonal type of deflection and four with a marginal de-
flection of (distal) 10q were technically validated by
array CGH (Figure S2 in Additional file 1). Intratu-
moral heterogeneity was detected in 15 out of 17 LGGs
analyzed for this purpose; 68% of the CNAs (84/124)
were not homogeneously present in spatially distinct
regions obtained during the same surgery, such as loss
of chromosomal arm 5q, chromosome 13 and gain of
11p (Figure 5A). Co-deletion of 1p and 19q was the
only CNA that was consistently present in all spatially
distinct regions of LGGs with this combination of
CNAs; others, such as gain of chromosomal arm 7q,
were most often, but not always, clonal. Loss of 10q
was heterogeneously present in seven out of eight
patients (Figure 5B). Histological variability did not
correspond to the extent of heterogeneity.
Temporal evolution of CNAs in LGGs
Forty-seven out of 98 patients were subjected to a second
surgery because of tumor progression. Of 20 patients, 24
recurrent tumors could be retrieved from medical ar-
chives. Almost 50% of CNAs (99/207) in the initial and
paired recurrent tumors were shared and 15% (31/207)
were uniquely detected in the initial tumor. A substantial
proportion (37%, 77/207) of CNAs was uniquely identified
in the recurrent tumor, such as loss of genomic regions at
chromosomes 4, 10 and 15 (Figures 5C and 6). 1p/19q
co-deletion was consistently identified in initial as well as
recurrent tumors and there were no cases with new
1p/19q co-deletion. In four patients, de novo loss of
10q (including distal 10q losses) surfaced in the recur-
rence. In hindsight, marginal deflection of 10q was ob-
served in the initial tumor of one of these four patients,
and was not detected by the calling algorithm [12]. In
two out of four patients with new loss of 10q a higher
malignancy grade (WHO grade III or IV) had been
assigned to the recurrent tumor (Figure 5D). In one of
the three patients for which both spatially distinct re-
gions of the initial tumor and recurrences were ana-
lyzed, subclonal 10q loss was present in one of the
regions of the initial tumor, but undetectable in the re-
currence (Additional file 3). In the other two patients,
10q loss was detected in both the initial and paired re-
current tumor.
Discussion
Intratumoral heterogeneity at the genomic level has been
observed in numerous types of cancer, although its impli-
cations for treatment often remain undetermined. In the
present study, archival LGG material and matched clinical
data provide insight into spatial and temporal evolution of
Table 3 Association of clinical and genetic parameters with overall survival in the discovery cohort
Parameter n P-value HR
Age >50 years 23/98 0.187 1.57 (0.80-3.07)
Pre-operative KPS score <80 5/83 0.101 2.42 (0.79-7.05)
Pre-operative use of steroids 18/85 0.068 1.84 (0.99-3.58)
Pre-operative mass effect 37/71 0.0008 3.31 (1.61-6.73)
Pre-operative enhancement 35/79 0.031 2.16 (1.05-4.43)
Partial resection 69/90 0.029 2.85 (1.19-7.47)
Oligodendroglial histology 42/98 0.016 0.47 (0.25-0.87)
IDH1 or IDH2 mutation 86/97 0.071 0.47 (0.21-1.07)
1p/19q co-deletion without 10q loss 41/98 0.0001 0.30 (0.15-0.58)
Loss of 10q without 1p/19q co-deletion 15/98 0.001 2.91 (1.53-5.55)
Results were determined using a log rank test. n, patients in subgroup compared with total number of patients with available data for each parameter; HR, hazard
ratio (95% confidence interval). KPS, Karnofsky Performance Score.
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Figure 4 Chromosomal copy number profiles for sample 240 demonstrating intratumoral copy number heterogeneity. (A) CNA profile
of initial tumor, clonal 1p/19q co-deletion, loss of chromosome 4 and intermediate level of loss of chromosome 10. (B) Hematoxylin and eosin
stained slide showing regions used for DNA isolation: the red dotted line corresponds to the region used for chromosomal profile of 4A and
regions outlined with a solid black line (labeled i to iv) were used for the chromosomal profiles of 4C. (C) CNA profiles from four non-overlapping
regions. Insets at the top right corner of each profile show histological features representative for individual regions. In all regions the histopathological
diagnosis was LGG, although within a tumor the regions analyzed for spatial heterogeneity often showed some variation in microscopic features, such
as cellularity and nuclear size and shape. (i) Clonal 1p/19q co-deletion and loss of chromosome 4; (ii) clonal 1p/19q co-deletion, loss of chromosome 4
and intermediate loss of chromosome 10; (iii) clonal 1p/19q co-deletion, loss of chromosome 4, intermediate loss of chromosome 10 and intermediate
gain of chromosome 11; (iv) clonal 1p/19q co-deletion, intermediate loss of chromosomes 4, 10q, 13, 15 and 18. The y-axis represents normalized log2






































































Figure 5 Spatial and temporal evolution of CNAs in LGGs and paired recurrent tumors. (A) CNAs in spatially distinct regions of LGGs of 17
patients. CNAs are categorized by detection in all regions (left panel), more than one region but not all regions (middle), or one region (right).
Patients are ordered by the number of regions analyzed of each LGG from high to low. (B) Summary of prognostically relevant CNAs in spatially
distinct regions and histology. No intratumoral heterogeneity was observed for 1p/19q co-deletion in any of the tumors, while distal 10q loss was
often only detected in subclones. OII, oligodendroglioma; AII, astrocytoma; OAII, oligoastrocytoma. (C) CNAs in initial and paired recurrent tumors
of 20 patients. CNAs are categorized by detection in initial tumor only (left panel), both initial and recurrence (middle) or detection uniquely in
the recurrence (right). Patients are ordered by the histological malignancy grade of the recurrent tumor. (D) Summary of prognostically relevant
CNAs in paired initial and recurrent tumors. 1p/19q co-deletion is stable over time, while distal 10q loss surfaces in recurrences, including two
with a higher malignancy grade than LGG. Patients are color-coded on the x-axis and chromosomes are ordered on the y-axis, 1 to 22 from
bottom to top. Shades of green enable visualization of individual chromosomal arms, their size varying by the number of regions. Hence, a
chromosomal arm with many breakpoints based on CNAs is depicted as larger compared with one with fewer breakpoints. CNAs smaller than 5
Mbp were excluded from this figure. Red, copy number loss; blue, copy number gain; black, no CNA. The arrowhead indicates patient 240, the
black squares three LGGs analyzed for both spatial and temporal evolution.
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prognostically relevant CNAs. All LGG samples collected
for this study were included for copy number profiling by
shallow WGS combined with a depth of coverage ap-
proach, yielding high quality data without technical drop-
outs. This approach proved to be particularly beneficial
for our study, since no matched normal DNA is required,
which is a major advantage when analyzing long-term ar-
chived FFPE tumor samples. While shallow WGS cannot
detect copy-neutral loss of heterozygosity or rearrange-
ments, it is cost-effective, with a quality comparable to
array CGH and applicable to DNA isolated from the FFPE
samples. This allowed us to include samples that had been
archived for over 30 years and collate a representative co-
hort, including LGG patients with long survival.
The relatively low incidence of LGGs and relatively long
overall survival of patients necessitated this retrospective,
multi-center approach. The observed variability in post-
operative treatment can be attributed to the lack of a
standard of treatment for these patients. Despite these
variations, distal 10q loss (including whole chromosome
losses) was significantly associated with an unfavorable
prognosis in the discovery, validation and confirmation
cohorts. Previously, some studies with smaller cohorts
of specific histological subgroups of LGG have reported
a correlation between 10q and survival [6,7]. Further-
more, a high prevalence of whole chromosome 10 loss
and strong negative correlation with survival have been
reported for grade III and IV gliomas [14-17]. Partial
loss of 10q is much more frequently detected in histo-
logical grade II diffuse gliomas compared with grade III
and IV gliomas. In each of the previously published
studies the whole of chromosome 10 or the entire 10q
arm was taken into account. Here we demonstrate that,
different from higher grade gliomas, the distal end of
10q is frequently lost and associates with overall sur-
vival in three cohorts. Spatial as well as temporal ana-
lyses suggest that subclones with distal loss of 10q are
involved in tumor progression, since the loss surfaces
in paired recurrent tumors with a higher malignancy
grade.
Identification of the genes and their proteins affected
by CNAs may elucidate the biological underpinnings of
their clinical relevance but can be challenging, especially
when a genomic region is large. Only after many years
were mutations in CIC and FUBP1 associated with co-
deletion of chromosomal arms 1p and 19q [18,19]. In
total 148 genes are located on 10q25.2-qter, including
MGMT, DMBT1 and ERCC6 [16,20,21], while the usual
suspect, PTEN, is located more proximal to the centro-
mere [16] and is preferentially lost in higher grade gli-
omas [4].
Based on our findings, we suggest that patients with
an LGG should be simultaneously tested for both 1p/19q
co-deletion and distal loss of 10q, since these two phe-
nomena seem to have counteractive effects on survival.
Introduction of heterogeneous CNAs, such as distal 10q
loss, in daily clinical practice requires a robust diagnostic
test. The well-known clonal features of 1p/19q co-deletion
have been helpful to interpret these intermediate copy
number levels in LGGs [13]. Analysis of multiple spatially
distinct regions could reveal subclones. We currently favor
genome-wide analysis, which visualizes chromosomes 1p,
distal 10q and 19q simultaneously, and at the same time
may provide insight into intratumoral heterogeneity
within one region. Both extent of resection as well as
the subclonal character of important markers for progres-
sion command alternative diagnostic procedures to assess















Figure 6 CNAs in initial and recurrent tumors. (A) Gains; (B) losses. The top of each graph shows the initial tumors, and the bottom the
recurrences. Partial loss of chromosomal arm 4q, 9p and 10q were more frequently detected in recurrences. Bins are ordered by genomic
position and from chromosomes 1 to 22 on the x-axis; percentages of cases showing CNAs are depicted on the y-axis.
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the future be offered through peripheral blood screening
[4]. Meanwhile, detailed registration of the positions of
samples from different regions within a tumor obtained
during the same surgery may provide more accurate
insight into biologically relevant topics such as the
physical distance and direction of growth of tumor sub-
clones as well as the overall extent of heterogeneity of a
tumor [22].
Conclusions
Copy number analysis by shallow WGS is a robust ap-
proach for archival clinical LGG specimens. For a large
proportion of LGG patients, analysis of CNAs with
prognostic value may improve personalized timing of
therapy. Thereby, loss of distal 10q without 1p/19q co-
deletion is indicative for urgent postoperative treatment,
while in LGGs without loss of 10q and with 1p/19q co-
deletion a wait-and-scan policy should be considered.
The subclonal character of whole or distal 10q loss in a
subset of samples emphasizes the need for maximal extent
of resection, illustrates that single sample diagnostics may
be insufficient for LGG and favors future studies on
genome-wide analysis of multiple spatially distinct sam-
ples to map tumor progression.
Materials and methods
Clinical data and sample collection for discovery,
validation and confirmation cohorts
Approval for collection of clinical data and FFPE tumor
samples for the 98 patients of the discovery cohort was
obtained from the institutional review boards of all five
Dutch hospitals, namely the Medical Ethical Committee
(in Dutch: Medisch-Ethische Toetsingsingscommissie or
METc) of the Academical Medical Center (AMC), the
METc of the Isala klinieken in Zwolle, the METc of the
VU University Medical Center (VUmc) in Amsterdam,
the METc of the St Elisabeth Hospital in Tilburg, and
the METc of the Arnhem - Nijmegen Region for samples
from Radboud University Medical Center in Nijmegen
(CMO). Experimental methods in this manuscript are in
compliance with the Helsinki Declaration. Inclusion cri-
teria and characteristics of the discovery cohort are sum-
marized in Figure 1 and Table 1. Clinical features of the
validation cohort, from a French hospital, can be found
in Table 1; materials and methods are presented in more
detail by Alentorn et al. [5]. For the confirmation cohort,
copy number data of 531 lower grade glioma patients
from the TCGA database were downloaded on 12 June
2014 via the Cancer Browser at UCSC [23]. Clinical data
were available for 373 of these patients, including grade
and overall survival; 184 of these samples were catego-
rized as ‘diffuse glioma histological grade 2’ and selected
as a confirmation cohort [10]. Presumably as a conse-
quence of the fact that only fresh frozen samples were
included in the TCGA cohort, a limited number of pa-
tients are contained in the dataset that had deceased
during follow-up.
Laboratory techniques
Histological revision of samples in the discovery cohort
was performed by two experienced neuropathologists
(EA and PW). For all samples in the discovery cohort, in-
cluding paired recurrent tumors, areas containing >60%
tumor cells were outlined on hematoxylin and eosin
stained slides, and tumor cell percentage estimated and
registered for each sample (Additional files 2 and 3 and
Table S1 in Additional file 4) and 10 adjacent sections
were used for DNA isolation [24]. For the assessment of
intratumoral heterogeneity, spatially distinct regions
were selected based on histological variability and/or
plain physical distance (Additional file 4). These samples
were obtained either from one FFPE block, or individual
blocks from the same surgery (Table S1 in Additional file 4).
DNA (500 ng) was fragmented by sonication (Covaris™
S2, Woburn, MA, USA), and sequenced using a 50 bp
single-read (50 bp SR) modus (Illumina TruSeq DNA-
kit and HiSeq 2000, San Diego, CA, USA). The 100 bp
paired-end (100 bp PE) sequencing modus and array
CGH were used for comparison and technical validation.
Array CGH was performed as described previously [25].
IDH1 and IDH2 mutation analysis was performed as de-
scribed previously [5].
Statistical analysis
Copy number data from shallow WGS were analyzed
using a novel Bioconductor script called QDNAseq [26].
QDNAseq infers copy numbers through depth of coverage
by binning reads uniquely aligned to the human reference
genome build GRCh37/hg19 with Burrow’s Wheeler
Alignment (BWA) [27]. PCR duplicates and reads with
mapping qualities below 37 (highest value returned by
BWA) were filtered. Copy numbers were inferred from
the number of sequence reads per 15 kb bin. A simul-
taneous Loess correction for sequence mappability and
GC content is applied within QDNAseq, which reduces
noise of the copy number profiles, particularly for those
with more degraded DNA. Problematic genome regions
were furthermore filtered by applying our procedures to
sequence data from the 1000 Genomes Project [28] to ob-
tain a blacklist that eliminates problematic regions and the
most common copy number variants of germ-line origin.
Sequence data as well as all array CGH data have been
uploaded to the European Genome-phenome Archive
(EGA; accession number EGAS00001000643).
Calling of CNAs into discreet categories (normal, gain
or loss) for the discovery and validation set was per-
formed with the Bioconductor/R-package CGHcall
[12]. A weighted hierarchical clustering of the CNAs
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was performed using call probabilities to assess similar-
ity of chromosomal profiles [29]. Association with sur-
vival was tested using a log rank test with significance
estimated over 10,000 permutations. After discovery of
regions of interest for survival, consecutive regions in
the same chromosome with P-values <0.05 were fused
together to final regions and the log rank test was re-
peated. Chromosomal regions that were still significant
in the discovery set after multiple testing correction ac-
cording to Benjamini-Hochberg were verified in the inde-
pendent French validation cohort. Therefore, genomic
coordinates were converted to the NCBI35/hg17 genome
build using the UCSC liftOver tool [30] and P-values were
calculated with the log rank test and adjusted with the
more stringent Holm-Bonferroni method. The statistical
significance of a CNA was calculated compared to the
rest of the cohort not bearing this CNA - for example,
samples with loss of distal 10q versus samples without
loss of distal 10q.
Regions significant in both the discovery and validation
cohorts were tested in the TCGA confirmation cohort for
which CNA data were generated with Affymetrix SNP 6.0
arrays (Santa Clara, CA, USA). TCGA level 3 copy num-
ber data were publicly available at the time of download
and mapped to NCBI36/hg18. These level 3 data involve
beginning and end positions of chromosomal segments
with deflection values, resulting from TCGA preprocessing
(for level definitions and preprocessing see [31]). Segment
values were converted to CNA discreet categories by setting
thresholds whereby a log2 ratio of >0.20 is gain, < -0.23
is loss and all other values are normal copy number;
these values correspond to 30% of the tumor cells with
that CNA. Those segments overlapping for at least 90%
of the 1p, 19q (excluding centromeres) or 10q25.2-qter
region (corresponding to NCBI35/hg17: chr10: 112939991-
135323881 and NCBI36/hg18: chr10:112939991-135284990)
were taken into consideration. At this setting 14 patients
had a distal 10q loss, of which 4 deceased during follow-
up and no patients had both distal 10q and 1p/19q loss.
P-value calculations were performed as described above
without corrections since only one region was tested for
confirmation. The threshold settings were selected
based on the fact that a deletion in 30% of the tumor
cells, as observed for the chromosome 10 loss in LGG
sample 240 (Figure S3 in Additional file 1), should not
be missed. All other threshold values for calling losses
of these regions were stepwise tested as well as the per-
centage of overlap with the 10q25.2-qter region and are
presented in Table S2 in Additional file 4. Significance
for the 10q loss remained for many different settings,
but the number of patients with this loss substantially
decreased with widening margins for calling CNAs to
lower than should be expected based on the discovery
and validation cohorts.
To assess the presence of CNAs between spatially distinct
regions and/or recurrences from the same patient, common
regions were detected with CGHregions [32], and regions
smaller than 5 Mbp were excluded. Clinical parameters
were analyzed with log rank test. All reported P-values were
two-sided, and <0.05 was considered statistically significant.
Data availability
Both array CGH and sequence data have been uploaded
to the European Genome-phenome Archive (EGA; ac-
cession number EGAS00001000643).
Additional files
Additional file 1: Figure S1. Evaluation of shallow WGS for genome-wide
copy number analysis for read lengths of sample LGG 284. Copy number
profiles were produced by counting the number of uniquely mapped
sequence tags per 15 kb bin for different settings. (A) Paired-end 100
(PE100), 100 bp reads from both ends. (B) Single-end 100 (SR100),
100 bp reads. (C) Single-end 50 (SR50), 50 bp reads from one end.
(D) Technical validation by array CGH of the same sample. Y-axis, normalized
log 2 sequence read counts per bin; x-axis, 15 kb bins ordered by genomic
position from chromosomes 1 to22. Figure S2. Technical validation of shallow
WGS by array CGH CNA analysis of eight LGGs tested on both platforms.
The level of deflection of CNAs was comparable. Also, heterogeneously
present CNAs with only marginal deflection could be reproduced; LGGs
168, 184 and 193 show clonal distal 10q loss, while LGGs 187, 189, 210,
211 and 224 show subclonal loss of 10q. Figure S3. Minimal tumor cell
percentage required for detection of CNAs. Calculation of the percentage of
tumor cells with a chromosome 10 deletion in LGG240. To simulate a limited
tumor percentage, a virtual tumor-normal mixture experiment was performed
with LGG240 (diffuse low-grade glioma) and NA18960 ((1000 Genomes Project
Consortium). Figure S4. Technical validation of shallow WGS by array CGH.
Technical validation of LGG240 (original) and three spatially distinct regions.
Additional file 2: Copy number profiles generated with shallow WGS
of original LGGs of the discovery cohort and spatially distinct regions
of this tumor obtained during the same surgery. A representative
picture of histology (hematoxylin and eosin staining, original
magnification × 200) is depicted in the top left corner of each profile.
Additional file 3: Copy number profiles generated with shallow
WGS of initial LGGs and paired recurrent tumors. A representative
picture of histology (hematoxylin and eosin staining, original
magnification × 200) is depicted in the top left corner of each profile.
Additional file 4: Table S1. Overview of all samples of the discovery
cohort, including paired recurrent tumors and spatially distinct regions.
Columns show ID number, relative spatial distance (one FFPE block or
individual FFPE block), histology, prognostically relevant CNAs, distal 10q
loss, 1p/19q co-deletion, read count, sequence depth and tumor cell
percentage as estimated by neuropathologists. Table S2A-C. Matrix with
P-values for overall survival of the TCGA LGG (grade 2) confirmation
cohort at various thresholds. Vertical rows: log2 ratio thresholds for calling
CNA discrete categories (loss, normal or gain) from the log2 ratio level 3
data downloaded from the Cancer Browser at UCSC [23]. Horizontal rows:
thresholds for overlap with the 10q25.2-qter region. Grey, non-significant
settings; shades of beige, significant settings (darker indicates higher
signioficance); bold, threshold settings used for Figure 3. (A) P-values
rounded to four decimal places for samples with or without a distal
chromosome 10q loss. (B) Number of grade 2 LGG patients with clinical
data (n =184) from the lower grade glioma TCGA dataset with a distal
10q deletion. (C) Number of grade 2 LGG patients (n =184) from the lower
grade glioma TCGA dataset with a distal 10q deletion that had deceased
during follow-up. Overall survival is significant for various settings of distal
10q loss. The number of patients with distal 10q loss substantially decreased
with widening margins for calling CNAs, to lower than should be expected
based on the French and Dutch cohorts.
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Summary of the original publications
The previous four chapters present origi-
nal, peer-reviewed publications that describe
three bioinformatic solutions for the analy-
sis of CNAs in cancer, and the application
of one of them on survival analysis of dif-
fuse low-grade glioma patients. This chapter
starts with a brief summary of each original
publication, and subsequently discusses them
together from today’s perspective.
CanGEM database for CNAs in
cancer
Chapter 2 (Scheinin et al., 2008) describes
a database developed for array CGH data
from cancer samples. The CanGEM (Cancer
GEnome Mine) database is compliant with
the MIAME standard (Brazma et al., 2001)
and accessible publicly on the Internet. The
areas where CanGEM extends upon existing
microarray databases, such as GEO (Barrett
et al., 2013) and ArrayExpress (Kolesnikov
et al., 2015), is in sample meta-data and mi-
croarray copy number analysis, and the sub-
sequent querying functionality.
The reason we decided to develop a new
database was that while the existing microar-
ray databases fulfilled an important role as
data repositories for published articles, they
were not designed to be approached from the
other direction: the data itself. The primary
use of existing databases was to allow data
sets to be retrieved with an accession num-
ber listed in a published article. What we
envisioned with CanGEM was a resource de-
signed to be queried based on clinical vari-
ables or processed microarray data. A solu-
tion that was designed to answer questions
such as “show me all samples with an EGFR
amplification”, or “all breast cancer cases di-
agnosed before age 30”. Existing databases
were not build for these types of tasks, and
that is why we decided to develop CanGEM.
Clinical data
Since the existing microarray databases house
data from different types of experiments on
various different species, little structure is im-
posed on sample meta-data. It is typically
collected in the form of free-text fields, where
users enter what is in their opinion the most
relevant description. Therefore, it can be dif-
ficult, or even impossible, to perform complex
queries based on sample meta-data.
Since the CanGEM database is focused
on CNAs in cancer, it uses relevant con-
trolled vocabularies for sample annotations.
These include chapter II (Neoplasms) of the
International Statistical Classification of Dis-
eases and Related Health Problems (10th
Revision; ICD-10) and International Classi-
fication of Disease for Oncology (3rd Edi-
tion; ICD-O-3) of the World Health Organi-
zation (WHO), the TNM Classification (Tu-
mor, lymph Nodes, Metastasis), and six of
the ten categories in the eVOC Ontology
(Kelso et al., 2003). Information is also stored
on patient sex, surgery outcome, survival,
cause of death, tumor size, and exposure to
environmental factors. All of these attributes
can be used to query for samples across stud-
ies in the CanGEM database.
Copy number analysis of microarray
data
Another defining factor for the existing
general-purpose microarray databases is that
they contain data from different types of
microarray experiments, from mRNA and
miRNA expression to DNA copy number and
methylation. This makes it a challenge to im-
plement querying functionality based on the
microarray data itself.
As CanGEM is focused on chromosomal
aberrations, copy number analysis of the raw
microarray data is performed with prepro-
cessing, segmentation, and calling (Figure
1.2). This allows users to perform queries for
106
specific CNAs, such as the example question
mentioned above. The copy number analysis
also allows overall aberration frequencies to
be calculated over desired data sets, which
can be defined as the result sets of search
queries, or constructed manually by com-
bining individual studies or samples within
them.
Due to the evolving picture of the hu-
man reference genome, different generations
of microarray platforms have been mapped
to different builds of the reference genome.
To make them comparable, microarray plat-
forms added to CanGEM are re-annotated
through a Megablast analysis of the DNA se-
quences of the array elements (Zhang et al.,
2000). This is performed separately for each
genome build. In addition to simplifying
comparison and combination of results from
different array generations, this type of re-
mapping has also been shown to lead to im-
proved accuracy over mappings provided by
array manufacturers (Elo et al., 2005).
The copy number analysis pipeline of
CanGEM consists of LOESS normalization
(Smyth and Speed, 2003) followed by seg-
mentation and calling, which were originally
performed with CGH-Explorer (Lingjaerde
et al., 2005). After publication of the original
article that describes the CanGEM database,
the pipeline was updated to use DNAcopy
(Venkatraman and Olshen, 2007) for segmen-
tation and CGHcall (van de Wiel et al., 2007)
for calling. Since different platforms have ar-
ray elements that target different positions
in the genome, the final step of the process-
ing pipeline is to define a copy number call
for every known human gene. The list of
their positions was retrieved from the En-
sembl database (Yates et al., 2016). For genes
whose positions in the genome overlaps with
positions of elements on the array, those over-
lapping elements are used to derive the gene-
specific copy number call. For genes with no
overlapping array elements, the last preced-
ing and first tailing element are used. This al-
lows results measured with different microar-
ray platforms to be integrated and queried
together.
Sample size calculations with
CGHpower
Chapter 3 (Scheinin et al., 2010) describes
a dedicated solution for sample size cal-
culations in the context of genome-wide
copy number experiments that compare two
groups of cancer samples. It estimates aver-
age power as a function of sample size, and
uses a pilot data set to estimate parameters.
It is a combination of a copy number analy-
sis pipeline and a statistical framework pre-
viously developed for sample size calculations
in the context of mRNA expression arrays
(Ferreira and Zwinderman, 2006a).
The question how many samples are sta-
tistically required affects every experiment
that aims to compare two groups of patients.
It is a crucial factor that affects not only the
scientific results of the experiments, but also
has a role in justifying the amount of fund-
ing sought with research grants. While there
were existing solutions to other such situa-
tions, no tool had been developed for the spe-
cific context of cancer CNAs. Methods for
sample size calculations usually either ask the
user to specify relevant parameters (such as
the effect size between groups, variance, and
desired levels of statistical significance and
power) or estimate these parameters from ex-
isting data. Because issues such as varying
cellularity, ploidy, and tumor heterogeneity
can affect observed effect sizes, they can be
difficult to estimate without prior measure-
ment data from the tumor type in question.
Therefore, we chose to develop a dedicated
solution that used a pilot data set to per-
form sample size calculations for experiments
that compare CNAs between two groups of
patients.
Copy number analysis and power cal-
culations
In the copy number analysis worklow (Fig-
ure 1.6), there are a number of points that
could be used as the basis for sample size
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calculations. After evaluation of alternative
strategies, the approach we chose was to use
a framework developed for sample size cal-
culations for mRNA expression arrays (Fer-
reira and Zwinderman, 2006a), and com-
bine it with a copy number analysis work-
low that consists of segmentation (Venkatra-
man and Olshen, 2007), calling (van de Wiel
et al., 2007), regioning (van de Wiel and
van Wieringen, 2007), and finally represent-
ing each region with its median log2-ratio.
For each region, t-statistics and p-values
from the normal distribution are calculated
between the two groups. Some of these re-
gions are expected to exhibit a true differ-
ence between the two groups, while others are
not. The p-values for the regions therefore
come from two separate distributions. For
the ones with no real difference, this distri-
bution is the uniform. For the ones with a
difference, the distribution is unknown. This
unknown distribution is estimated with two
estimators. These estimators depend on an-
other unknown parameter, which is the pro-
portion of regions with no real difference be-
tween groups. This proportion is estimated
by minimizing the distance between the two
estimators for the unknown p-value distribu-
tion. Once these estimates and the limiting
density of effect sizes have been calculated, an
adaptive version of the Benjamini-Hochberg
method for multiple testing is used to esti-
mate average power as a function of sample
size (Ferreira and Zwinderman, 2006b).
Diagnostic plots
The accuracy of power estimates produced by
CGHpower depend on the accuracy of model
parameters, which are estimated from a pilot
data set. If parameter estimation performs
poorly, validity of the power estimates will
also be questionable. The program output
contains a set of diagnostic plots that can be
used to assess the quality of parameter esti-
mation.
Performance of CGHpower was evalu-
ated with both simulated and real data sets.
Some cases were found to perform well, but
in a number of them parameter estimation
showed poor performance. This can happen
when model assumptions are not fulfilled. In
particular, the proportion of regions with no
real differences between groups has to be sub-
stantially less than one. In other words, if
only a very small number of regions (such as
1 %) show a true difference between the two
groups, there might be too few data points
available for estimation. While it is clear the
performance of the program is questionable
for some data sets, the diagnostic plots allow
its reliability to be assessed.
Copy number preprocessing with
QDNAseq
Chapter 4 (Scheinin et al., 2014) describes
QDNAseq, a DOC preprocessing method to
detect CNAs from NGS data. It improves
upon existing methods by 1) introducing a
simultaneous correction for GC content and
mappability, and 2) filtering out spurious re-
gions in the genome. It does not require use
of a control sample, can be used for a wide
range of sequence coverage, and performs well
with FFPE samples.
When we started with this project, the
rapid technological improvements and de-
creasing costs of NGS were turning it into
a more appealing alternative to microarrays.
While the technology showed a lot of promise,
data processing workflows to detect CNAs
were limited. False positive CNAs were ob-
served frequently and at recurrent locations,
and the published methods were often diffi-
cult to fit in full analytical workflows of larger
data sets.
Correction to read counts and identi-
fication of problematic regions in the
genome
GC content and mappability are both factors
that are known to affect observed sequence
coverage in NGS experiments. DOC methods
therefore usually include a correction for GC
content, and a correction and/or filtering for
mappability. QDNAseq was the first method
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to introduce a simultaneous LOESS correc-
tion for both GC content and mappability. In
case there was any interaction between the
two biases, a simultaneous correction could
lead to improved performance. Also, it is an
approach that can be extended to further di-
mensions, if additional sources of systematic
bias are discovered in the future.
The human genome includes regions that
are problematic to sequence and character-
ize with current methods. Long stretches of
highly repetitive sequence are hard to assem-
ble into an accurate reference genome. These
regions are especially pronounced near the
centromeres and telomeres, but can also be
found elsewhere in the genome. If left un-
filtered, these regions result in spurious calls
and make results more difficult to interpret.
ENCODE Project Consortium et al. (2012)
recommends that these regions are filtered
from analyses, and has published a blacklist
of such regions.
QDNAseq introduces a novel blacklist,
which is based on its simultaneous LOESS
correction for GC content and mappability,
and a control data set from the 1000 Genomes
project (1000 Genomes Project Consortium
et al., 2012). During the LOESS correction of
each sample, a residual was defined for each
bin. Median residuals were then calculated
across the data set, and bins with the ab-
solute value of median residuals higher than
4.0 standard deviations were included in the
blacklist. Both blacklists are optional and
can be used to filter bins from the analysis.
Performance evaluation
Performance of QDNAseq was evaluated in
comparison to an existing DOC preprocessing
method, array CGH, and also to theoretical
expectations. Compared to array CGH, both
NGS methods were shown to have higher
signal-to-noise ratios. Through a comparison
to a method with separate corrections for GC
content and mappability (Boeva et al., 2011),
we showed the simultaneous correction to be
always at least as good, and sometimes su-
perior. Furthermore, the noise of the pre-
processed data (as measured with a mean-
scaled and 0.1%-trimmed first-order estimate
of variance) was shown to be very close to the
theoretical statistical limit imposed by read
counting.
CNAs in low-grade gliomas
Chapter 5 (van Thuijl et al., 2014) uti-
lizes low-coverage WGS and the QDNAseq
method described in Chapter 4 (Scheinin
et al., 2014) to identify CNAs in archival ma-
terial from 98 patients with diffuse low-grade
glioma (LGG). Detected CNAs are used to
evaluate their association with survival, and
also to study intratumoral heterogeneity and
temporal evolution of LGGs.
LGGs are brain tumors that grow rela-
tively slow. Patients can live up to 30 years
with the disease, but in some cases survival
can be as short as two years (Claus and Black,
2006). Post-operative radiotherapy is effec-
tive in limiting tumor growth, but since its
side effects can be substantial, an accurate
characterization of the disease is crucial for
appropriate decisions on post-operative treat-
ment (Douw et al., 2009). CNA markers as-
sociated with survival could thus be highly
valuable.
Associations between CNAs and sur-
vival
LGGs commonly exhibit a 1p/19q co-
deletion, which is well known to be associated
with a less aggressive disease and better prog-
nosis (Erdem-Eraslan et al., 2013; van Thuijl
et al., 2012). In addition to this co-deletion,
other CNAs that were found to be statisti-
cally significantly associated with survival in-
cluded losses in 10q, 11p, 13q, and 22q, which
were all associated with poor prognosis. Of
these, the 10q loss was validated in an inde-
pendent French cohort of 126 patients (Alen-
torn et al., 2014), and confirmed also in a
set of 184 patients from The Cancer Genome
Atlas (TCGA) (Brennan et al., 2013). The
size of the loss varied from the whole chro-
mosome 10 to a 22.5 Mbp minimal common
109
region spanning from 10q25.5 to the end of
the long arm. This region contains 148 genes,
including for example MGMT, DMBT1, and
ERCC6, but not PTEN.
Evolving picture of glioma classification
When we started the low-grade glioma
project, the official classification of LGGs in-
cluded three histological subtypes: astrocy-
tomas, oligodendrogliomas, and the mixed
phenotype oligoastrocytoma. The 1p/19q
co-deletion (Reifenberger et al., 1994) was
known to be common among oligoden-
drogliomas, but there were also cases of oligo-
dendrogliomas without the co-deletion, and
cases of co-deletions in oligoastrocytomas and
even astrocytomas. Our set of 98 patients re-
flected this, and contained cases of all three
histological subtypes and both with and with-
out the co-deletion.
The understanding of tumorigenesis of
gliomas has since improved rapidly, which
has resulted in a new classification system,
now based not only on histopathological fea-
tures but also on molecular markers (Louis
et al., 2016). With the use of molecular
markers, it should now be possible to define
all cases previously diagnosed as the mixed
oligoastrocytoma subtype as either astrocy-
tomas or oligodendrogliomas. The defining
features of oligodendrogliomas are the pres-
ence of both the 1p/19q co-deletion and a
mutation in either IDH1 or IDH2 genes (Yan
et al., 2009). The new classification system
shows stronger association between disease
subtype and prognosis, and provides a bet-
ter basis for treatment decisions (Wesseling
et al., 2015).
Consistent with the role of the 1p/19q co-
deletion as a hallmark feature, are our obser-
vations regarding intratumoral heterogene-
ity and temporal evolution. When possible,
intratumoral heterogeneity was assessed by
isolating DNA from either spatially distinct
parts of the primary tumor, or from separate
FFPE blocks if they were available. Tem-
poral evolution was evaluated with a com-
parison of primary tumors and recurrences,
whenever they were available. Except for
the 1p/19q co-deletion, all other CNAs were
found to exhibit intratumoral heterogeneity,
and varying presence between the primary
tumors and recurrences. Contrastingly, the
1p/19q co-deletion was found to be consis-
tently present or absent across all spatially
distinct parts of the same tumor, and also
across primary tumors and recurrences. This
supports the role it is currently considered
to have as a defining feature of oligoden-




I will now discuss the presented orig-
inal publications from today’s perspective.
This discussion focuses on the three pre-
sented bioinformatic solutions: the CanGEM
database (chapter 2; Scheinin et al., 2008),
the CGHpower sample size tool (chapter 3;
Scheinin et al., 2010), and the QDNAseq pre-
processing method for copy number detection
from shallow WGS data (chapter 4; Scheinin
et al., 2014). I will use the names CanGEM,
CGHpower, and QDNAseq to refer to these
tools and to the original articles that describe
them.
Instead of the functionality of these tools,
I will focus mainly on the process of devel-
oping them. As technology evolves (both
in the wet and dry labs), most bioinformat-
ics tools get outdated at some point. Both
CanGEM and CGHpower were developed for
microarrays, and while they could technically
be easily used for DOC-type NGS copy num-
ber data, they are probably unlikely to see
much of such use. And while currently WES
and shallow WGS are excellent cost-efficient
solutions to study mutations and copy num-
ber, respectively, at some point in the future
both might be replaced with deep WGS, if se-
quencing costs continue their steady decline.
For this reason, I will focus on what I have
learned from the development process of the
presented bioinformatics tools. I hope this
provides a more insightful discussion topic
than their functionality. Although use of the
passive tense is common in scientific writing,
here I will frequently use active first-person
voice. I feel this better allows me to ex-
press views that might be somewhat subjec-
tive, but that I hope can be useful consid-
erations for others developing bioinformatics
software.
Academic software development
The majority of scientists who develop soft-
ware as part of their research are primar-
ily self-taught (Hannay et al., 2009; Prabhu
et al., 2011). As a result, they often lack
knowledge and experience with basic software
development practices such as writing main-
tainable code, using version control and issue
trackers, code reviews, unit testing, and task
automation (Wilson et al., 2014). I count my-
self in this group, and believe that inclusion of
more training on software development prin-
ciples in curricula of bioinformatics degree
programs could be beneficial and result in
better efficiency in development of bioinfor-
matics software.
Wilson et al. (2014) have published a list
of recommended best practices for scientific
computing. The list is based on their experi-
ence in both building scientific software and
teaching software development to scientists
(Wilson, 2006, 2014), and also on published
reports from others. One of the recommenda-
tions is to “make incremental changes” based
on fast feedback loops and frequent course
corrections when needed. This is crucial
in the research setting, where the situation
and exact requirements can see fast changes
(Segal, 2005; Kane et al., 2006; Pitt-Francis
et al., 2008; Killcoyne and Boyle, 2009; Pouil-
lon et al., 2011). Two more recommendations
from Wilson et al. (2014) will be described in
the upcoming discussion.
In addition to the points mentioned
above, I would like to discuss the target au-
dience of bioinformatics software, because
of implementation decisions affected by this
choice. The first aspect is whether software is
developed for internal or external users. It is
perhaps worth emphasizing that this question
is not about usage, but about development.
In probably the majority of cases, academic
software development is performed to answer
a need within the developers’ own research
group or among close collaborators (internal
users). If other research groups have simi-
lar needs, they might also be interested in
the software and might decide to adopt it for
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their use. These, possibly unknown to the
developers, people represent external users.
But in this case, the software was developed
for internal users, even though external users
might use it as well. This is always the
more straightforward case, because the in-
ternal needs are known, and are also known
to exist. Development for external users is
more complicated, because the details of the
requirements are not necessarily clear. Ful-
fillment of a perpetual internal need is also a
good way to ensure the sustainability of aca-
demic software development (Broman, 2014).
The second aspect of target audience is
easiest to discuss by starting from an imple-
mentation decision it affects. Software can
be roughly divided to graphical user inter-
face (GUI) and command-line interface (CLI)
programs. Those with a GUI are commonly
deemed easier to use than CLI software, and
are therefore seen as more accessible to a
wider audience. On the other hand, a GUI
program is often less flexible in terms of func-
tionality, and for the developer is typically
more laborious to implement, keep up-to-
date, and to include support across different
operating systems. CLI software is also easier
to automate, and is a good fit for reproducible
research as processing pipelines can be saved
in the form of scripts.
Here, I will make an artificial oversimpli-
fication and discuss two possible target au-
diences for bioinformatics software: bioinfor-
maticians and biologists. Bioinformatics is
an interdisciplinary field in the intersection
of biosciences, computer science, statistics,
mathematics, and engineering. Bioinformati-
cians are therefore a heterogeneous group
with diverse backgrounds, and it is not really
possible to define a boundary within the fluid
continuum between bioinformaticians and bi-
ologists. But in this text, I will use these
terms to refer to bioscientists who are com-
fortable with CLI programs (and computer
programming), and those who are not, re-
spectively. This is naturally an oversimpli-
fication, but while not a realistic definition,
it conceptually facilitates the discussion that
follows. I should also point out that just as
end users for software developed for internal
users might include external ones as well, the
list of end users can in reality very well con-
tain both bioinformaticians and biologists, re-
gardless of who the software was primarily
developed for. But rather than to attempt to
target both of these groups, I find it can be
valuable to prioritize one over the other.
One question related to target audience
and user interface is the division between
method development for new analytical meth-
ods, and mere software implementations of
existing algorithms. This division is some-
what cloudy; after all, new methods are in
practice often described through a software
implementation. Nevertheless, this too I be-
lieve is a conceptually useful distinction for
academic software development.
Bioinformatics software devel-
oped for this dissertation
I would now like to discuss the bioinformatic
solutions presented in previous chapters from
the perspective of software development. Of
the presented solutions, QDNAseq is perhaps
the most straightforward to discuss. QD-
NAseq is a DOC preprocessing method for the
detection of genome-wide chromosomal copy
number changes from WGS experiments. It
is implemented as a package for R (Ihaka and
Gentleman, 1996; R Core Team, 2016), which
is a statistical programming language with a
CLI user interface. It is distributed through
the Bioconductor suite (Huber et al., 2015),
which is an open source software project to
provide tools for the analysis and compre-
hension of high-throughput genomic data. It
is therefore a clear example of method de-
velopment for bioinformaticians (users com-
fortable with CLI software). QDNAseq was
developed to answer a clear need within our
own research group. It was therefore devel-
oped primarily for internal use, but was also
made available for external users as a part
of the Bioconductor suite. Since the user in-
terface is CLI-based, providing additional op-
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tions and settings for external users adds lit-
tle overhead.
In addition to the R package, GUI imple-
mentations for Chipster (Kallio et al., 2011)
and Galaxy (Afgan et al., 2016) were also de-
veloped, thus making the method more ac-
cessible to a wider audience. But these ef-
forts were separate from the main method de-
velopment process. This separation of mere
user interface implementations makes it eas-
ier to both develop and to maintain the main
method itself (Kelly et al., 2009).
Although it is the newest one of the bioin-
formatic solutions included in this disserta-
tion, QDNAseq is already the most cited one
(Table 6.1). Within the Bioconductor soft-
ware suite (Huber et al., 2015), it is among
the “top 20 %” most downloaded packages.
And in addition to being used in many pres-
tigious universities and research institutes
around the world, it is also in commercial
use in the whole-genome copy number assay
of the diagnostic company Blueprint Genetics
Ltd.
Relative to the other solutions presented
in this dissertation, I see QDNAseq as the
biggest success. I think part of the reason
stems from the implementation choices we
made. Most of the existing DOC methods
were developed for the analysis of individ-
ual samples at a time, and were designed
as standalone solutions for the entire copy
number analysis, including preprocessing, seg-
mentation and calling. In contrast, we de-
signed QDNAseq for the analysis of larger
data sets, and also focused it on the prepro-
cessing step only, leveraging other Biocon-
ductor packages for segmentation and call-
ing. One of the recommendations of Wil-
son et al. (2014) is “don’t repeat yourself (or
others)”, and when standard data structures
exist to bridge together multiple methods,
this allows them to better focus on their core
purpose. When we were evaluating the ex-
isting FREEC method (Boeva et al., 2011)
while developing QDNAseq, we noticed we
could actually improve its performance by
replacing the included segmentation method
(Harchaoui and Lévy-Leduc, 2008) with CBS
(Venkatraman and Olshen, 2007). While the
output of FREEC does include bin-level data,
and thus allows such use of an alternative seg-
mentation method, this is not the case for all
published methods. For example, the out-
put of readDepth (Miller et al., 2011) only
includes segment-level data, thus making it
impossible to combine its preprocessing with
any other segmentation method.
Development of the CGHpower sample
size calculation tool followed a somewhat dif-
ferent path. It was also written in R, but as it
was developed to be used by biologists, both
internal and external, in the planning stages
of new experiments, it was implemented as
a web application with a GUI. It is hosted
on the web site of the CanGEM database,
and can read in data sets directly from the
database, thus facilitating analyses for less
technical users.
Judging from the number of citations,
CGHpower has not generated much interest
(Table 6.1). As a power calculation tool, it
is intended mainly for the planning stage of
experiments, including as a justification for
adequate sample size and thus the amount
of required funding in grant applications. As
such, it might never receive a citation in the
resulting scientific article. CGHpower has
been used in several grant applications from
our research group in Amsterdam, The Tu-
mor Genome Analysis Core, including the
grant for the LGG study (Chapter 5; van
Thuijl et al., 2014). It is possible other groups
might have used the program in their grant
applications as well. However, the fact that
we found its performance to be sub-optimal
for many data sets is perhaps a more proba-
ble reason for the lack of interest. Neverthe-
less, it is difficult to utilize usage measures
to judge how successful our implementation
decisions were. Also, since the infrastructure
had already been built and was maintained
for CanGEM, implementing CGHpower as a
web application did not require as much re-
sources as it otherwise would have. Still, in
retrospect, I think the right approach would
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solution chapter reference journal impact factor citations
CanGEM 2 Scheinin et al., 2008 6.878 20
CGHpower 3 Scheinin et al., 2010 3.029 5
QDNAseq 4 Scheinin et al., 2014 14.630 36
Table 6.1: Number of citations for each of the included bioinformatics solutions, presented
as a measure of interest and as a proxy for success. Data obtained from Thomson Reuters
Web of Science. Impact factors are for the year of publication, and the number of citations
as of September 1, 2017.
have been to release it as an R package, as
a CLI tool for bioinformaticians. If deemed
useful, this could have been supplemented
with an additional GUI implementation, as
was done with QDNAseq.
During the development process, there
were a number of situations where a choice
could be made between two or more sta-
tistical options. Examples include whether
to use the Student’s t-test (which assumes
equal variances) or Welch’s t-test (which al-
lows unequal variances), or whether to cal-
culate p-values from the normal or Student’s
t-distribution. In a CLI program it is eas-
ier to offer many such choices to the user as
parameters, but we decided to leave these op-
tions out from the GUI implementation as we
felt at the time that would have caused un-
necessary clutter for the user interface.
Regarding CGHpower’s sub-optimal per-
formance for many data sets, there are at
least two factors that could potentially con-
tribute to the issue. The first one is the
assumption of a normal distribution for the
median log2-ratios of regions. While in gen-
eral this text favors the use of calls or call
probabilities over log2-ratios, here we made
this chose because the normal distribution
was the only one supported by the power
calculation framework (Ferreira and Zwinder-
man, 2006a). Since then, van Iterson et al.
(2013) have extended the framework to also
cover the F - and χ2-distributions. This al-
lows additional experimental designs besides
the two-group case, and also offers a more
suitable choice for copy number data than the
normal distribution we used.
The second factor is the number of data
points available to estimate the unknown dis-
tribution for regions with a real difference be-
tween groups. If this number is too small,
estimates are unstable and performance suf-
fers. The number of data points available for
estimation depends on the total number of
regions, and also on the proportion of regions
with a real difference between groups. The
examples of both Ferreira and Zwinderman
(2006a) and van Iterson et al. (2013) were
from mRNA expression, and the dimension-
ality of the (real and simulated) data sets
in the range of thousands or tens of thou-
sands. Contrastingly, the number of regions
for a copy number experiment is often in the
range of hundreds, as was the case for all the
(real and simulated) evaluation data sets in
Scheinin et al. (2010). Also, since the num-
ber of regions with a real difference between
groups could potentially be small, the power
calculation framework might simply have two
few data points available to estimate from.
Since the estimation of the power calcula-
tion framework works in an asymptotic man-
ner, it actually benefits from high dimension-
ality. Therefore, while this text in general
favors use of regions instead of the original
features (array elements or sequencing bins),
the reduced dimensionality can be a challenge
for the power calculation framework.
Of the three presented bioinformatic so-
lutions, CanGEM is perhaps the most inter-
esting discussion topic. It is a centralized
database, and the public data sets can be ac-
cessed by all users. (Data sets can also be
kept private, and read/write access granted
on a per user account basis.) This requires it
to be implemented on a centralized server. It
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was developed to be accessible to a wide audi-
ence of biologists, both internal and external,
and therefore has a GUI.
Now, nine years after CanGEM was pub-
lished in the peer-reviewed journal Nucleic
Acids Research, it is probably safe to say that
it has not been a success. It does work as in-
tended, but what I mean with it not being a
success is reflected in the title of the original
article: “CanGEM: mining gene copy number
changes in cancer”. Rather than a description
of its functionality, the title is a reflection of
CanGEM’s ultimate purpose and motivation:
to allow data mining studies. However, there
is one crucial step from a database that works
as intended to one that is a great source for
data mining. That step is data.
The rationale behind CanGEM was 1) to
develop a database that answered the needs
of our research group in Helsinki, the Labo-
ratory of Cytomolecular Genetics (CMG): to
provide a service where we could store our
microarray data, and to be able to query
it based on clinical attributes and specific
CNAs. Then, 2) if other research groups had
similar needs, they might also be interested
in using it. And finally, 3) as this could lead
to accumulation of data, it would allow novel
experiments that utilized data across a num-
ber of original experiments.
Today, the CanGEM database contains
(as publicly accessible) the raw and processed
data of 35 individual studies (Table 6.2). The
vast majority of data submissions (28) were
performed by people in the CMG group. As
collaborators submitted data for six studies,
only one submission came from an external
source. I see this as a clear demonstration
that CanGEM did not succeed in its intended
purposes 2 and 3. Below, I discuss some al-
ternative implementation decisions we could
have made. It is impossible to know if they
might have lead to more success, but the aim
is to present considerations for future efforts
in academic bioinformatics software develop-
ment.
I would like to start by iterating the use-
fulness of general software development best
practices. During its development process,
CanGEM saw one complete rewrite of the en-
tire user interface code, because the original
implementation scaled poorly as functional-
ity grew more complex. Also, the initial copy
number analysis pipeline was based on a com-
bination of R scripts and segmentation and
calling with CGH-Explorer (Lingjaerde et al.,
2005). But since CGH-Explorer is a GUI pro-
gram, only the R parts of the pipeline could
be automated, leaving in a step that had to
be executed manually. A couple of years af-
ter the original publication, CGH-Explorer
was replaced with DNAcopy (Venkatraman
and Olshen, 2007) and CGHcall (van de Wiel
et al., 2007), in order to make the pipeline
fully automated. One of the recommenda-
tions of Wilson et al. (2014) is to “let the com-
puter do the work” and automate processes
that can be automated. This reduces poten-
tial for human error, improves reproducibil-
ity, and improves sustainability. For these
reasons, the copy number analysis pipeline of
CanGEM should have been designed as fully
automated from the beginning. (However, it
should perhaps be noted that this particu-
lar recommendation of Wilson et al. (2014)
should not be over-interpreted in the context
of exploratory data analysis, which can re-
quire evaluation of intermediate results in-
stead of full automation.)
In addition to the factors that have
been mentioned, another reason to develop
CanGEM was that data submissions to the
existing databases were difficult for biolo-
gists. They required the original raw data
files generated by the image analysis software
to be processed to another format, whereas
CanGEM was designed to only require the
original files. This need could have been an-
swered in another way. Instead of replicating
the data warehousing functionality of exist-
ing microarray databases, such as GEO (Bar-
rett et al., 2013) or ArrayExpress (Kolesnikov
et al., 2015), we could have developed a ded-
icated internal tool to help the submission
process to, for example, GEO. And then
develop CanGEM as a copy number anal-
115
article source submission arrays
Armengol et al., 2007 internal internal 10
Atiye et al., 2005 internal internal 22
Borze et al., 2008 internal internal 37
Borze et al., 2010 internal internal 41
Buffart et al., 2008 GEO internal 2
Cancer Genome Atlas Research Network, 2008 TCGA collaborator 238
Catrina Ene et al., 2014 internal internal 20
Ferreira et al., 2008 GEO internal 25
Heinonen et al., 2008 collaborator collaborator 32
Järvinen et al., 2008 collaborator collaborator 61
Junnila et al., 2010a collaborator collaborator 31
Junnila et al., 2010b collaborator collaborator 20
Kaur et al., 2006a internal internal 18
Kaur et al., 2006b internal internal 12
Kaur et al., 2007 internal internal 7
Kaur et al., 2008 internal internal 19
Koski et al., 2009 collaborator collaborator 15
Larramendy et al., 2006 internal internal 4
Lindholm et al., 2007 internal internal 22
Myllykangas et al., 2008 internal internal 94
Niini et al., 2010 internal internal 13
Niini et al., 2011 internal internal 22
Nymark et al., 2006 internal internal 20
Savola et al., 2009 internal internal 47
Siggberg et al., 2011 internal internal 9
Siggberg et al., 2012 internal internal 35
Stephan et al., 2008 GEO internal 25
Szabó et al., 2010 GEO internal 11
Tap et al., 2011 external external 46
Tyybäkinoja et al., 2006 internal internal 4
Usvasalo et al., 2010 internal internal 103
Vauhkonen et al., 2006a internal internal 25
Vauhkonen et al., 2006b internal internal 11
Yamashita et al., 2007 GEO internal 32
Ässämäki et al., 2007 internal internal 47
Table 6.2: Publicly available data sets in CanGEM.
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ysis and querying tool that leveraged raw
data stored in GEO. This would have turned
CanGEM into more of an indexing tool (in-
stead of raw storage) and thus allowed it to
focus more on its core purpose.
Also, instead of requiring sample meta-
data in a specific file format, CanGEM al-
lowed it to be entered using easy-to-use web
forms (while also accepting such a prefor-
matted file for batch submissions). While
CanGEM aimed for detailed clinical informa-
tion and used controlled vocabularies when-
ever possible, the granularity of sample meta-
data can be a mixed blessing. Having to an-
swer many detailed questions is much more
laborious than a simple free-text field. Also,
as with all modern biomedical studies, CNA
experiments in cancer research are necessarily
a team effort, and can involve clinicians, on-
cologists, pathologists, geneticists, lab tech-
nicians, bioinformaticians, mathematicians,
statisticians, and software engineers. While
some of the people involved undoubtedly have
the information and expertise to answer de-
tailed questions on, for example, the cell-of-
origin for a specific tumor type, the person
tasked with database submissions might not.
If data submissions seem too laborious, it can
raise the bar to perform them in the first
place. In retrospect, I think we might have
aimed too high with CanGEM, and while try-
ing to collect too much information, as a re-
sult we received less.
As a service targeted to a wide audience of
external biologists, CanGEM needed to have
a GUI. But with so little data submissions
from external users (Table 6.2), I think it is
relevant to ask if the decision on target au-
dience was the right one. If instead of its
present form, CanGEM was an indexing tool
built on top of raw data stored in GEO and
had a CLI for bioinformaticians to use, this
would have allowed a lot of resources to be
spent on, for example, going through exist-
ing published data sets and annotating sam-
ples with more detailed clinical data. Also,
all data input could have been performed in-
ternally, and only a querying interface for the
results built for external use, similar to how
Kilpinen et al. (2008) did with mRNA ex-
pression data from 9,783 samples that repre-
sented 68 cancer types, 64 other diseases, and
43 normal human tissue types.
There is also an additional challenge asso-
ciated with maintaining a centralized service
that depends on external users for data input.
A centralized service requires long-term in-
frastructure, whereas funding in academia is
often based on grants for individual research
projects. A common approach is to assign
some defined percentage of research grants
for longer-term infrastructure needs, possibly
on the institution level. While this might se-
cure the necessary resources operationally, a
service such as CanGEM that expects exter-
nal users to submit data also has to convince
them of long-term sustainability. If a poten-
tial user considering submission of their data
into the database is worried whether the ser-
vice will still exist in a few years, they are less
likely to go through the trouble. While soft-
ware as a service (SaaS) has proved to be a
good business model for many circumstances
and many companies, it is a challenging one
for academic software development. Another
related challenge is the mobility of people in
academia; what happens to the service if the
people responsible for its development (often
PhD students) or the principal investigator
leaves?
With all this auto-criticism of the im-
plementation decisions we made with the
CanGEM solution, it is fair to also say
that no other database has succeeded either
in what we tried to achieve. The Cancer
Genome Atlas (TCGA; Cancer Genome At-
las Research Network et al., 2013) is per-
haps the closest comparison, and has been a
tremendously useful and valuable resource for
the cancer research community. It is a cen-
tralized repository of processed copy number
data across experiments with different cancer
types, and is targeted to a wide audience of
biologists with a GUI on the web. But it was
also built for data submissions from within
the consortium instead of external users, and
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also with more solid financial backing than
an individual research group.
To summarize the preceding paragraphs,
in retrospect I would rather implement
CanGEM to 1) leverage existing microarray
databases for raw data storage, 2) allow data
input only from internal users, and possi-
bly through a CLI, and 3) provide a GUI
querying interface to the database contents
for both internal and external users.
The discussion above attempts to summa-
rize my personal lessons learned from devel-
oping the presented bioinformatic solutions. I
hope it can provide at least some useful con-
siderations to people who develop software




Like all modern genomics, the study of genome-wide chromosomal copy number aberrations
in cancer relies heavily on computational methods to handle and analyze the large amounts
of generated data. Much of the needed software is developed within academic research groups
according to their custom needs. This dissertation presents three such bioinformatic solu-
tions. The lessons learned from the development process of these solutions are summarized
below.
1. Although software is a crucial component for their work, as software de-
velopers most scientists are self-taught. They therefore lack exposure to
common software development practices, such as unit tests and code review.
These practices have been shown to result in better efficiency in software
development, and program code that is less error-prone and easier to main-
tain. Their value and usefulness is well-known among software engineers,
and developers of academic software could benefit from better awareness
and utilization of these practices.
2. Software development to answer internal needs is more straightforward than
targeting external users. The specific requirements are known more accu-
rately, and it is easier to form fast feedback loops necessary for agile decision-
making. Software developed primarily for internal users can be valuable for
external users as well, possibly with small modifications. But as a general
rule for academic software development, it is perhaps not advisable to be
dependent on external users, for example for data submissions.
3. Method development for new analytical algorithms can benefit from mod-
ularization. Separation of logically distinct components allows each com-
ponent to be optimized and reused individually, leading to better overall
performance. This is especially true for separation of the program’s busi-
ness logic and user interface.
4. Characteristics of the academic work environment can also have implications
for software development. Project-based nature of grant funding and high
mobility of key personnel can both have implications for long-term main-
tenance and support of developed software solutions. These characteristics
should be taken into account early on in the development process.
Academic software development could benefit from closer attention to the software de-
velopment process itself. Providing training for useful software development practices, and
more careful considerations of implementation choices and their consequences could result in
procedural efficiency, better software, and thus better science.
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